👪

Inheritance

1

Polygenic (multifactorial) liability HP:0010982

AUD is not Mendelian. Liability is conferred by many common variants of small effect together with environmental exposure; the two largest-effect known loci (ADH1B, ALDH2) act on ethanol metabolism and are protective rather than causative. Twin and adoption meta-analysis places heritability near 50%, with a modest shared-environment component.

polygenic inheritance

Show evidence (3 references)

PMID:25171596 SUPPORT Human Clinical

"AUD is approximately 50% heritable."

Meta-analysis of 12 twin and 5 adoption studies gives the reference heritability estimate for AUD liability.

PMID:25171596 SUPPORT Human Clinical

"We also found evidence for modest shared environmental effects suggesting that environmental factors also contribute to the familial aggregation of AUDs."

Supports the multifactorial framing: familial aggregation is not purely genetic.

PMID:38062264 SUPPORT Human Clinical

"We observed a high degree of cross-ancestral similarity in the genetic architecture of PAU and identified 110 independent risk variants in within- and cross-ancestry analyses."

The largest multi-ancestry GWAS of problematic alcohol use demonstrates the highly polygenic architecture expected under multifactorial inheritance.

?

Discussions and Knowledge Gaps

2

Does pharmacological targeting of the extended-amygdala stress systems (CRF1, kappa-opioid) translate into clinical benefit in human AUD, given that the preclinical evidence is strong but no such agent is approved?

KNOWLEDGE GAP aud_extended_amygdala_translation

Attached to

pathophysiology#Extended Amygdala Stress-System Recruitment

The CRF and dynorphin/kappa-opioid arms of the withdrawal/negative affect stage are supported almost entirely by rodent pharmacology (local antagonist infusion, dependence-induced escalation), while the human evidence curated here is a review-level framework rather than a controlled trial. The node's clinical actionability is therefore an open question rather than settled biology.

Proposed experiments

Randomized trial of kappa-opioid or CRF1 antagonism stratified by negative-affect phenotype

exp_aud_kor_crf1_rct

Adequately powered randomized placebo-controlled trial of a kappa-opioid or CRF1 antagonist in AUD, stratified by withdrawal severity or a negative-affect/hyperkatifeia phenotype, with heavy drinking days and craving as endpoints.

Human imaging or CSF measures of extended-amygdala stress-system engagement

exp_aud_extended_amygdala_imaging

PET or CSF assessment of CRF and dynorphin system engagement in the extended amygdala in people with AUD, correlated with negative-affect drinking measures, to test whether the rodent mechanism is engaged in humans.

Does the ventral-to-dorsolateral striatal shift in control over alcohol seeking, demonstrated in alcohol-preferring rats, occur in human AUD?

HUMAN MODEL MISMATCH aud_habit_system_human_fidelity

Attached to

pathophysiology#Dorsolateral Striatal Habit System Recruitment

The habit-system claim rests on outcome-devaluation and punishment-resistance paradigms in rats, which have no direct human equivalent: human compulsivity is assessed by self-report diagnostic criteria rather than by devaluation insensitivity. The anatomical localization to anterior dorsolateral striatum is therefore extrapolated, not measured, in patients.

Proposed experiments

Human fMRI outcome-devaluation and punished-seeking paradigm in AUD

exp_aud_human_devaluation_fmri

Test whether people with AUD show devaluation-insensitive, punishment-resistant alcohol seeking accompanied by dorsal rather than ventral striatal engagement, relative to matched controls.

Longitudinal imaging across the transition to AUD

exp_aud_longitudinal_striatal_shift

Follow hazardous drinkers longitudinally with repeated imaging to test whether a ventral-to-dorsal striatal shift precedes, rather than follows, the emergence of compulsive drinking.

⚙

Pathophysiology

14

Polygenic and Metabolic-Gene Susceptibility

Inherited liability to AUD is polygenic, with common variants of small effect distributed across brain-expressed genes, plus two large-effect protective loci acting on ethanol metabolism (ADH1B rs1229984, ALDH2 rs671). Genetic loading does not by itself produce the disorder; it shifts the probability that repeated alcohol exposure escalates to compulsive use.

ADH1B hgnc:250 ALDH2 hgnc:404 GABRA2 hgnc:4076 OPRM1 hgnc:8156

Downstream

Ethanol Exposure and Acetaldehyde-Generating Oxidative Metabolism ADH1B and ALDH2 coding variants directly set the rate at which ingested ethanol is oxidized and at which the acetaldehyde intermediate is cleared.

Mesolimbic Dopamine and Endogenous Opioid Reward Signaling Non-metabolic susceptibility loci such as GABRA2 and OPRM1 act on the inhibitory and opioidergic signalling that shapes alcohol's acute reinforcing effect.

Show evidence (2 references)

PMID:28118990 SUPPORT Human Clinical

"The heritability of alcohol use disorders is estimated at approximately 50-60% of the total phenotypic variability."

Quantifies the inherited component that this susceptibility node represents.

PMID:28118990 SUPPORT Human Clinical

"Vulnerability to alcohol use disorders can be due to multiple genetic or environmental factors or their interaction which gives rise to extensive and daunting heterogeneity."

Supports modelling susceptibility as a probabilistic upstream node rather than a deterministic cause.

Ethanol Exposure and Acetaldehyde-Generating Oxidative Metabolism

Ingested ethanol is oxidized by alcohol dehydrogenase to acetaldehyde, a reactive and toxic intermediate, which aldehyde dehydrogenase (principally mitochondrial ALDH2) then oxidizes to acetate. The balance of these two enzymatic steps determines systemic and local acetaldehyde exposure and is the biochemical layer on which the metabolic-gene protective variants act.

alcohol metabolic process GO:0006066

alcohol dehydrogenase (NAD+) activity GO:0004022 aldehyde dehydrogenase (NAD+) activity GO:0004029

liver UBERON:0002107

Downstream

Acute GABA-A Potentiation and NMDA Receptor Inhibition Unmetabolized ethanol reaching the brain acts directly on ligand-gated ion channels.

Aversive Acetaldehyde Accumulation and Flushing Response When ADH activity is high or ALDH2 activity is impaired, acetaldehyde accumulates faster than it is cleared.

Show evidence (2 references)

PMID:17718394 SUPPORT Human Clinical

"The main pathway of ethanol metabolism involves its conversion (i.e., oxidation) to acetaldehyde, a reaction that is mediated (i.e., catalyzed) by enzymes known as alcohol dehydrogenases (ADHs)."

Establishes the ADH-catalyzed first step of the two-step oxidative pathway modelled by this node.

PMID:17718394 SUPPORT Human Clinical

"In a second reaction catalyzed by aldehyde dehydrogenase (ALDH) enzymes, acetaldehyde is oxidized to acetate."

Establishes the ALDH-catalyzed second step.

Aversive Acetaldehyde Accumulation and Flushing Response

Acetaldehyde accumulation produces an aversive reaction — facial flushing, nausea, tachycardia — that discourages further drinking. This is the mechanistic basis both of the strong genetic protection conferred by ADH1B*2 and ALDH2*2 and of disulfiram pharmacotherapy, which reproduces the same reaction by inhibiting ALDH. It is a protective branch of the pathograph: it terminates rather than propagates the escalation cascade.

Show evidence (2 references)

PMID:17718394 SUPPORT Human Clinical

"Acetaldehyde is a toxic substance whose accumulation leads to a highly aversive reaction that includes facial flushing, nausea, and rapid heart beat (i.e., tachycardia)."

Describes the aversive physiological response modelled by this node.

PMID:16822169 SUPPORT Human Clinical

"For each gene, possession of 1 variant *2 allele was protective against alcohol dependence, and possession of a 2nd *2 allele did not offer significant additional protection."

Meta-analysis in Asian populations quantifies the protection conferred by the ALDH2 and ADH1B variants that drive this node.

Acute GABA-A Potentiation and NMDA Receptor Inhibition

Acute ethanol positively modulates GABA-A receptor-mediated inhibitory transmission and inhibits NMDA receptor-mediated glutamatergic transmission. The net shift toward inhibition produces the sedative, anxiolytic, and cognitively impairing acute effects of intoxication and is the substrate on which chronic compensatory neuroadaptation later develops.

GABAergic neuron CL:0000617

response to ethanol GO:0045471 GABAergic synaptic transmission GO:0051932 ↑ INCREASED glutamatergic synaptic transmission GO:0035249 ↓ DECREASED

GABA-A receptor activity GO:0004890 ↑ INCREASED NMDA glutamate receptor activity GO:0004972 ↓ DECREASED

Downstream

Mesolimbic Dopamine and Endogenous Opioid Reward Signaling Ethanol's action on inhibitory transmission onto ventral tegmental neurons is one route by which acute alcohol raises accumbal dopamine.

GABAergic and Glutamatergic Neuroadaptation and Tolerance Repetition of the acute inhibitory shift drives compensatory receptor plasticity.

Show evidence (2 references)

PMID:28931433 SUPPORT Model Organism

"GABAergic inhibitory transmission is involved in the acute and chronic effects of ethanol on the brain and behavior."

Supports GABAergic transmission as the acute target modelled here.

PMID:25954150 SUPPORT Other

"Glutamatergic receptors implicated in the effects of ethanol include the ionotropic glutamate receptors (AMPA, Kainate, and NMDA) and some metabotropic glutamate receptors."

Supports ionotropic glutamate receptors, including NMDA, as direct targets of ethanol.

Mesolimbic Dopamine and Endogenous Opioid Reward Signaling

Acute alcohol increases dopamine release from ventral tegmental projections to the nucleus accumbens, an effect involving endogenous opioid peptide release acting at mu-opioid receptors. This is the positive reinforcement that sustains drinking in the binge/intoxication stage and is the target of opioid-antagonist pharmacotherapy.

dopaminergic neuron CL:0000700 GABAergic interneuron CL:0011005

dopamine secretion GO:0014046 ↑ INCREASED opioid receptor signaling GO:0038003

ventral tegmental area UBERON:0002691 nucleus accumbens UBERON:0001882

Downstream

Incentive Salience Sensitization and Alcohol Cue Reactivity Repeated dopaminergic reinforcement in the basal ganglia converts alcohol-paired stimuli into powerful motivational cues.

Dorsolateral Striatal Habit System Recruitment Sustained reinforcement progressively transfers behavioural control from ventral (goal-directed) to dorsal (habitual) striatal circuits.

Show evidence (2 references)

PMID:27475769 SUPPORT Other

"Drug addiction represents a dramatic dysregulation of motivational circuits that is caused by a combination of exaggerated incentive salience and habit formation, reward deficits and stress surfeits, and compromised executive function in three stages."

States the three-stage neurocircuitry framework this node opens.

PMID:33318153 SUPPORT Other

"Compulsive drug seeking that is associated with addiction is hypothesized to follow a heuristic framework that involves three stages (binge/intoxication, withdrawal/negative affect, and preoccupation/anticipation) and three domains of dysfunction (incentive salience/pathologic habits, negative..."

Assigns the binge/intoxication stage modelled here to basal ganglia circuitry.

Incentive Salience Sensitization and Alcohol Cue Reactivity

Alcohol-associated cues acquire exaggerated motivational value and elicit robust limbic and prefrontal activation in people with AUD. Cue-elicited ventral striatal activation tracks behavioural measures of craving and is reduced by treatment, making it the most frequently used circuit-level correlate of craving.

ventral striatum UBERON:0005403 prefrontal cortex UBERON:0000451

Downstream

Compulsive Alcohol Seeking and Loss of Control Cue-driven motivational states precipitate drinking episodes and relapse.

Show evidence (2 references)

PMID:22574861 SUPPORT Human Clinical

"Among cases, alcohol cues elicited robust activation of limbic and prefrontal regions, including ventral striatum, anterior cingulate and ventromedial prefrontal cortex."

Coordinate-based meta-analysis of 28 functional imaging studies localizes cue reactivity to the circuitry modelled in this node.

PMID:22574861 SUPPORT Human Clinical

"Cue-elicited activation of ventral striatum was most frequently correlated with behavioral measures and most frequently reduced by treatment, but these results were often derived from region-of-interest analyses that interrogated only limbic regions."

Supports the behavioural relevance of cue-elicited striatal activation while noting the region-of-interest limitation of the underlying studies.

GABAergic and Glutamatergic Neuroadaptation and Tolerance

Repeated ethanol exposure drives compensatory changes in GABA-A receptor subunit composition and upregulation of glutamatergic signalling, opposing the acute inhibitory effect. These adaptations produce tolerance while alcohol is present and leave the CNS in a hyperexcitable state when it is withdrawn. In chronic intermittent ethanol models the changes become persistent rather than transient.

glutamatergic synaptic transmission GO:0035249 ↑ INCREASED GABAergic synaptic transmission GO:0051932 ↓ DECREASED

GABA-A receptor activity GO:0004890 ↓ DECREASED

Downstream

CNS and Autonomic Hyperexcitability during Alcohol Withdrawal Removal of alcohol unmasks the compensatory hyperexcitable state.

Prefrontal Executive Control Deficit The same glutamatergic dysregulation degrades the prefrontal and insular afferents that carry top-down control over drinking.

Show evidence (2 references)

PMID:28931433 SUPPORT Model Organism

"After chronic intermittent ethanol (CIE) treatment the same changes are observed but they become persistent after 30 or more doses, lasting for at least 120 days in the rat, and probably for life."

Establishes that the receptor adaptations become durable with chronic intermittent exposure, which is what distinguishes tolerance from a transient acute effect.

PMID:25954150 SUPPORT Other

"The development of tolerance and the expression of withdrawal effects, which manifest as dependence, have been to a great extent attributed to neuroadaptations within the mesocorticolimbic and extended amygdala systems."

Attributes tolerance and withdrawal to the neuroadaptive process this node represents.

CNS and Autonomic Hyperexcitability during Alcohol Withdrawal

On abrupt cessation or reduction of drinking in a physiologically dependent person, the unopposed hyperglutamatergic and hypo-GABAergic state produces tremor, insomnia, anxiety, nausea, and autonomic hyperactivity, and can progress to generalized tonic-clonic seizures and alcohol withdrawal delirium (delirium tremens). Roughly half of people with AUD who stop abruptly develop withdrawal signs.

glutamatergic synaptic transmission GO:0035249 ↑ INCREASED

Downstream

Extended Amygdala Stress-System Recruitment Repeated withdrawal episodes recruit brain stress systems in the extended amygdala.

Compulsive Alcohol Seeking and Loss of Control Drinking to relieve or avoid withdrawal is itself one of the DSM-5 pharmacological criteria and a direct route back into consumption.

Show evidence (3 references)

PMID:34523874 SUPPORT Human Clinical

"Approximately one-half of patients with alcohol use disorder who abruptly stop or reduce their alcohol use will develop signs or symptoms of alcohol withdrawal syndrome."

Quantifies how often the withdrawal state modelled by this node occurs.

PMID:34523874 SUPPORT Human Clinical

"The syndrome is due to overactivity of the central and autonomic nervous systems, leading to tremors, insomnia, nausea and vomiting, hallucinations, anxiety, and agitation."

States the CNS and autonomic hyperexcitability mechanism and its clinical expression.

PMID:25307573 SUPPORT Other

"Clinical features of alcohol withdrawal include signs of central nervous system hyperexcitability, heightened autonomic nervous system activation, and a constellation of symptoms contributing to psychologic discomfort and negative affect."

Independent review supports the same hyperexcitability framing and links it to negative affect.

Extended Amygdala Stress-System Recruitment

Chronic alcohol exposure and repeated withdrawal recruit brain stress neurotransmitter systems — notably corticotropin-releasing factor and dynorphin acting at kappa-opioid receptors — within the central amygdala and bed nucleus of the stria terminalis. This between-system neuroadaptation is what converts withdrawal from a transient physiological event into a persistent motivational state.

response to stress GO:0006950 ↑ INCREASED

central amygdala UBERON:0002883 bed nucleus of stria terminalis UBERON:0001880

Downstream

Hyperkatifeia and Mesolimbic Reward Deficit Stress-system recruitment together with reduced dopaminergic tone produces the negative emotional state of the withdrawal stage.

Show evidence (3 references)

PMID:27475769 SUPPORT Other

"The increases in negative emotional states and dysphoric and stress-like responses in the withdrawal/negative affect stage involve decreases in the function of the dopamine component of the reward system and recruitment of brain stress neurotransmitters, such as corticotropin-releasing factor..."

Names the two mediators and the anatomical circuit modelled by this node.

PMID:22459870 SUPPORT Model Organism

"Dr. Brendan Walker presented data characterizing the effects of KOR antagonism within the extended amygdala on withdrawal-induced escalation of alcohol self-administration in dependent animals."

Preclinical kappa-opioid antagonism within the extended amygdala provides causal support for the dynorphin arm of this node.

PMID:26247973 SUPPORT Model Organism

"Intra-VTA CRF6-33 and A2B reduced EtOH intake dose dependently in mice during DID."

Local manipulation of CRF-system components reduces binge ethanol intake, supporting a causal role for CRF signalling; support is partial because the effect was seen in the ventral tegmental area, whereas intra-central amygdala infusion in the same study did not change consumption.

Hyperkatifeia and Mesolimbic Reward Deficit

The withdrawal/negative affect stage combines a deficit in reward-system function with an excess of stress-system activity, producing dysphoria, anxiety, irritability, and anhedonia that persist beyond acute withdrawal. Drinking to relieve this state is negative reinforcement, and it is a distinct motivational driver from the positive reinforcement of the binge/intoxication stage.

dopamine secretion GO:0014046 ↓ DECREASED

Downstream

Compulsive Alcohol Seeking and Loss of Control Negative reinforcement — drinking to remove an aversive internal state — sustains compulsive use independently of alcohol's rewarding effects.

Show evidence (2 references)

PMID:33318153 SUPPORT Other

"This review focuses on neurochemical/neurocircuitry dysregulations that contribute to hyperkatifeia, defined as a greater intensity of negative emotional/motivational signs and symptoms during withdrawal from drugs of abuse in the withdrawal/negative affect stage of the addiction cycle."

Defines the hyperkatifeia construct that names this node.

PMID:33318153 SUPPORT Other

"Such neurochemical/neurocircuitry dysregulations are hypothesized to mediate a negative hedonic set point that gradually gains allostatic load and shifts from a homeostatic hedonic state to an allostatic hedonic state."

The allostatic set-point account is explicitly framed as a hypothesis by its author, so it supports this node's framing only partially.

Dorsolateral Striatal Habit System Recruitment

With prolonged use, control over alcohol seeking shifts to dopamine-dependent mechanisms in the anterior dorsolateral striatum that implement habit learning. Individuals whose seeking has become more habitual — less sensitive to devaluation of the outcome — are more likely to continue seeking alcohol despite punishment.

dorsal striatum UBERON:0005382

Downstream

Compulsive Alcohol Seeking and Loss of Control Habitual control predicts the emergence of punishment-resistant, that is compulsive, seeking and drinking.

Show evidence (1 reference)

PMID:33955649 SUPPORT Model Organism

"With prolonged use, control over alcohol seeking devolves to anterior dorsolateral striatum, dopamine-dependent mechanisms implicated in habit learning and individuals in whom alcohol seeking relies more on these mechanisms are more likely to persist in seeking alcohol despite the risk of punishment."

Localizes habitual control of alcohol seeking to the dorsolateral striatum. Evidence is from alcohol-preferring rats, so the anatomical claim is not directly demonstrated in humans.

Prefrontal Executive Control Deficit

Craving and impaired executive function in the preoccupation/anticipation stage involve dysregulation of glutamatergic projections from prefrontal cortex and insula to basal ganglia and extended amygdala, degrading top-down inhibitory control over drinking. Structural imaging shows corresponding cortical thickness differences in AUD.

glutamatergic pyramidal neuron CL:0000598

glutamatergic synaptic transmission GO:0035249 ⚠ ABNORMAL

prefrontal cortex UBERON:0000451

Downstream

Compulsive Alcohol Seeking and Loss of Control Loss of top-down control removes the brake on cue- and withdrawal-motivated drinking.

Show evidence (2 references)

PMID:32643841 SUPPORT Human Clinical

"On measures of cortical thickness, AUD was associated with significant differences bilaterally in the fusiform gyrus, inferior temporal gyrus, temporal pole, superior frontal gyrus, and rostral and caudal anterior cingulate gyri."

ENIGMA-protocol meta-analysis documents frontal and cingulate cortical differences in AUD cases versus controls. Cross-sectional case-control data cannot establish the direction of causation.

PMID:32643841 SUPPORT Human Clinical

"Alcohol use disorder (AUD) and cannabis use disorder (CUD) are associated with brain alterations particularly involving fronto-cerebellar and meso-cortico-limbic circuitry."

Supports frontal involvement in the circuitry affected by AUD.

Compulsive Alcohol Seeking and Loss of Control

The convergent clinical endpoint of the cycle: compulsion to seek and consume alcohol, loss of control over intake, and continued use despite knowledge of harm. Three motivational routes feed it — cue-driven incentive salience, negative reinforcement from hyperkatifeia, and habitual control — with prefrontal executive deficit removing the counterweight.

Downstream

Sustained Heavy Alcohol Exposure and Multiorgan Toxicity Loss of control sustains the cumulative ethanol dose that produces end-organ injury.

Show evidence (1 reference)

PMID:27475769 SUPPORT Other

"Drug addiction can be defined as a chronically relapsing disorder, characterised by compulsion to seek and take the drug, loss of control in limiting intake, and emergence of a negative emotional state (eg, dysphoria, anxiety, irritability) when access to the drug is prevented."

Defines the compulsive-use endpoint modelled by this node.

Sustained Heavy Alcohol Exposure and Multiorgan Toxicity

Chronic heavy drinking produces cumulative injury across organ systems — hepatic steatosis progressing to cirrhosis, pancreatitis, cardiomyopathy, peripheral neuropathy — and, via caloric substitution and malabsorption, thiamine deficiency causing Wernicke encephalopathy and Korsakoff psychosis. These sequelae are downstream of the drinking behaviour rather than part of the CNS mechanism that produces it; alcohol-related liver disease is curated separately.

liver UBERON:0002107

Show evidence (2 references)

PMID:30281514 SUPPORT Other

"Wernicke encephalopathy (WE) and Korsakoff psychosis (KP), together termed Wernicke-Korsakoff syndrome (WKS), are distinct yet overlapping neuropsychiatric disorders associated with thiamine deficiency."

Supports the thiamine-deficiency arm of chronic alcohol-related organ injury.

PMID:30146330 SUPPORT Human Clinical

"For populations aged 50 years and older, cancers accounted for a large proportion of total alcohol-attributable deaths in 2016, constituting 27·1% (95% UI 21·2-33·3) of total alcohol-attributable female deaths and 18·9% (15·3-22·6) of male deaths."

Quantifies one major component of the end-organ disease burden produced by the sustained exposure this node represents.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

22

Cardiovascular 2

Autonomic Hyperactivity Tachycardia HP:0001649

Temporal: ACUTE

Show evidence (1 reference)

PMID:25307573 SUPPORT Other

"Clinical features of alcohol withdrawal include signs of central nervous system hyperexcitability, heightened autonomic nervous system activation, and a constellation of symptoms contributing to psychologic discomfort and negative affect."

Establishes autonomic activation as a core withdrawal feature.

Dilated Cardiomyopathy HP:0001644

Show evidence (1 reference)

PMID:30146330 SUPPORT Human Clinical

"Alcohol use is a leading risk factor for global disease burden and causes substantial health loss."

Supports alcohol as a cause of major somatic disease burden; a cardiomyopathy-specific citation is a curation gap.

Digestive 4

Nausea and Vomiting HP:0002017

Temporal: ACUTE

Show evidence (1 reference)

PMID:34523874 SUPPORT Human Clinical

"The syndrome is due to overactivity of the central and autonomic nervous systems, leading to tremors, insomnia, nausea and vomiting, hallucinations, anxiety, and agitation."

Lists nausea and vomiting among withdrawal manifestations.

Hepatic Steatosis HP:0001397

Show evidence (1 reference)

PMID:30146330 SUPPORT Human Clinical

"For populations aged 50 years and older, cancers accounted for a large proportion of total alcohol-attributable deaths in 2016, constituting 27·1% (95% UI 21·2-33·3) of total alcohol-attributable female deaths and 18·9% (15·3-22·6) of male deaths."

Documents that alcohol causes major somatic end-organ disease burden. Hepatic steatosis specifically is curated with primary evidence in the Alcoholic_Liver_Disease entry.

Cirrhosis HP:0001394

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:42070571 SUPPORT Human Clinical

"Alcohol use disorder accounts for 5% of deaths worldwide annually, and there is an urgent need for new therapeutic interventions."

Supports the lethal burden of AUD, of which liver disease is a major component; the trial report does not itself quantify cirrhosis incidence.

Pancreatitis HP:0001733

Show evidence (1 reference)

PMID:30146330 SUPPORT Human Clinical

"Alcohol use is a leading risk factor for global disease burden and causes substantial health loss."

Supports alcohol as a cause of major somatic disease burden; a pancreatitis-specific citation is a curation gap.

Nervous System 10

Tremor HP:0001337

Temporal: ACUTE

Show evidence (1 reference)

PMID:34523874 SUPPORT Human Clinical

"The syndrome is due to overactivity of the central and autonomic nervous systems, leading to tremors, insomnia, nausea and vomiting, hallucinations, anxiety, and agitation."

Lists tremor as a core alcohol withdrawal sign.

Alcohol Withdrawal Seizures Bilateral tonic-clonic seizure HP:0002069

Temporal: ACUTE

Show evidence (1 reference)

PMID:34523874 SUPPORT Human Clinical

"If untreated or inadequately treated, withdrawal can progress to generalized tonic-clonic seizures, delirium tremens, and death."

Identifies withdrawal seizures as a complication of untreated withdrawal.

Alcohol Withdrawal Delirium HP:0031258

Temporal: ACUTE Severity: SEVERE

Show evidence (1 reference)

PMID:34523874 SUPPORT Human Clinical

"If untreated or inadequately treated, withdrawal can progress to generalized tonic-clonic seizures, delirium tremens, and death."

Establishes delirium tremens as the severe end of the withdrawal spectrum.

Withdrawal Hallucinations HP:0000738

Temporal: ACUTE

Show evidence (1 reference)

PMID:34523874 SUPPORT Human Clinical

"The syndrome is due to overactivity of the central and autonomic nervous systems, leading to tremors, insomnia, nausea and vomiting, hallucinations, anxiety, and agitation."

Lists hallucinations among the withdrawal manifestations.

Insomnia HP:0100785

Show evidence (1 reference)

PMID:34523874 SUPPORT Human Clinical

"The syndrome is due to overactivity of the central and autonomic nervous systems, leading to tremors, insomnia, nausea and vomiting, hallucinations, anxiety, and agitation."

Lists insomnia among the withdrawal manifestations.

Anxiety HP:0000739

Show evidence (2 references)

PMID:34523874 SUPPORT Human Clinical

"The syndrome is due to overactivity of the central and autonomic nervous systems, leading to tremors, insomnia, nausea and vomiting, hallucinations, anxiety, and agitation."

Documents anxiety as an acute withdrawal feature.

PMID:27475769 SUPPORT Other

"Drug addiction can be defined as a chronically relapsing disorder, characterised by compulsion to seek and take the drug, loss of control in limiting intake, and emergence of a negative emotional state (eg, dysphoria, anxiety, irritability) when access to the drug is prevented."

Supports anxiety as part of the negative emotional state beyond acute withdrawal.

Depression HP:0000716

Show evidence (2 references)

PMID:32217228 SUPPORT Human Clinical

"Patients with AUD spent more time depressed and had more suicide attempts during follow-up."

Five-year prospective psychiatric cohort links comorbid AUD to a worse depressive course.

PMID:26039070 SUPPORT Human Clinical

"Significant associations were found between 12-month and lifetime AUD and other substance use disorders, major depressive and bipolar I disorders, and antisocial and borderline personality disorders across all levels of AUD severity, with odds ratios ranging from 1.2 (95% CI, 1.08-1.36) to 6.4..."

Nationally representative data quantify the association between AUD and major depressive disorder.

Memory Impairment HP:0002354

Show evidence (1 reference)

PMID:30281514 SUPPORT Other

"The identification and individualized treatment of WE based on the etiology is vital to prevent the development of the amnestic state associated with KP in genetically predisposed individuals."

Supports the amnestic phenotype arising from thiamine-deficiency complications of chronic alcohol use.

Ataxia HP:0001251

Show evidence (1 reference)

PMID:30281514 SUPPORT Other

"Wernicke encephalopathy (WE) and Korsakoff psychosis (KP), together termed Wernicke-Korsakoff syndrome (WKS), are distinct yet overlapping neuropsychiatric disorders associated with thiamine deficiency."

The review establishes Wernicke encephalopathy as a thiamine-deficiency complication; the abstract does not itself enumerate the clinical triad, so support for ataxia specifically is partial.

Peripheral Neuropathy HP:0009830

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:30146330 SUPPORT Human Clinical

"Alcohol use is a leading risk factor for global disease burden and causes substantial health loss."

The GBD analysis supports alcohol as a cause of substantial health loss but does not itemize peripheral neuropathy, so this citation supports the general claim only. A neuropathy-specific citation is a curation gap.

Other 6

Addictive Alcohol Use VERY_FREQUENT HP:0030955

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:27475769 SUPPORT Other

"Drug addiction can be defined as a chronically relapsing disorder, characterised by compulsion to seek and take the drug, loss of control in limiting intake, and emergence of a negative emotional state (eg, dysphoria, anxiety, irritability) when access to the drug is prevented."

Compulsion and loss of control over intake are the defining features of the disorder, so this phenotype is present in essentially all cases, which is the basis for the VERY_FREQUENT band.

Problematic Alcohol Consumption HP:5200329

Show evidence (1 reference)

PMID:31194891 SUPPORT Other

"This review describes and discusses the alcohol diagnoses within this section of ICD-11, including Alcohol Dependence, Harmful Pattern of Use of Alcohol, and entities such as Alcohol Intoxication, Alcohol Withdrawal, and several alcohol-induced mental disorders, and briefly covers Hazardous..."

Documents the ICD-11 diagnostic structure that grades problematic drinking into harmful use and dependence.

Craving

No `phenotype_term` is bound: HPO has no general craving term (only the food-specific HP:0030083, HP:0030221 and HP:6000785), and using one of those or a generic behavioural parent would misdescribe the claim. Needs term / NTR candidate.

Show evidence (2 references)

PMID:22574861 SUPPORT Human Clinical

"A comprehensive understanding of the neurobiology of alcohol cue reactivity is critical in identifying the neuropathology of alcohol use disorders (AUD) and developing treatments that may attenuate alcohol craving and reduce relapse risk."

Establishes craving as a central clinical target in AUD and ties it to cue reactivity.

PMID:39937469 SUPPORT Human Clinical

"significantly reduced drinks per drinking day (β, -0.41; 95% CI, -0.73 to -0.09; P = .04) and weekly alcohol craving (β, -0.39; 95% CI, -0.73 to -0.06; P = .01)"

Craving is measured prospectively as a distinct trial endpoint in AUD pharmacotherapy studies, separable from consumption measures.

Hazardous Alcohol Use HP:6000028

Show evidence (1 reference)

PMID:31194891 SUPPORT Other

"Alcohol use disorders form a key part of the section of Disorders due to Substance Use and Addictive Behaviours."

Supports the nosological placement of hazardous use alongside the alcohol use disorders; the review does not quantify how often it co-occurs with diagnosed AUD, so support is partial.

Impaired Executive Functioning HP:0033051

Show evidence (1 reference)

PMID:27475769 SUPPORT Other

"The craving and deficits in executive function in the so-called preoccupation/anticipation stage involve the dysregulation of key afferent projections from the prefrontal cortex and insula, including glutamate, to the basal ganglia and extended amygdala."

Identifies executive dysfunction as a defined domain of the addiction cycle.

Facial Flushing After Alcohol Intake HP:0001033

Show evidence (1 reference)

PMID:17718394 SUPPORT Human Clinical

"Acetaldehyde is a toxic substance whose accumulation leads to a highly aversive reaction that includes facial flushing, nausea, and rapid heart beat (i.e., tachycardia)."

Ties the flushing phenotype to acetaldehyde accumulation.

🧬

Genetic Associations

6

ADH1B (The fast-metabolizing rs1229984 (ADH1B*2) allele accelerates oxidation of ethanol to acetaldehyde, producing an aversive reaction that protects against alcohol dependence.)

Gene: ADH1B hgnc:250 relationship_type: PROTECTIVE

Show evidence (2 references)

PMID:17718394 SUPPORT Human Clinical

"For example, certain ADH1B and ADH1C alleles encode particularly active ADH enzymes, resulting in more rapid conversion of alcohol (i.e., ethanol) to acetaldehyde; these alleles have a protective effect on the risk of alcoholism."

States the protective mechanism and direction of effect for fast ADH alleles.

PMID:16822169 SUPPORT Human Clinical

"Recruitment strategy and gender moderated the effect of ADH1B*2."

Meta-analysis of ADH1B in Asian populations establishes the association and identifies moderators of its magnitude.

ALDH2 (The rs671 (ALDH2*2, Glu504Lys) allele encodes an essentially inactive mitochondrial aldehyde dehydrogenase; acetaldehyde accumulates and the resulting flushing reaction strongly protects against alcohol dependence. The allele is common in East Asian populations and essentially absent elsewhere.)

Gene: ALDH2 hgnc:404 relationship_type: PROTECTIVE

Show evidence (2 references)

PMID:17718394 SUPPORT Human Clinical

"A variant of the ALDH2 gene encodes an essentially inactive ALDH enzyme, resulting in acetaldehyde accumulation and a protective effect."

States the loss-of-function mechanism and the protective direction of effect.

PMID:16822169 SUPPORT Human Clinical

"Diagnostic criteria, recruitment strategy, and Japanese ethnicity moderated the effect of ALDH2*2."

Meta-analysis quantifying the ALDH2*2 protective effect in Asian populations and its moderators.

GABRA2 (One of the earliest and most replicated non-metabolic susceptibility loci, implicating GABA-A receptor-mediated inhibitory signalling and neural excitability in dependence risk.)

Gene: GABRA2 hgnc:4076 relationship_type: SUSCEPTIBILITY

Show evidence (2 references)

PMID:15024690 SUPPORT Human Clinical

"Thirty-one SNPs in GABRA2, but only 1 of the 20 SNPs in the flanking genes, showed significant association with alcoholism."

Family-based association study localizing the signal specifically to GABRA2 within the chromosome 4p GABA-A receptor gene cluster.

PMID:15024690 SUPPORT Human Clinical

"No coding differences were found between the high-risk and low-risk haplotypes, suggesting that the effect is mediated through gene regulation."

Characterizes the likely regulatory rather than coding mechanism of the GABRA2 association.

OPRM1 (The common A118G (rs1799971) variant of the mu-opioid receptor gene has been proposed as a moderator of alcohol-induced euphoria and of naltrexone treatment response. The pharmacogenomic claim is contested: a genotype-stratified randomized trial found no effect of rs1799971 on naltrexone response, and routine genotyping is not clinically indicated.)

Gene: OPRM1 hgnc:8156 relationship_type: MODIFIER

Show evidence (2 references)

PMID:22909206 SUPPORT Human Clinical

"Although screening of patients in a clinical setting remains premature, results suggest the A118G substitution may influence one etiological pathway to alcoholism, for which naltrexone pharmacotherapy is more effective."

Review supporting a modifier role while explicitly cautioning that clinical screening is premature.

PMID:38706338 REFUTE Human Clinical

"Neither rs2832407 nor rs1799971 had effects on topiramate and naltrexone treatments, respectively."

A prospective genotype-stratified randomized trial refutes a clinically actionable pharmacogenomic effect of OPRM1 rs1799971 on naltrexone response.

GCKR (Beyond the metabolic loci, liability to problematic alcohol use is spread across many common variants of small effect, including consumption-linked metabolic loci such as GCKR. The largest cross-ancestry meta-analysis identified 110 independent risk variants.)

Gene: GCKR hgnc:4196 relationship_type: SUSCEPTIBILITY

Show evidence (2 references)

PMID:38062264 SUPPORT Human Clinical

"Here we conducted a large cross-ancestry meta-analysis of PAU in 1,079,947 individuals (European, N = 903,147; African, N = 122,571; Latin American, N = 38,962; East Asian, N = 13,551; and South Asian, N = 1,716 ancestries)."

Establishes the scale and multi-ancestry composition of the discovery sample from which the polygenic architecture is inferred.

PMID:38062264 SUPPORT Human Clinical

"Genetic correlations between PAU and other traits were observed in multiple ancestries, with other substance use traits having the highest correlations."

Documents shared genetic liability between problematic alcohol use and other substance use disorders.

KLB (Beta-klotho, the co-receptor for FGF21, is a replicated locus for alcohol consumption phenotypes, implicating a liver-brain endocrine axis in the regulation of alcohol preference.)

Gene: KLB hgnc:15527 relationship_type: SUSCEPTIBILITY

Show evidence (1 reference)

PMID:38062264 SUPPORT Human Clinical

"Prioritizing genes through gene expression and chromatin interaction in brain tissues identified multiple genes associated with PAU."

The multi-ancestry GWAS supports brain-expressed gene prioritization for problematic alcohol use; it does not name KLB in the abstract, so this citation supports the polygenic framing rather than the specific KLB claim. A KLB-specific primary citation is a curation gap.

💊

Medical Actions

12

Oral Naltrexone

Action: Pharmacotherapy NCIT:C15986

Agent: naltrexone CHEBI:7465

Mu-opioid receptor antagonist that blunts the reinforcing effects of alcohol; a first-line pharmacotherapy at 50 mg/d, reducing both return to any drinking and return to heavy drinking. A long-acting injectable formulation is also approved.

Mechanism Target:

INHIBITS Mesolimbic Dopamine and Endogenous Opioid Reward Signaling — Opioid receptor antagonism interrupts the endogenous-opioid step by which alcohol raises mesolimbic dopamine, reducing alcohol's rewarding effect.

Show evidence (1 reference)

PMID:22909206 SUPPORT Human Clinical

"This article critically evaluates the evidence that the A118G substitution affects subjective, behavioral and neurobiological responses to alcohol and the opioid receptor antagonist, naltrexone."

Frames naltrexone as an opioid receptor antagonist acting on the subjective and neurobiological response to alcohol.

Show evidence (2 references)

PMID:37934220 SUPPORT Human Clinical

"Compared with placebo, oral naltrexone (50 mg/d) was associated with lower rates of return to heavy drinking, with a number needed to treat of 11 (95% CI, 5-41)."

Systematic review and meta-analysis of 118 trials quantifies the efficacy of oral naltrexone.

PMID:37934220 SUPPORT Human Clinical

"In conjunction with psychosocial interventions, these findings support the use of oral naltrexone at 50 mg/d and acamprosate as first-line pharmacotherapies for alcohol use disorder."

States the first-line recommendation and the requirement for concurrent psychosocial treatment.

Extended-Release Injectable Naltrexone

Action: Pharmacotherapy NCIT:C15986

Agent: naltrexone CHEBI:7465

Monthly intramuscular naltrexone (XR-NTX), a separately approved formulation of the same mu-opioid antagonist. Modelled apart from the oral drug because the once-monthly route removes daily adherence from the equation, which is the main practical reason to choose it, and because the trial evidence is reported separately.

Mechanism Target:

INHIBITS Mesolimbic Dopamine and Endogenous Opioid Reward Signaling — Same mu-opioid antagonism as the oral formulation, delivered on a monthly schedule.

Show evidence (1 reference)

PMID:37934220 SUPPORT Human Clinical

"Injectable naltrexone was associated with fewer drinking days over the 30-day treatment period (weighted mean difference, -4.99 days; 95% CI, -9.49 to -0.49 days)"

The same systematic review reports the injectable formulation's effect separately from oral naltrexone.

Acamprosate

Action: Pharmacotherapy NCIT:C15986

Agent: acamprosate CHEBI:51041

Modulator of glutamatergic and GABAergic signalling used to maintain abstinence after withdrawal, hypothesized to normalize the post-withdrawal hyperglutamatergic state. First-line alongside naltrexone.

Mechanism Target:

INHIBITS GABAergic and Glutamatergic Neuroadaptation and Tolerance — Acamprosate is used to counteract the persistent glutamatergic hyperexcitability left by chronic alcohol exposure.

Show evidence (1 reference)

PMID:25954150 SUPPORT Other

"Given the hyperglutamatergic/hyperexcitable state of the central nervous system induced by chronic alcohol abuse and withdrawal, the evidence thus far indicates that a restoration of glutamatergic concentrations and activity within the mesocorticolimbic system and extended amygdala as well as..."

Supports normalization of glutamatergic signalling as a treatment strategy for the neuroadaptive state; the review does not attribute this specific mechanism to acamprosate, so support is partial.

Show evidence (2 references)

PMID:37934220 SUPPORT Human Clinical

"The numbers needed to treat to prevent 1 person from returning to any drinking were 11 (95% CI, 1-32) for acamprosate and 18 (95% CI, 4-32) for oral naltrexone at a dose of 50 mg/d."

Quantifies acamprosate efficacy for preventing return to any drinking.

PMID:35653782 SUPPORT Human Clinical

"Our review found that acamprosate (2-3 g/d), disulfiram (250-500 mg/d), baclofen (30 mg/d), and oral naltrexone (50 mg/d) had the best evidence for improving abstinence and heavy drinking for patients with AUD."

Network meta-analysis of 156 trials independently supports acamprosate dosing and efficacy.

Disulfiram

Action: Pharmacotherapy NCIT:C15986

Agent: disulfiram CHEBI:4659

Aldehyde dehydrogenase inhibitor that makes drinking aversive by reproducing the acetaldehyde flush reaction. Deterrent rather than anti-craving, so its efficacy depends on supervised administration.

Mechanism Target:

ACTIVATES Aversive Acetaldehyde Accumulation and Flushing Response — By inhibiting ALDH, disulfiram deliberately induces the same acetaldehyde accumulation that protects ALDH2*2 carriers.

Show evidence (1 reference)

PMID:17718394 SUPPORT Human Clinical

"This reaction is similar to that experienced by alcoholics who consume alcohol after taking disulfiram"

Explicitly equates the disulfiram reaction with the genetically determined acetaldehyde flush this node models.

Show evidence (1 reference)

PMID:35653782 SUPPORT Human Clinical

"For reduced heavy drinking, disulfiram (RR = 0.19; 95% CI, 0.10-0.35), baclofen (RR = 0.72; 95% CI, 0.57-0.91), acamprosate (RR = 0.78; 95% CI, 0.70-0.86), and oral naltrexone (RR = 0.81; 95% CI, 0.73-0.90) were efficacious against placebo."

Network meta-analysis reports disulfiram efficacy for reducing heavy drinking.

Topiramate

Action: Pharmacotherapy NCIT:C15986

Agent: topiramate CHEBI:63631

Off-label anticonvulsant with glutamatergic and GABAergic actions. In a genotype-stratified head-to-head randomized trial it was at least as effective as naltrexone for heavy drinking and superior for craving, BMI, and gamma-glutamyltransferase.

Show evidence (1 reference)

PMID:38706338 SUPPORT Human Clinical

"Topiramate is at least as effective and safe as the first-line medication, naltrexone, in reducing heavy alcohol consumption, and superior in reducing some clinical outcomes."

Head-to-head 12-week randomized trial supports topiramate as an alternative to naltrexone.

Gabapentin

Action: Pharmacotherapy NCIT:C15986

Agent: gabapentin CHEBI:42797

Off-label agent used for mild withdrawal symptoms and for withdrawal-adjacent anxiety and insomnia in early abstinence; also improves total abstinence relative to placebo in network meta-analysis.

Show evidence (2 references)

PMID:35653782 SUPPORT Human Clinical

"gabapentin (RR = 1.66; 95% CI, 1.04-2.67), acamprosate (RR = 1.33; 95% CI, 1.15-1.54), and oral naltrexone (RR = 1.15; 95% CI, 1.01-1.32) improved total abstinence over placebo"

Network meta-analysis quantifies gabapentin's effect on total abstinence.

PMID:34523874 SUPPORT Human Clinical

"Mild symptoms can be treated with carbamazepine or gabapentin."

Supports gabapentin for mild withdrawal symptoms in ambulatory management.

Baclofen

Action: Pharmacotherapy NCIT:C15986

Agent: baclofen CHEBI:2972

GABA-B receptor agonist used off-label for AUD, particularly in Europe and in patients with hepatic impairment. Network meta-analysis places it among the agents with the best evidence for abstinence and reduced heavy drinking, and it caused fewer dropouts than placebo.

Show evidence (2 references)

PMID:35653782 SUPPORT Human Clinical

"Our review found that acamprosate (2-3 g/d), disulfiram (250-500 mg/d), baclofen (30 mg/d), and oral naltrexone (50 mg/d) had the best evidence for improving abstinence and heavy drinking for patients with AUD."

Network meta-analysis of 156 trials places baclofen among the best-evidenced agents and gives its dose.

PMID:35653782 SUPPORT Human Clinical

"Baclofen (RR = 0.83; 95% CI, 0.70-0.97) and pregabalin (RR = 0.63; 95% CI, 0.43-0.94) caused fewer dropouts than placebo."

Quantifies baclofen's tolerability relative to placebo in the same network meta-analysis.

Benzodiazepine Withdrawal Management

Action: Pharmacotherapy NCIT:C15986

Agent: benzodiazepine NCIT:C1012

Benzodiazepines are first-line for moderate to severe alcohol withdrawal, given on a symptom-triggered or fixed schedule, and are what prevent progression to withdrawal seizures and delirium tremens. This treats the acute withdrawal syndrome, not the underlying disorder — long-term AUD treatment must be offered in addition.

Mechanism Target:

INHIBITS CNS and Autonomic Hyperexcitability during Alcohol Withdrawal — Positive allosteric modulation of GABA-A receptors substitutes for the lost ethanol-driven inhibition, suppressing the hyperexcitable state.

Show evidence (1 reference)

PMID:34523874 SUPPORT Human Clinical

"Benzodiazepines are first-line therapy for moderate to severe symptoms, with carbamazepine and gabapentin as potential adjunctive or alternative therapies."

Establishes benzodiazepines as the first-line treatment for the withdrawal state this node represents.

Show evidence (1 reference)

PMID:34523874 SUPPORT Human Clinical

"Primary care physicians should offer to initiate long-term treatment for alcohol use disorder, including pharmacotherapy, in addition to withdrawal management."

Makes explicit that withdrawal management alone is not treatment of the disorder.

Thiamine Repletion

Action: Supportive Care NCIT:C15747

Agent: thiamine CHEBI:18385

Parenteral thiamine given to prevent and treat Wernicke encephalopathy in people with chronic heavy alcohol use, administered before glucose to avoid precipitating the syndrome.

Show evidence (1 reference)

PMID:30281514 SUPPORT Other

"The identification and individualized treatment of WE based on the etiology is vital to prevent the development of the amnestic state associated with KP in genetically predisposed individuals."

Supports early treatment of Wernicke encephalopathy to prevent the irreversible Korsakoff amnestic state.

Cognitive Behavioral Therapy

Action: Cognitive Behavior Therapy NCIT:C64345

Structured psychosocial treatment targeting drinking-related cognitions, coping skills, and relapse prevention. More effective than no treatment, minimal treatment, or a nonspecific control, though not superior to other specific active therapies.

Show evidence (2 references)

PMID:31599606 SUPPORT Human Clinical

"The current meta-analysis shows that CBT is more effective than a no treatment, minimal treatment, or nonspecific control."

Meta-analysis of 30 randomized controlled trials quantifies CBT efficacy against each contrast condition.

PMID:31599606 SUPPORT Human Clinical

"CBT effects in contrast to a specific therapy were consistently nonsignificant across outcomes and follow-up time points."

Bounds the claim: CBT is not superior to other specific evidence-based modalities.

Alcoholics Anonymous and Twelve-Step Facilitation

Action: Behavioral Counseling NCIT:C181743

Peer-led mutual-help participation and professionally delivered twelve-step facilitation. Manualized twelve-step facilitation outperforms other established treatments including CBT for increasing abstinence, and probably produces substantial healthcare cost savings.

Show evidence (2 references)

PMID:32159228 SUPPORT Human Clinical

"There is high quality evidence that manualized AA/TSF interventions are more effective than other established treatments, such as CBT, for increasing abstinence."

Cochrane review conclusion on manualized twelve-step facilitation.

PMID:32159228 SUPPORT Human Clinical

"AA/TSF probably produces substantial healthcare cost savings among people with alcohol use disorder."

Supports the health-economic component of the same Cochrane review.

Semaglutide (investigational)

Action: Pharmacotherapy NCIT:C15986

Agent: semaglutide CHEBI:167574

GLP-1 receptor agonist under investigation for AUD. A phase 2 trial in 48 non-treatment-seeking adults reduced laboratory alcohol self-administration and weekly craving, and a 26-week trial in 108 treatment-seeking patients with AUD and comorbid obesity, on a background of cognitive behavioural therapy, reduced heavy drinking days relative to placebo. Not approved for this indication.

Show evidence (2 references)

PMID:39937469 SUPPORT Human Clinical

"These findings provide initial prospective evidence that low-dose semaglutide can reduce craving and some drinking outcomes, justifying larger clinical trials to evaluate GLP-1RAs for alcohol use disorder."

Phase 2 randomized trial establishes preliminary efficacy on craving and some drinking outcomes.

PMID:42070571 SUPPORT Human Clinical

"Semaglutide was associated with a reduction in heavy drinking days (-41·1 percentage points from baseline, 95% CI -48·7 to -33·5) compared with placebo (-26·4, -34·1 to -18·6; estimated treatment difference -13·7 percentage points, -22·0 to -5·4; p=0·0015), and had substantial effects on..."

A 26-week randomized placebo-controlled trial quantifies the reduction in heavy drinking days in patients with AUD and comorbid obesity.

🌍

Environmental Factors

1

Chronic heavy alcohol consumption

Repeated exposure to ethanol is the necessary environmental cause: no amount of genetic liability produces AUD without drinking. Pattern matters as well as volume — heavy episodic (binge) drinking and early age of drinking onset are established risk amplifiers.

Show evidence (1 reference)

PMID:30146330 SUPPORT Human Clinical

"The level of alcohol consumption that minimised harm across health outcomes was zero (95% UI 0·0-0·8) standard drinks per week."

GBD analysis of 195 countries characterizes the dose-response of alcohol exposure to health harm.

Mechanism Target:

TRIGGERS Ethanol Exposure and Acetaldehyde-Generating Oxidative Metabolism — Ingestion is the route by which ethanol enters the oxidative metabolic pathway and reaches the brain.

Show evidence (1 reference)

PMID:17718394 SUPPORT Human Clinical

"The main site of ethanol metabolism is the liver, although some metabolism also occurs in other tissues and can cause local damage there."

Establishes that ingested ethanol is routed into hepatic oxidative metabolism, the mechanism node this exposure triggers.

TRIGGERS GABAergic and Glutamatergic Neuroadaptation and Tolerance — Chronic intermittent exposure, rather than any single dose, is what makes the receptor adaptations persistent.

Show evidence (1 reference)

PMID:28931433 SUPPORT Model Organism

"After chronic intermittent ethanol (CIE) treatment the same changes are observed but they become persistent after 30 or more doses, lasting for at least 120 days in the rat, and probably for life."

Shows that repeated exposure is the variable that converts transient receptor plasticity into a durable adaptation.

🔬

Biochemical Markers

4

Phosphatidylethanol (PEth) (Elevated with recent heavy alcohol consumption)

Show evidence (2 references)

PMID:37569551 SUPPORT Human Clinical

"In recent years, phosphatidylethanol (PEth) in blood has emerged as a marker of unhealthy alcohol use."

Systematic review establishes PEth as a biomarker of unhealthy alcohol use.

PMID:37569551 SUPPORT Human Clinical

"PEth interpretative cut-offs varied greatly among the included records, ranging from 4.2 ng/mL to 250 ng/mL, with sensitivity and specificity in the ranges of 58-100% and 64-100%, respectively."

Quantifies the wide variation in reported cut-offs and diagnostic accuracy, which limits how prescriptively the marker can be used.

Gamma-Glutamyltransferase (GGT) (Elevated with sustained heavy alcohol consumption)

Reference Ranges

Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma –85.0 U/L (males; screening cutoff for heavy drinking)

Cutoff for detecting heavy drinking, not a general clinical reference interval. The LOINC code was verified against the NLM clinical-tables LOINC service; LOINC is not covered by the repository's OAK term validation.

Show evidence (1 reference)

PMID:17767129 SUPPORT Human Clinical

"The GGT test used a cutoff of 85 U/L for males and 65 U/L for females."

Source of the sex-specific GGT cutoffs used to screen for heavy drinking.

Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma –65.0 U/L (females; screening cutoff for heavy drinking)

Cutoff for detecting heavy drinking, not a general clinical reference interval. The LOINC code was verified against the NLM clinical-tables LOINC service; LOINC is not covered by the repository's OAK term validation.

Show evidence (1 reference)

PMID:17767129 SUPPORT Human Clinical

"The GGT test used a cutoff of 85 U/L for males and 65 U/L for females."

Source of the sex-specific GGT cutoffs used to screen for heavy drinking.

Show evidence (2 references)

PMID:16799164 SUPPORT Human Clinical

"The sensitivity of GGT-CDT (90%) in correctly classifying heavy drinkers exceeded that of CDT (63%), GGT (58%), mean corpuscular volume (MCV) (45%), aspartate aminotransferase (AST) (47%), and alanine aminotransferase (ALT) (50%), being also essentially similar for alcoholics with (93%) or..."

Quantifies the sensitivity of each conventional marker and of the combined GGT-CDT index in a cohort of 165 heavy drinkers against moderate-drinker and abstainer references.

PMID:16799164 SUPPORT Human Clinical

"GGT-CDT improves the sensitivity of detecting excessive ethanol consumption as compared with the traditional markers of ethanol consumption."

States the study's conclusion that the combined GGT-CDT index outperforms the individual conventional markers.

Carbohydrate-Deficient Transferrin (CDT) (Elevated with sustained heavy alcohol consumption)

Reference Ranges

Transferrin.carbohydrate deficient/Transferrin.total in Serum or Plasma –1.7 % (adults; %disialotransferrin by HPLC candidate reference method)

The LOINC code was verified against the NLM clinical-tables LOINC service; LOINC is not covered by the repository's OAK term validation.

Show evidence (1 reference)

PMID:25698630 SUPPORT Human Clinical

"Serum CDT was measured by the candidate HPLC reference method and expressed as relative amount of disialotransferrin (%DST: cutoff 1.7%)."

Source of the %CDT (disialotransferrin) upper-limit cutoff used clinically.

Mean Corpuscular Volume (MCV) (Elevated with sustained heavy alcohol consumption (macrocytosis))

Reference Ranges

MCV [Entitic mean volume] in Red Blood Cells –96.0 fL (abstainers (NORIP reference data))

The LOINC code was verified against the NLM clinical-tables LOINC service; LOINC is not covered by the repository's OAK term validation.

Show evidence (1 reference)

PMID:16581347 SUPPORT Human Clinical

"the upper normal limit for MCV based on the data from moderate drinkers was 98 fl, as compared with 96 fl from abstainers"

Source of the abstainer upper normal limit for MCV, derived from NORIP reference data.

MCV [Entitic mean volume] in Red Blood Cells –98.0 fL (moderate drinkers (NORIP reference data))

The higher upper limit in moderate drinkers versus abstainers itself reflects a dose-related response of MCV to ethanol intake. The LOINC code was verified against the NLM clinical-tables LOINC service; LOINC is not covered by the repository's OAK term validation.

Show evidence (1 reference)

PMID:16581347 SUPPORT Human Clinical

"the upper normal limit for MCV based on the data from moderate drinkers was 98 fl, as compared with 96 fl from abstainers"

Source of the moderate-drinker upper normal limit for MCV, derived from NORIP reference data.

Show evidence (1 reference)

PMID:16799164 SUPPORT Human Clinical

"The sensitivity of GGT-CDT (90%) in correctly classifying heavy drinkers exceeded that of CDT (63%), GGT (58%), mean corpuscular volume (MCV) (45%), aspartate aminotransferase (AST) (47%), and alanine aminotransferase (ALT) (50%), being also essentially similar for alcoholics with (93%) or..."

Quantifies MCV's individual sensitivity (45%) for classifying heavy drinkers, well below the combined GGT-CDT index.

🔬

Diagnosis

2

DSM-5 and ICD-11 clinical diagnostic criteria

Diagnosis is clinical and behavioural. DSM-5 requires at least 2 of 11 criteria within 12 months, graded mild/moderate/severe by symptom count. ICD-11 places alcohol diagnoses within Disorders due to Substance Use and Addictive Behaviours, distinguishing Harmful Pattern of Use of Alcohol from Alcohol Dependence, with Hazardous Alcohol Use listed separately as a health risk factor. There is no genetic or laboratory confirmatory test.

Show evidence (1 reference)

PMID:31194891 SUPPORT Other

"This review describes and discusses the alcohol diagnoses within this section of ICD-11, including Alcohol Dependence, Harmful Pattern of Use of Alcohol, and entities such as Alcohol Intoxication, Alcohol Withdrawal, and several alcohol-induced mental disorders, and briefly covers Hazardous..."

Authoritative description of the ICD-11 alcohol diagnostic structure.

AUDIT and AUDIT-C screening

The WHO Alcohol Use Disorders Identification Test and its 3-item short form AUDIT-C are the dominant screening instruments and the usual phenotype definition in large genetic studies. Both are self-report and subject to recall bias and under-reporting, which is the rationale for complementary objective biomarkers such as PEth.

Show evidence (2 references)

PMID:37569551 SUPPORT Human Clinical

"The Alcohol Use Disorders Identification Test (AUDIT) and its short form, the AUDIT-C, the main clinical instruments used to identify unhealthy drinking behaviors, are influenced by memory bias and under-reporting."

Identifies AUDIT/AUDIT-C as the main screening instruments and states their principal limitation.

PMID:34523874 SUPPORT Human Clinical

"The three-question Alcohol Use Disorders Identification Test-Consumption and the Single Alcohol Screening Question instrument have the best accuracy for assessing unhealthy alcohol use in adults 18 years and older."

Supports AUDIT-C as a preferred screening instrument on accuracy grounds.

📊

Prevalence

2

US adults (NESARC-III, 2012-2013, DSM-5 criteria), 12-month

Period Prevalence 13900.0 per 100,000 >1 in 1,000

12-month prevalence of DSM-5 AUD in a nationally representative US adult sample (N = 36,309).

Show evidence (1 reference)

PMID:26039070 SUPPORT Human Clinical

"Twelve-month and lifetime prevalences of AUD were 13.9% and 29.1%, respectively."

NESARC-III provides the reference US 12-month prevalence estimate for DSM-5 AUD.

US adults (NESARC-III, 2012-2013, DSM-5 criteria), lifetime

Lifetime Prevalence 29100.0 per 100,000 >1 in 1,000

Lifetime prevalence of DSM-5 AUD; prevalence was highest in men (36.0% lifetime) and in younger and never-married adults.

Show evidence (2 references)

PMID:26039070 SUPPORT Human Clinical

"Twelve-month and lifetime prevalences of AUD were 13.9% and 29.1%, respectively."

The same NESARC-III survey reports the lifetime figure alongside the 12-month figure.

PMID:26039070 SUPPORT Human Clinical

"Prevalence was generally highest for men (17.6% and 36.0%, respectively), white (14.0% and 32.6%, respectively) and Native American (19.2% and 43.4%, respectively), respondents, and younger (26.7% and 37.0%, respectively) and previously married (11.4% and 27.1%, respectively) or never married..."

Documents the demographic stratification underlying the pooled lifetime estimate.

⚖️

Clinical Burden

High

AUD is disabling in proportion to severity, is a leading global risk factor for death and disability, and its complications span liver disease, cancer, injury, and suicide. Burden is compounded by a very large treatment gap: only about one in five people with lifetime AUD is ever treated.

Show evidence (3 references)

PMID:30146330 SUPPORT Human Clinical

"Globally, alcohol use was the seventh leading risk factor for both deaths and DALYs in 2016"

GBD 2016 ranks alcohol among the leading global contributors to death and disability.

PMID:30146330 SUPPORT Human Clinical

"Among the population aged 15-49 years, alcohol use was the leading risk factor globally in 2016, with 3·8% (95% UI 3·2-4·3) of female deaths and 12·2% (10·8-13·6) of male deaths attributable to alcohol use."

Establishes alcohol as the leading risk factor in working-age adults, supporting a HIGH burden assignment.

PMID:26039070 SUPPORT Human Clinical

"Only 19.8% of respondents with lifetime AUD were ever treated."

Quantifies the treatment gap that compounds the burden of the disorder.

🔬

Clinical Trials

2

NCT05520775 PHASE_II COMPLETED

Phase 2 double-blind randomized parallel-arm trial of once-weekly subcutaneous semaglutide over 9 weeks in 48 non-treatment-seeking adults with AUD, with laboratory alcohol self-administration as the primary outcome.

Target Phenotypes: Addictive alcohol use HP:0030955

Show evidence (1 reference)

PMID:39937469 SUPPORT Human Clinical

"Low-dose semaglutide reduced the amount of alcohol consumed during a posttreatment laboratory self-administration task, with evidence of medium to large effect sizes for grams of alcohol consumed"

Reports the primary laboratory self-administration outcome of this trial.

NCT05895643 PHASE_II COMPLETED

26-week single-centre randomized double-blind placebo-controlled trial of once-weekly semaglutide 2.4 mg added to standard cognitive behavioural therapy in 108 treatment-seeking patients with moderate to severe AUD and comorbid obesity, with reduction in heavy drinking days as the primary endpoint.

Target Phenotypes: Problematic alcohol consumption HP:5200329

Show evidence (1 reference)

PMID:42070571 SUPPORT Human Clinical

"Semaglutide showed robust therapeutic effects in treatment-seeking participants with obesity and alcohol use disorder and this trial supports previous preclinical and clinical findings suggesting GLP-1 receptor agonists as a potential novel treatment target for alcohol use disorder."

States the trial's overall conclusion for its treatment-seeking, comorbid-obesity population.

🐁

Animal Models

3

Selectively bred alcohol-preferring (P) and high-alcohol-drinking (HAD1, HAD2) lines Rattus norvegicus Selectively bred (polygenic) rat lines

Bidirectional selective breeding for voluntary ethanol preference produced the P and HAD lines, which drink to pharmacologically relevant blood alcohol concentrations without induction. They are the reference polygenic rodent model for AUD liability and supply the compulsive- and relapse-drinking paradigms this entry's habit and negative-reinforcement nodes depend on. Limitation: they model early-onset high-consumption liability rather than the full DSM-5 criterion set, and their alcohol pharmacokinetics differ from human.

Species

Rattus norvegicus

Genotype

Selectively bred alcohol-preferring (P) and high-alcohol-drinking (HAD1, HAD2) lines

Show evidence (2 references)

PMID:24268381 SUPPORT Model Organism

"The P line of rats meets all of the originally proposed criteria for a suitable animal model of alcoholism."

States that the P line satisfies the accepted formal criteria for an animal model of alcoholism.

PMID:24268381 SUPPORT Model Organism

"The P line also exhibits excessive binge-like alcohol drinking, attaining blood alcohol concentrations (BACs) of 200 mg% on a daily basis."

Documents that the model reaches pharmacologically meaningful blood alcohol concentrations, which is what makes it usable for the binge/intoxication stage.

High Alcohol Preferring (HAP1, HAP2) and Low Alcohol Preferring (LAP1, LAP2) lines Mus musculus Bidirectionally selectively bred mouse lines

The only extant mouse lines bred specifically for divergent alcohol preference, and therefore the main mouse resource for mapping loci that influence voluntary consumption. Because the lines are not inbred, they support QTL designs that inbred strains cannot.

Species

Mus musculus

Genotype

High Alcohol Preferring (HAP1, HAP2) and Low Alcohol Preferring (LAP1, LAP2) lines

Show evidence (2 references)

PMID:16482403 SUPPORT Model Organism

"The High- and Low-Alcohol Preferring (HAP1/LAP1 and HAP2/LAP2) mouse lines were developed by selective breeding for differences in alcohol preference."

Establishes the derivation and purpose of the HAP/LAP lines.

PMID:16482403 SUPPORT Model Organism

"They represent the only extant selectively bred mouse lines developed for this alcohol phenotype."

Supports the claim that these are the unique mouse resource for this phenotype.

High Drinking in the Dark (HDID-1, HDID-2) selected lines, from an HS/Npt heterogeneous stock Mus musculus Selectively bred model of drinking to intoxication

Bred specifically for reaching high blood alcohol concentrations in a limited-access binge paradigm, so this is the model of the binge/intoxication stage rather than of preference per se. Mechanistically informative in a negative direction: the high-drinking phenotype tracks reduced sensitivity to alcohol's aversive effects, not increased sensitivity to its rewarding effects, which qualifies any assumption that heavy drinking simply reflects greater reward.

Species

Mus musculus

Genotype

High Drinking in the Dark (HDID-1, HDID-2) selected lines, from an HS/Npt heterogeneous stock

Show evidence (2 references)

PMID:23910826 SUPPORT Model Organism

"These results indicate that high blood alcohol levels after drinking in the HDID mice is genetically related to attenuated aversion to alcohol, while sensitivity to alcohol reward is not altered in these mice."

Dissociates aversion sensitivity from reward sensitivity in the binge-drinking model, constraining how the reward node may be extrapolated from it.

PMID:23910826 SUPPORT Model Organism

"HDID and HS mice showed comparable development of alcohol-induced conditioned place preference."

Shows no difference in conditioned reward between the selected line and its progenitor stock, the observation the dissociation rests on.

{ }

Source YAML

click to show

name: Alcohol Use Disorder
creation_date: "2026-08-09T14:40:00Z"
category: Psychiatric
description: >-
  Alcohol use disorder (AUD) is a chronic, relapsing substance use disorder
  defined by impaired control over alcohol intake, continued drinking despite
  harm, and the emergence of a negative emotional state during abstinence.
  DSM-5 merged the earlier DSM-IV categories of alcohol abuse and alcohol
  dependence into a single graded diagnosis (mild/moderate/severe), while
  ICD-11 retains a distinction between harmful pattern of use of alcohol and
  alcohol dependence. Its pathophysiology is conventionally organized as a
  three-stage neuroadaptive cycle — binge/intoxication, withdrawal/negative
  affect, and preoccupation/anticipation — mapped onto basal ganglia, extended
  amygdala, and prefrontal circuits respectively.
disease_term:
  preferred_term: alcohol use disorder
  term:
    id: MONDO:0007079
    label: alcohol dependence
synonyms:
- Alcoholism
- Alcohol dependence
- Alcohol addiction
- Problematic alcohol use
parents:
- Substance Use Disorder
- Mental Health Disorder
notes: >-
  Terminology and identifier caveat. MONDO has no single term for the DSM-5
  construct "alcohol use disorder"; it carries the two pre-DSM-5 entities
  separately (MONDO:0007079 alcohol dependence, OMIM:103780, ICD10CM:F10.2;
  and MONDO:0002046 alcohol abuse, ICD10CM:F10.1). This entry is bound to
  MONDO:0007079 because that is the term carrying the OMIM susceptibility
  entry and the dependence phenotype that most of the cited mechanism
  literature studies, and the entry name uses the current clinical label.
  Curators adding claims specific to the narrower DSM-IV "alcohol abuse" pole
  should say so explicitly rather than assuming the binding covers it.

  Somatic sequelae of chronic heavy drinking are deliberately kept shallow
  here. Alcohol-related liver disease has its own dismech entry
  (Alcoholic_Liver_Disease); this entry models the CNS disorder of drinking
  behaviour and treats end-organ damage as a downstream consequence node with
  representative phenotypes rather than re-deriving those cascades.

  Known curation gaps, recorded rather than papered over. (1) The
  neuroimmune/neuroinflammatory arm (ethanol- and acetaldehyde-driven TLR4
  signalling in microglia and Kupffer cells) is a real mechanism surfaced by
  the deep-research pass but is not modelled here as its own node, because no
  abstract-quotable primary source for it was verified in this session; it is
  referenced only obliquely via the neuroimmune term in the cited hyperkatifeia
  review. (2) Several end-organ phenotypes (peripheral neuropathy,
  cardiomyopathy, pancreatitis) currently carry only a general
  alcohol-burden citation at `supports: PARTIAL`; each needs an organ-specific
  primary reference. (3) Psychiatric comorbidity (major depressive disorder,
  anxiety disorders, PTSD, bipolar disorder) is captured here only as
  phenotypes with association statistics. The bidirectional relationship
  belongs in a `kb/comorbidities/` entry — the `Disease` class has no
  `comorbidities` slot — and is left as follow-up work rather than forced into
  this entry.
prevalence:
- population: US adults (NESARC-III, 2012-2013, DSM-5 criteria), 12-month
  measure_type: PERIOD_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 13900.0
  notes: 12-month prevalence of DSM-5 AUD in a nationally representative US adult sample (N = 36,309).
  evidence:
  - reference: PMID:26039070
    reference_title: "Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Twelve-month and lifetime prevalences of AUD were 13.9% and 29.1%,
      respectively.
    explanation: >-
      NESARC-III provides the reference US 12-month prevalence estimate for
      DSM-5 AUD.
- population: US adults (NESARC-III, 2012-2013, DSM-5 criteria), lifetime
  measure_type: LIFETIME_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 29100.0
  notes: >-
    Lifetime prevalence of DSM-5 AUD; prevalence was highest in men (36.0%
    lifetime) and in younger and never-married adults.
  evidence:
  - reference: PMID:26039070
    reference_title: "Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Twelve-month and lifetime prevalences of AUD were 13.9% and 29.1%,
      respectively.
    explanation: >-
      The same NESARC-III survey reports the lifetime figure alongside the
      12-month figure.
  - reference: PMID:26039070
    reference_title: "Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Prevalence was generally highest for men (17.6% and 36.0%,
      respectively), white (14.0% and 32.6%, respectively) and Native American
      (19.2% and 43.4%, respectively), respondents, and younger (26.7% and
      37.0%, respectively) and previously married (11.4% and 27.1%,
      respectively) or never married (25.0% and 35.5%, respectively) adults.
    explanation: >-
      Documents the demographic stratification underlying the pooled lifetime
      estimate.
clinical_burden:
  burden_level: HIGH
  rationale: >-
    AUD is disabling in proportion to severity, is a leading global risk factor
    for death and disability, and its complications span liver disease, cancer,
    injury, and suicide. Burden is compounded by a very large treatment gap:
    only about one in five people with lifetime AUD is ever treated.
  evidence:
  - reference: PMID:30146330
    reference_title: "Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Globally, alcohol use was the seventh leading risk factor for both deaths
      and DALYs in 2016
    explanation: >-
      GBD 2016 ranks alcohol among the leading global contributors to death and
      disability.
  - reference: PMID:30146330
    reference_title: "Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among the population aged 15-49 years, alcohol use was the leading risk
      factor globally in 2016, with 3·8% (95% UI 3·2-4·3) of female deaths and
      12·2% (10·8-13·6) of male deaths attributable to alcohol use.
    explanation: >-
      Establishes alcohol as the leading risk factor in working-age adults,
      supporting a HIGH burden assignment.
  - reference: PMID:26039070
    reference_title: "Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Only 19.8% of respondents with lifetime AUD were ever treated.
    explanation: >-
      Quantifies the treatment gap that compounds the burden of the disorder.
inheritance:
- name: Polygenic (multifactorial) liability
  inheritance_term:
    preferred_term: polygenic inheritance
    term:
      id: HP:0010982
      label: Polygenic inheritance
  description: >-
    AUD is not Mendelian. Liability is conferred by many common variants of
    small effect together with environmental exposure; the two largest-effect
    known loci (ADH1B, ALDH2) act on ethanol metabolism and are protective
    rather than causative. Twin and adoption meta-analysis places heritability
    near 50%, with a modest shared-environment component.
  evidence:
  - reference: PMID:25171596
    reference_title: "The heritability of alcohol use disorders: a meta-analysis of twin and adoption studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      AUD is approximately 50% heritable.
    explanation: >-
      Meta-analysis of 12 twin and 5 adoption studies gives the reference
      heritability estimate for AUD liability.
  - reference: PMID:25171596
    reference_title: "The heritability of alcohol use disorders: a meta-analysis of twin and adoption studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We also found evidence for modest shared environmental effects suggesting
      that environmental factors also contribute to the familial aggregation of
      AUDs.
    explanation: >-
      Supports the multifactorial framing: familial aggregation is not purely
      genetic.
  - reference: PMID:38062264
    reference_title: "Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We observed a high degree of cross-ancestral similarity in the genetic
      architecture of PAU and identified 110 independent risk variants in
      within- and cross-ancestry analyses.
    explanation: >-
      The largest multi-ancestry GWAS of problematic alcohol use demonstrates
      the highly polygenic architecture expected under multifactorial
      inheritance.
pathophysiology:
- name: Polygenic and Metabolic-Gene Susceptibility
  biological_scale: MOLECULAR
  description: >-
    Inherited liability to AUD is polygenic, with common variants of small
    effect distributed across brain-expressed genes, plus two large-effect
    protective loci acting on ethanol metabolism (ADH1B rs1229984, ALDH2
    rs671). Genetic loading does not by itself produce the disorder; it shifts
    the probability that repeated alcohol exposure escalates to compulsive use.
  genes:
  - preferred_term: ADH1B
    term:
      id: hgnc:250
      label: ADH1B
  - preferred_term: ALDH2
    term:
      id: hgnc:404
      label: ALDH2
  - preferred_term: GABRA2
    term:
      id: hgnc:4076
      label: GABRA2
  - preferred_term: OPRM1
    term:
      id: hgnc:8156
      label: OPRM1
  downstream:
  - target: Ethanol Exposure and Acetaldehyde-Generating Oxidative Metabolism
    causal_link_type: DIRECT
    description: >-
      ADH1B and ALDH2 coding variants directly set the rate at which ingested
      ethanol is oxidized and at which the acetaldehyde intermediate is
      cleared.
    evidence:
    - reference: PMID:17718394
      reference_title: "The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Which ADH or ALDH alleles a person carries influence his or her level of
        alcohol consumption and risk of alcoholism.
      explanation: >-
        Establishes the metabolic-genotype-to-consumption link that this edge
        asserts.
  - target: Mesolimbic Dopamine and Endogenous Opioid Reward Signaling
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Altered GABA-A receptor expression and neural excitability
    - Altered mu-opioid receptor signalling
    description: >-
      Non-metabolic susceptibility loci such as GABRA2 and OPRM1 act on the
      inhibitory and opioidergic signalling that shapes alcohol's acute
      reinforcing effect.
    evidence:
    - reference: PMID:15024690
      reference_title: "Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The very strong association of GABRA2 with both alcohol dependence and
        the beta frequency of the electroencephalogram, combined with
        biological evidence for a role of this gene in both phenotypes, suggest
        that GABRA2 might influence susceptibility to alcohol dependence by
        modulating the level of neural excitation.
      explanation: >-
        Links a replicated susceptibility locus to the neural excitability that
        underlies alcohol's reinforcing action.
  evidence:
  - reference: PMID:28118990
    reference_title: "Genetic studies of alcohol dependence in the context of the addiction cycle."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The heritability of alcohol use disorders is estimated at approximately
      50-60% of the total phenotypic variability.
    explanation: >-
      Quantifies the inherited component that this susceptibility node
      represents.
  - reference: PMID:28118990
    reference_title: "Genetic studies of alcohol dependence in the context of the addiction cycle."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Vulnerability to alcohol use disorders can be due to multiple genetic or
      environmental factors or their interaction which gives rise to extensive
      and daunting heterogeneity.
    explanation: >-
      Supports modelling susceptibility as a probabilistic upstream node rather
      than a deterministic cause.
- name: Ethanol Exposure and Acetaldehyde-Generating Oxidative Metabolism
  biological_scale: MOLECULAR
  description: >-
    Ingested ethanol is oxidized by alcohol dehydrogenase to acetaldehyde, a
    reactive and toxic intermediate, which aldehyde dehydrogenase (principally
    mitochondrial ALDH2) then oxidizes to acetate. The balance of these two
    enzymatic steps determines systemic and local acetaldehyde exposure and is
    the biochemical layer on which the metabolic-gene protective variants act.
  biological_processes:
  - preferred_term: alcohol metabolic process
    term:
      id: GO:0006066
      label: alcohol metabolic process
  molecular_functions:
  - preferred_term: alcohol dehydrogenase (NAD+) activity
    term:
      id: GO:0004022
      label: alcohol dehydrogenase (NAD+) activity
  - preferred_term: aldehyde dehydrogenase (NAD+) activity
    term:
      id: GO:0004029
      label: aldehyde dehydrogenase (NAD+) activity
  chemical_entities:
  - preferred_term: ethanol
    term:
      id: CHEBI:16236
      label: ethanol
  - preferred_term: acetaldehyde
    term:
      id: CHEBI:15343
      label: acetaldehyde
  - preferred_term: acetate
    term:
      id: CHEBI:30089
      label: acetate
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  triggers:
  - preferred_term: exposure to alcohol consumption
    term:
      id: ECTO:0001082
      label: exposure to alcohol consumption
  downstream:
  - target: Acute GABA-A Potentiation and NMDA Receptor Inhibition
    causal_link_type: DIRECT
    description: >-
      Unmetabolized ethanol reaching the brain acts directly on ligand-gated
      ion channels.
  - target: Aversive Acetaldehyde Accumulation and Flushing Response
    causal_link_type: DIRECT
    description: >-
      When ADH activity is high or ALDH2 activity is impaired, acetaldehyde
      accumulates faster than it is cleared.
    evidence:
    - reference: PMID:17718394
      reference_title: "The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        A variant of the ALDH2 gene encodes an essentially inactive ALDH enzyme,
        resulting in acetaldehyde accumulation and a protective effect.
      explanation: >-
        States the enzymatic imbalance that produces the acetaldehyde
        accumulation this edge points to.
  evidence:
  - reference: PMID:17718394
    reference_title: "The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The main pathway of ethanol metabolism involves its conversion (i.e.,
      oxidation) to acetaldehyde, a reaction that is mediated (i.e., catalyzed)
      by enzymes known as alcohol dehydrogenases (ADHs).
    explanation: >-
      Establishes the ADH-catalyzed first step of the two-step oxidative
      pathway modelled by this node.
  - reference: PMID:17718394
    reference_title: "The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In a second reaction catalyzed by aldehyde dehydrogenase (ALDH) enzymes,
      acetaldehyde is oxidized to acetate.
    explanation: >-
      Establishes the ALDH-catalyzed second step.
- name: Aversive Acetaldehyde Accumulation and Flushing Response
  biological_scale: ORGANISM
  description: >-
    Acetaldehyde accumulation produces an aversive reaction — facial flushing,
    nausea, tachycardia — that discourages further drinking. This is the
    mechanistic basis both of the strong genetic protection conferred by
    ADH1B*2 and ALDH2*2 and of disulfiram pharmacotherapy, which reproduces the
    same reaction by inhibiting ALDH. It is a protective branch of the
    pathograph: it terminates rather than propagates the escalation cascade.
  chemical_entities:
  - preferred_term: acetaldehyde
    term:
      id: CHEBI:15343
      label: acetaldehyde
  evidence:
  - reference: PMID:17718394
    reference_title: "The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Acetaldehyde is a toxic substance whose accumulation leads to a highly
      aversive reaction that includes facial flushing, nausea, and rapid heart
      beat (i.e., tachycardia).
    explanation: >-
      Describes the aversive physiological response modelled by this node.
  - reference: PMID:16822169
    reference_title: "Meta-analyses of ALDH2 and ADH1B with alcohol dependence in Asians."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For each gene, possession of 1 variant *2 allele was protective against
      alcohol dependence, and possession of a 2nd *2 allele did not offer
      significant additional protection.
    explanation: >-
      Meta-analysis in Asian populations quantifies the protection conferred by
      the ALDH2 and ADH1B variants that drive this node.
- name: Acute GABA-A Potentiation and NMDA Receptor Inhibition
  biological_scale: MOLECULAR
  description: >-
    Acute ethanol positively modulates GABA-A receptor-mediated inhibitory
    transmission and inhibits NMDA receptor-mediated glutamatergic
    transmission. The net shift toward inhibition produces the sedative,
    anxiolytic, and cognitively impairing acute effects of intoxication and is
    the substrate on which chronic compensatory neuroadaptation later develops.
  biological_processes:
  - preferred_term: response to ethanol
    term:
      id: GO:0045471
      label: response to ethanol
  - preferred_term: GABAergic synaptic transmission
    term:
      id: GO:0051932
      label: synaptic transmission, GABAergic
    modifier: INCREASED
  - preferred_term: glutamatergic synaptic transmission
    term:
      id: GO:0035249
      label: synaptic transmission, glutamatergic
    modifier: DECREASED
  molecular_functions:
  - preferred_term: GABA-A receptor activity
    term:
      id: GO:0004890
      label: GABA-A receptor activity
    modifier: INCREASED
  - preferred_term: NMDA glutamate receptor activity
    term:
      id: GO:0004972
      label: NMDA glutamate receptor activity
    modifier: DECREASED
  cell_types:
  - preferred_term: GABAergic neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  downstream:
  - target: Mesolimbic Dopamine and Endogenous Opioid Reward Signaling
    causal_link_type: DIRECT
    description: >-
      Ethanol's action on inhibitory transmission onto ventral tegmental
      neurons is one route by which acute alcohol raises accumbal dopamine.
  - target: GABAergic and Glutamatergic Neuroadaptation and Tolerance
    causal_link_type: DIRECT
    description: >-
      Repetition of the acute inhibitory shift drives compensatory receptor
      plasticity.
    evidence:
    - reference: PMID:28931433
      reference_title: "Role of GABA(A) receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        One-dose ethanol exposure induces transient plastic changes in GABAA
        receptor subunit levels, composition, and regional and subcellular
        localization.
      explanation: >-
        Shows that a single acute exposure already initiates the receptor
        plasticity that becomes persistent with repetition.
  evidence:
  - reference: PMID:28931433
    reference_title: "Role of GABA(A) receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      GABAergic inhibitory transmission is involved in the acute and chronic
      effects of ethanol on the brain and behavior.
    explanation: >-
      Supports GABAergic transmission as the acute target modelled here.
  - reference: PMID:25954150
    reference_title: "Targeting glutamate uptake to treat alcohol use disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Glutamatergic receptors implicated in the effects of ethanol include the
      ionotropic glutamate receptors (AMPA, Kainate, and NMDA) and some
      metabotropic glutamate receptors.
    explanation: >-
      Supports ionotropic glutamate receptors, including NMDA, as direct
      targets of ethanol.
- name: Mesolimbic Dopamine and Endogenous Opioid Reward Signaling
  biological_scale: CELLULAR
  description: >-
    Acute alcohol increases dopamine release from ventral tegmental
    projections to the nucleus accumbens, an effect involving endogenous opioid
    peptide release acting at mu-opioid receptors. This is the positive
    reinforcement that sustains drinking in the binge/intoxication stage and is
    the target of opioid-antagonist pharmacotherapy.
  cell_types:
  - preferred_term: dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  - preferred_term: GABAergic interneuron
    term:
      id: CL:0011005
      label: GABAergic interneuron
  locations:
  - preferred_term: ventral tegmental area
    term:
      id: UBERON:0002691
      label: ventral tegmental area
  - preferred_term: nucleus accumbens
    term:
      id: UBERON:0001882
      label: nucleus accumbens
  biological_processes:
  - preferred_term: dopamine secretion
    term:
      id: GO:0014046
      label: dopamine secretion
    modifier: INCREASED
  - preferred_term: opioid receptor signaling
    term:
      id: GO:0038003
      label: G protein-coupled opioid receptor signaling pathway
  downstream:
  - target: Incentive Salience Sensitization and Alcohol Cue Reactivity
    causal_link_type: DIRECT
    description: >-
      Repeated dopaminergic reinforcement in the basal ganglia converts
      alcohol-paired stimuli into powerful motivational cues.
    evidence:
    - reference: PMID:27475769
      reference_title: "Neurobiology of addiction: a neurocircuitry analysis."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The rewarding effects of drugs of abuse, development of incentive
        salience, and development of drug-seeking habits in the
        binge/intoxication stage involve changes in dopamine and opioid
        peptides in the basal ganglia.
      explanation: >-
        Places incentive salience downstream of dopamine and opioid signalling
        in the binge/intoxication stage.
  - target: Dorsolateral Striatal Habit System Recruitment
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Progressive ventral-to-dorsal shift in striatal control over alcohol seeking with repeated reinforcement
    description: >-
      Sustained reinforcement progressively transfers behavioural control from
      ventral (goal-directed) to dorsal (habitual) striatal circuits.
  evidence:
  - reference: PMID:27475769
    reference_title: "Neurobiology of addiction: a neurocircuitry analysis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Drug addiction represents a dramatic dysregulation of motivational
      circuits that is caused by a combination of exaggerated incentive
      salience and habit formation, reward deficits and stress surfeits, and
      compromised executive function in three stages.
    explanation: >-
      States the three-stage neurocircuitry framework this node opens.
  - reference: PMID:33318153
    reference_title: "Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Compulsive drug seeking that is associated with addiction is hypothesized
      to follow a heuristic framework that involves three stages
      (binge/intoxication, withdrawal/negative affect, and
      preoccupation/anticipation) and three domains of dysfunction (incentive
      salience/pathologic habits, negative emotional states, and executive
      function, respectively) via changes in the basal ganglia, extended
      amygdala/habenula, and frontal cortex, respectively.
    explanation: >-
      Assigns the binge/intoxication stage modelled here to basal ganglia
      circuitry.
- name: Incentive Salience Sensitization and Alcohol Cue Reactivity
  biological_scale: CELLULAR
  description: >-
    Alcohol-associated cues acquire exaggerated motivational value and elicit
    robust limbic and prefrontal activation in people with AUD. Cue-elicited
    ventral striatal activation tracks behavioural measures of craving and is
    reduced by treatment, making it the most frequently used circuit-level
    correlate of craving.
  locations:
  - preferred_term: ventral striatum
    term:
      id: UBERON:0005403
      label: ventral striatum
  - preferred_term: prefrontal cortex
    term:
      id: UBERON:0000451
      label: prefrontal cortex
  downstream:
  - target: Compulsive Alcohol Seeking and Loss of Control
    causal_link_type: DIRECT
    description: >-
      Cue-driven motivational states precipitate drinking episodes and relapse.
  evidence:
  - reference: PMID:22574861
    reference_title: "Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among cases, alcohol cues elicited robust activation of limbic and
      prefrontal regions, including ventral striatum, anterior cingulate and
      ventromedial prefrontal cortex.
    explanation: >-
      Coordinate-based meta-analysis of 28 functional imaging studies localizes
      cue reactivity to the circuitry modelled in this node.
  - reference: PMID:22574861
    reference_title: "Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cue-elicited activation of ventral striatum was most frequently
      correlated with behavioral measures and most frequently reduced by
      treatment, but these results were often derived from region-of-interest
      analyses that interrogated only limbic regions.
    explanation: >-
      Supports the behavioural relevance of cue-elicited striatal activation
      while noting the region-of-interest limitation of the underlying studies.
- name: GABAergic and Glutamatergic Neuroadaptation and Tolerance
  biological_scale: MOLECULAR
  description: >-
    Repeated ethanol exposure drives compensatory changes in GABA-A receptor
    subunit composition and upregulation of glutamatergic signalling, opposing
    the acute inhibitory effect. These adaptations produce tolerance while
    alcohol is present and leave the CNS in a hyperexcitable state when it is
    withdrawn. In chronic intermittent ethanol models the changes become
    persistent rather than transient.
  biological_processes:
  - preferred_term: glutamatergic synaptic transmission
    term:
      id: GO:0035249
      label: synaptic transmission, glutamatergic
    modifier: INCREASED
  - preferred_term: GABAergic synaptic transmission
    term:
      id: GO:0051932
      label: synaptic transmission, GABAergic
    modifier: DECREASED
  molecular_functions:
  - preferred_term: GABA-A receptor activity
    term:
      id: GO:0004890
      label: GABA-A receptor activity
    modifier: DECREASED
  downstream:
  - target: CNS and Autonomic Hyperexcitability during Alcohol Withdrawal
    causal_link_type: DIRECT
    description: >-
      Removal of alcohol unmasks the compensatory hyperexcitable state.
    evidence:
    - reference: PMID:28931433
      reference_title: "Role of GABA(A) receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Compensatory up-regulation of synaptically localized α4 and α2
        subunit-containing GABAA receptor subtypes, mediating ethanol-sensitive
        synaptic inhibitory currents follow, but exhibit altered
        physio-pharmacology, seizure susceptibility, hyperexcitability,
        anxiety, and tolerance to GABAergic positive allosteric modulators,
        corresponding to heightened alcohol withdrawal syndrome.
      explanation: >-
        Directly links the compensatory GABA-A subunit switch to withdrawal
        hyperexcitability and seizure susceptibility.
  - target: Prefrontal Executive Control Deficit
    causal_link_type: DIRECT
    description: >-
      The same glutamatergic dysregulation degrades the prefrontal and insular
      afferents that carry top-down control over drinking.
    evidence:
    - reference: PMID:27475769
      reference_title: "Neurobiology of addiction: a neurocircuitry analysis."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The craving and deficits in executive function in the so-called
        preoccupation/anticipation stage involve the dysregulation of key
        afferent projections from the prefrontal cortex and insula, including
        glutamate, to the basal ganglia and extended amygdala.
      explanation: >-
        Attributes the executive-function deficit to dysregulated glutamatergic
        prefrontal afferents, the adaptation this node models.
  evidence:
  - reference: PMID:28931433
    reference_title: "Role of GABA(A) receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      After chronic intermittent ethanol (CIE) treatment the same changes are
      observed but they become persistent after 30 or more doses, lasting for
      at least 120 days in the rat, and probably for life.
    explanation: >-
      Establishes that the receptor adaptations become durable with chronic
      intermittent exposure, which is what distinguishes tolerance from a
      transient acute effect.
  - reference: PMID:25954150
    reference_title: "Targeting glutamate uptake to treat alcohol use disorders."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The development of tolerance and the expression of withdrawal effects,
      which manifest as dependence, have been to a great extent attributed to
      neuroadaptations within the mesocorticolimbic and extended amygdala
      systems.
    explanation: >-
      Attributes tolerance and withdrawal to the neuroadaptive process this
      node represents.
- name: CNS and Autonomic Hyperexcitability during Alcohol Withdrawal
  biological_scale: ORGANISM
  description: >-
    On abrupt cessation or reduction of drinking in a physiologically dependent
    person, the unopposed hyperglutamatergic and hypo-GABAergic state produces
    tremor, insomnia, anxiety, nausea, and autonomic hyperactivity, and can
    progress to generalized tonic-clonic seizures and alcohol withdrawal
    delirium (delirium tremens). Roughly half of people with AUD who stop
    abruptly develop withdrawal signs.
  biological_processes:
  - preferred_term: glutamatergic synaptic transmission
    term:
      id: GO:0035249
      label: synaptic transmission, glutamatergic
    modifier: INCREASED
  downstream:
  - target: Extended Amygdala Stress-System Recruitment
    causal_link_type: DIRECT
    description: >-
      Repeated withdrawal episodes recruit brain stress systems in the extended
      amygdala.
  - target: Compulsive Alcohol Seeking and Loss of Control
    causal_link_type: DIRECT
    description: >-
      Drinking to relieve or avoid withdrawal is itself one of the DSM-5
      pharmacological criteria and a direct route back into consumption.
  evidence:
  - reference: PMID:34523874
    reference_title: "Alcohol Withdrawal Syndrome: Outpatient Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Approximately one-half of patients with alcohol use disorder who abruptly
      stop or reduce their alcohol use will develop signs or symptoms of alcohol
      withdrawal syndrome.
    explanation: >-
      Quantifies how often the withdrawal state modelled by this node occurs.
  - reference: PMID:34523874
    reference_title: "Alcohol Withdrawal Syndrome: Outpatient Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The syndrome is due to overactivity of the central and autonomic nervous
      systems, leading to tremors, insomnia, nausea and vomiting,
      hallucinations, anxiety, and agitation.
    explanation: >-
      States the CNS and autonomic hyperexcitability mechanism and its clinical
      expression.
  - reference: PMID:25307573
    reference_title: "Neurochemical mechanisms of alcohol withdrawal."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Clinical features of alcohol withdrawal include signs of central nervous
      system hyperexcitability, heightened autonomic nervous system activation,
      and a constellation of symptoms contributing to psychologic discomfort
      and negative affect.
    explanation: >-
      Independent review supports the same hyperexcitability framing and links
      it to negative affect.
- name: Extended Amygdala Stress-System Recruitment
  biological_scale: CELLULAR
  description: >-
    Chronic alcohol exposure and repeated withdrawal recruit brain stress
    neurotransmitter systems — notably corticotropin-releasing factor and
    dynorphin acting at kappa-opioid receptors — within the central amygdala
    and bed nucleus of the stria terminalis. This between-system
    neuroadaptation is what converts withdrawal from a transient physiological
    event into a persistent motivational state.
  locations:
  - preferred_term: central amygdala
    term:
      id: UBERON:0002883
      label: central amygdaloid nucleus
  - preferred_term: bed nucleus of stria terminalis
    term:
      id: UBERON:0001880
      label: bed nucleus of stria terminalis
  biological_processes:
  - preferred_term: response to stress
    term:
      id: GO:0006950
      label: response to stress
    modifier: INCREASED
  downstream:
  - target: Hyperkatifeia and Mesolimbic Reward Deficit
    causal_link_type: DIRECT
    description: >-
      Stress-system recruitment together with reduced dopaminergic tone
      produces the negative emotional state of the withdrawal stage.
    evidence:
    - reference: PMID:33318153
      reference_title: "Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Neurobiological targets for hyperkatifeia in addiction involve
        neurocircuitry of the extended amygdala and its connections via
        within-system neuroadaptations in dopamine, enkephalin/endorphin opioid
        peptide, and γ-aminobutyric acid/glutamate systems and between-system
        neuroadaptations in prostress corticotropin-releasing factor,
        norepinephrine, glucocorticoid, dynorphin, hypocretin, and neuroimmune
        systems and antistress neuropeptide Y, nociceptin, endocannabinoid, and
        oxytocin systems.
      explanation: >-
        Places hyperkatifeia downstream of extended-amygdala stress-system
        recruitment.
  evidence:
  - reference: PMID:27475769
    reference_title: "Neurobiology of addiction: a neurocircuitry analysis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The increases in negative emotional states and dysphoric and stress-like
      responses in the withdrawal/negative affect stage involve decreases in the
      function of the dopamine component of the reward system and recruitment
      of brain stress neurotransmitters, such as corticotropin-releasing factor
      and dynorphin, in the neurocircuitry of the extended amygdala.
    explanation: >-
      Names the two mediators and the anatomical circuit modelled by this node.
  - reference: PMID:22459870
    reference_title: "Targeting dynorphin/kappa opioid receptor systems to treat alcohol abuse and dependence."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Dr. Brendan Walker presented data characterizing the effects of KOR
      antagonism within the extended amygdala on withdrawal-induced escalation
      of alcohol self-administration in dependent animals.
    explanation: >-
      Preclinical kappa-opioid antagonism within the extended amygdala provides
      causal support for the dynorphin arm of this node.
  - reference: PMID:26247973
    reference_title: "Corticotropin Releasing Factor Binding Protein and CRF2 Receptors in the Ventral Tegmental Area: Modulation of Ethanol Binge Drinking in C57BL/6J Mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Intra-VTA CRF6-33 and A2B reduced EtOH intake dose dependently in mice
      during DID.
    explanation: >-
      Local manipulation of CRF-system components reduces binge ethanol intake,
      supporting a causal role for CRF signalling; support is partial because
      the effect was seen in the ventral tegmental area, whereas intra-central
      amygdala infusion in the same study did not change consumption.
- name: Hyperkatifeia and Mesolimbic Reward Deficit
  biological_scale: ORGANISM
  description: >-
    The withdrawal/negative affect stage combines a deficit in reward-system
    function with an excess of stress-system activity, producing dysphoria,
    anxiety, irritability, and anhedonia that persist beyond acute withdrawal.
    Drinking to relieve this state is negative reinforcement, and it is a
    distinct motivational driver from the positive reinforcement of the
    binge/intoxication stage.
  biological_processes:
  - preferred_term: dopamine secretion
    term:
      id: GO:0014046
      label: dopamine secretion
    modifier: DECREASED
  downstream:
  - target: Compulsive Alcohol Seeking and Loss of Control
    causal_link_type: DIRECT
    description: >-
      Negative reinforcement — drinking to remove an aversive internal state —
      sustains compulsive use independently of alcohol's rewarding effects.
    evidence:
    - reference: PMID:33318153
      reference_title: "Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Hyperkatifeia provides an additional source of motivation for
        compulsive drug seeking via negative reinforcement.
      explanation: >-
        States exactly the causal relation this edge asserts.
  evidence:
  - reference: PMID:33318153
    reference_title: "Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      This review focuses on neurochemical/neurocircuitry dysregulations that
      contribute to hyperkatifeia, defined as a greater intensity of negative
      emotional/motivational signs and symptoms during withdrawal from drugs of
      abuse in the withdrawal/negative affect stage of the addiction cycle.
    explanation: >-
      Defines the hyperkatifeia construct that names this node.
  - reference: PMID:33318153
    reference_title: "Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Such neurochemical/neurocircuitry dysregulations are hypothesized to
      mediate a negative hedonic set point that gradually gains allostatic load
      and shifts from a homeostatic hedonic state to an allostatic hedonic
      state.
    explanation: >-
      The allostatic set-point account is explicitly framed as a hypothesis by
      its author, so it supports this node's framing only partially.
- name: Dorsolateral Striatal Habit System Recruitment
  biological_scale: CELLULAR
  description: >-
    With prolonged use, control over alcohol seeking shifts to
    dopamine-dependent mechanisms in the anterior dorsolateral striatum that
    implement habit learning. Individuals whose seeking has become more
    habitual — less sensitive to devaluation of the outcome — are more likely
    to continue seeking alcohol despite punishment.
  locations:
  - preferred_term: dorsal striatum
    term:
      id: UBERON:0005382
      label: dorsal striatum
  downstream:
  - target: Compulsive Alcohol Seeking and Loss of Control
    causal_link_type: DIRECT
    description: >-
      Habitual control predicts the emergence of punishment-resistant, that is
      compulsive, seeking and drinking.
    evidence:
    - reference: PMID:33955649
      reference_title: "Individual differences in the engagement of habitual control over alcohol seeking predict the development of compulsive alcohol seeking and drinking."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        After seeking behaviour was well established, subjects that had
        developed greater resistance to outcome devaluation (were more
        habitual) were more likely to show punishment-resistant (compulsive)
        alcohol seeking.
      explanation: >-
        Provides the within-animal predictive relationship between habitual
        control and compulsivity that this edge asserts.
  evidence:
  - reference: PMID:33955649
    reference_title: "Individual differences in the engagement of habitual control over alcohol seeking predict the development of compulsive alcohol seeking and drinking."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      With prolonged use, control over alcohol seeking devolves to anterior
      dorsolateral striatum, dopamine-dependent mechanisms implicated in habit
      learning and individuals in whom alcohol seeking relies more on these
      mechanisms are more likely to persist in seeking alcohol despite the risk
      of punishment.
    explanation: >-
      Localizes habitual control of alcohol seeking to the dorsolateral
      striatum. Evidence is from alcohol-preferring rats, so the anatomical
      claim is not directly demonstrated in humans.
- name: Prefrontal Executive Control Deficit
  biological_scale: TISSUE
  description: >-
    Craving and impaired executive function in the preoccupation/anticipation
    stage involve dysregulation of glutamatergic projections from prefrontal
    cortex and insula to basal ganglia and extended amygdala, degrading
    top-down inhibitory control over drinking. Structural imaging shows
    corresponding cortical thickness differences in AUD.
  locations:
  - preferred_term: prefrontal cortex
    term:
      id: UBERON:0000451
      label: prefrontal cortex
  cell_types:
  - preferred_term: glutamatergic pyramidal neuron
    term:
      id: CL:0000598
      label: pyramidal neuron
  biological_processes:
  - preferred_term: glutamatergic synaptic transmission
    term:
      id: GO:0035249
      label: synaptic transmission, glutamatergic
    modifier: ABNORMAL
  downstream:
  - target: Compulsive Alcohol Seeking and Loss of Control
    causal_link_type: DIRECT
    description: >-
      Loss of top-down control removes the brake on cue- and
      withdrawal-motivated drinking.
    evidence:
    - reference: PMID:27475769
      reference_title: "Neurobiology of addiction: a neurocircuitry analysis."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The craving and deficits in executive function in the so-called
        preoccupation/anticipation stage involve the dysregulation of key
        afferent projections from the prefrontal cortex and insula, including
        glutamate, to the basal ganglia and extended amygdala.
      explanation: >-
        States the prefrontal-to-subcortical dysregulation that this edge
        represents.
  evidence:
  - reference: PMID:32643841
    reference_title: "How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross-disorder meta-analytic comparison using the ENIGMA consortium findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      On measures of cortical thickness, AUD was associated with significant
      differences bilaterally in the fusiform gyrus, inferior temporal gyrus,
      temporal pole, superior frontal gyrus, and rostral and caudal anterior
      cingulate gyri.
    explanation: >-
      ENIGMA-protocol meta-analysis documents frontal and cingulate cortical
      differences in AUD cases versus controls. Cross-sectional case-control
      data cannot establish the direction of causation.
  - reference: PMID:32643841
    reference_title: "How do substance use disorders compare to other psychiatric conditions on structural brain abnormalities? A cross-disorder meta-analytic comparison using the ENIGMA consortium findings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Alcohol use disorder (AUD) and cannabis use disorder (CUD) are associated
      with brain alterations particularly involving fronto-cerebellar and
      meso-cortico-limbic circuitry.
    explanation: >-
      Supports frontal involvement in the circuitry affected by AUD.
- name: Compulsive Alcohol Seeking and Loss of Control
  biological_scale: ORGANISM
  description: >-
    The convergent clinical endpoint of the cycle: compulsion to seek and
    consume alcohol, loss of control over intake, and continued use despite
    knowledge of harm. Three motivational routes feed it — cue-driven incentive
    salience, negative reinforcement from hyperkatifeia, and habitual control —
    with prefrontal executive deficit removing the counterweight.
  downstream:
  - target: Sustained Heavy Alcohol Exposure and Multiorgan Toxicity
    causal_link_type: DIRECT
    description: >-
      Loss of control sustains the cumulative ethanol dose that produces
      end-organ injury.
  evidence:
  - reference: PMID:27475769
    reference_title: "Neurobiology of addiction: a neurocircuitry analysis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Drug addiction can be defined as a chronically relapsing disorder,
      characterised by compulsion to seek and take the drug, loss of control in
      limiting intake, and emergence of a negative emotional state (eg,
      dysphoria, anxiety, irritability) when access to the drug is prevented.
    explanation: >-
      Defines the compulsive-use endpoint modelled by this node.
- name: Sustained Heavy Alcohol Exposure and Multiorgan Toxicity
  biological_scale: ORGANISM
  description: >-
    Chronic heavy drinking produces cumulative injury across organ systems —
    hepatic steatosis progressing to cirrhosis, pancreatitis, cardiomyopathy,
    peripheral neuropathy — and, via caloric substitution and malabsorption,
    thiamine deficiency causing Wernicke encephalopathy and Korsakoff
    psychosis. These sequelae are downstream of the drinking behaviour rather
    than part of the CNS mechanism that produces it; alcohol-related liver
    disease is curated separately.
  chemical_entities:
  - preferred_term: ethanol
    term:
      id: CHEBI:16236
      label: ethanol
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:30281514
    reference_title: "Review of thiamine deficiency disorders: Wernicke encephalopathy and Korsakoff psychosis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Wernicke encephalopathy (WE) and Korsakoff psychosis (KP), together
      termed Wernicke-Korsakoff syndrome (WKS), are distinct yet overlapping
      neuropsychiatric disorders associated with thiamine deficiency.
    explanation: >-
      Supports the thiamine-deficiency arm of chronic alcohol-related organ
      injury.
  - reference: PMID:30146330
    reference_title: "Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For populations aged 50 years and older, cancers accounted for a large
      proportion of total alcohol-attributable deaths in 2016, constituting
      27·1% (95% UI 21·2-33·3) of total alcohol-attributable female deaths and
      18·9% (15·3-22·6) of male deaths.
    explanation: >-
      Quantifies one major component of the end-organ disease burden produced
      by the sustained exposure this node represents.
phenotypes:
- category: Behavioral
  name: Addictive Alcohol Use
  description: >-
    Compulsive alcohol use with impaired control — drinking more or longer than
    intended, persistent unsuccessful efforts to cut down, and continued use
    despite knowledge of physical or psychological harm. This is the defining
    clinical feature.
  phenotype_term:
    preferred_term: Addictive alcohol use
    term:
      id: HP:0030955
      label: Addictive alcohol use
    clinical_course: PROGRESSIVE
  frequency: VERY_FREQUENT
  diagnostic: true
  evidence:
  - reference: PMID:27475769
    reference_title: "Neurobiology of addiction: a neurocircuitry analysis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Drug addiction can be defined as a chronically relapsing disorder,
      characterised by compulsion to seek and take the drug, loss of control in
      limiting intake, and emergence of a negative emotional state (eg,
      dysphoria, anxiety, irritability) when access to the drug is prevented.
    explanation: >-
      Compulsion and loss of control over intake are the defining features of
      the disorder, so this phenotype is present in essentially all cases,
      which is the basis for the VERY_FREQUENT band.
- category: Behavioral
  name: Problematic Alcohol Consumption
  description: >-
    A pattern of drinking causing harm to health or social functioning, graded
    in DSM-5 as mild (2-3 criteria), moderate (4-5), or severe (6 or more) and
    separated in ICD-11 into harmful pattern of use versus dependence.
  phenotype_term:
    preferred_term: Problematic alcohol consumption
    term:
      id: HP:5200329
      label: Problematic alcohol consumption
  diagnostic: true
  evidence:
  - reference: PMID:31194891
    reference_title: "Alcohol Use Disorders in ICD-11: Past, Present, and Future."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      This review describes and discusses the alcohol diagnoses within this
      section of ICD-11, including Alcohol Dependence, Harmful Pattern of Use
      of Alcohol, and entities such as Alcohol Intoxication, Alcohol
      Withdrawal, and several alcohol-induced mental disorders, and briefly
      covers Hazardous Alcohol Use, which is listed separately as a health risk
      factor.
    explanation: >-
      Documents the ICD-11 diagnostic structure that grades problematic
      drinking into harmful use and dependence.
- category: Behavioral
  name: Craving
  description: >-
    A strong desire or urge to drink — a DSM-5 diagnostic criterion, the
    subjective correlate of cue-elicited limbic activation, and the endpoint
    most often used in pharmacotherapy trials.
  notes: >-
    No `phenotype_term` is bound: HPO has no general craving term (only the
    food-specific HP:0030083, HP:0030221 and HP:6000785), and using one of
    those or a generic behavioural parent would misdescribe the claim. Needs
    term / NTR candidate.
  diagnostic: true
  evidence:
  - reference: PMID:22574861
    reference_title: "Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A comprehensive understanding of the neurobiology of alcohol cue
      reactivity is critical in identifying the neuropathology of alcohol use
      disorders (AUD) and developing treatments that may attenuate alcohol
      craving and reduce relapse risk.
    explanation: >-
      Establishes craving as a central clinical target in AUD and ties it to
      cue reactivity.
  - reference: PMID:39937469
    reference_title: "Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      significantly reduced drinks per drinking day (β, -0.41; 95% CI, -0.73 to
      -0.09; P = .04) and weekly alcohol craving (β, -0.39; 95% CI, -0.73 to
      -0.06; P = .01)
    explanation: >-
      Craving is measured prospectively as a distinct trial endpoint in AUD
      pharmacotherapy studies, separable from consumption measures.
- category: Behavioral
  name: Hazardous Alcohol Use
  description: >-
    Recurrent drinking in physically hazardous situations or at levels that
    place the person at risk of harm, listed in ICD-11 as a health risk factor
    separately from the alcohol use disorders themselves.
  phenotype_term:
    preferred_term: Hazardous alcohol use
    term:
      id: HP:6000028
      label: Hazardous alcohol use
  evidence:
  - reference: PMID:31194891
    reference_title: "Alcohol Use Disorders in ICD-11: Past, Present, and Future."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Alcohol use disorders form a key part of the section of Disorders due to
      Substance Use and Addictive Behaviours.
    explanation: >-
      Supports the nosological placement of hazardous use alongside the alcohol
      use disorders; the review does not quantify how often it co-occurs with
      diagnosed AUD, so support is partial.
- category: Neurologic
  name: Tremor
  description: >-
    Postural and action tremor is among the earliest signs of alcohol
    withdrawal, appearing within hours of the last drink.
  phenotype_term:
    preferred_term: Tremor
    term:
      id: HP:0001337
      label: Tremor
    temporality: ACUTE
  evidence:
  - reference: PMID:34523874
    reference_title: "Alcohol Withdrawal Syndrome: Outpatient Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The syndrome is due to overactivity of the central and autonomic nervous
      systems, leading to tremors, insomnia, nausea and vomiting,
      hallucinations, anxiety, and agitation.
    explanation: >-
      Lists tremor as a core alcohol withdrawal sign.
- category: Neurologic
  name: Alcohol Withdrawal Seizures
  description: >-
    Generalized tonic-clonic seizures occurring during untreated or
    inadequately treated alcohol withdrawal, typically in the first 12-48 hours
    after the last drink.
  phenotype_term:
    preferred_term: Generalized tonic-clonic seizure
    term:
      id: HP:0002069
      label: Bilateral tonic-clonic seizure
    temporality: ACUTE
  evidence:
  - reference: PMID:34523874
    reference_title: "Alcohol Withdrawal Syndrome: Outpatient Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      If untreated or inadequately treated, withdrawal can progress to
      generalized tonic-clonic seizures, delirium tremens, and death.
    explanation: >-
      Identifies withdrawal seizures as a complication of untreated withdrawal.
- category: Neurologic
  name: Alcohol Withdrawal Delirium
  description: >-
    Delirium tremens — fluctuating disturbance of consciousness with
    disorientation, hallucinations, and marked autonomic hyperactivity —
    typically emerging 24-72 hours after the last drink and the most severe
    manifestation of alcohol withdrawal.
  phenotype_term:
    preferred_term: Delirium
    term:
      id: HP:0031258
      label: Delirium
    temporality: ACUTE
    severity: SEVERE
  evidence:
  - reference: PMID:34523874
    reference_title: "Alcohol Withdrawal Syndrome: Outpatient Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      If untreated or inadequately treated, withdrawal can progress to
      generalized tonic-clonic seizures, delirium tremens, and death.
    explanation: >-
      Establishes delirium tremens as the severe end of the withdrawal
      spectrum.
- category: Neurologic
  name: Withdrawal Hallucinations
  description: >-
    Visual and tactile hallucinations occurring during alcohol withdrawal, with
    or without accompanying delirium.
  phenotype_term:
    preferred_term: Hallucinations
    term:
      id: HP:0000738
      label: Hallucinations
    temporality: ACUTE
  evidence:
  - reference: PMID:34523874
    reference_title: "Alcohol Withdrawal Syndrome: Outpatient Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The syndrome is due to overactivity of the central and autonomic nervous
      systems, leading to tremors, insomnia, nausea and vomiting,
      hallucinations, anxiety, and agitation.
    explanation: >-
      Lists hallucinations among the withdrawal manifestations.
- category: Neurologic
  name: Insomnia
  description: Sleep disturbance during withdrawal and into protracted abstinence.
  phenotype_term:
    preferred_term: Insomnia
    term:
      id: HP:0100785
      label: Insomnia
  evidence:
  - reference: PMID:34523874
    reference_title: "Alcohol Withdrawal Syndrome: Outpatient Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The syndrome is due to overactivity of the central and autonomic nervous
      systems, leading to tremors, insomnia, nausea and vomiting,
      hallucinations, anxiety, and agitation.
    explanation: >-
      Lists insomnia among the withdrawal manifestations.
- category: Behavioral
  name: Anxiety
  description: >-
    Anxiety occurs acutely in withdrawal and persists as part of the negative
    emotional state (hyperkatifeia) of protracted abstinence.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:34523874
    reference_title: "Alcohol Withdrawal Syndrome: Outpatient Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The syndrome is due to overactivity of the central and autonomic nervous
      systems, leading to tremors, insomnia, nausea and vomiting,
      hallucinations, anxiety, and agitation.
    explanation: >-
      Documents anxiety as an acute withdrawal feature.
  - reference: PMID:27475769
    reference_title: "Neurobiology of addiction: a neurocircuitry analysis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Drug addiction can be defined as a chronically relapsing disorder,
      characterised by compulsion to seek and take the drug, loss of control in
      limiting intake, and emergence of a negative emotional state (eg,
      dysphoria, anxiety, irritability) when access to the drug is prevented.
    explanation: >-
      Supports anxiety as part of the negative emotional state beyond acute
      withdrawal.
- category: Constitutional
  name: Autonomic Hyperactivity
  description: >-
    Tachycardia, diaphoresis, and hypertension reflecting autonomic nervous
    system activation during withdrawal.
  phenotype_term:
    preferred_term: Tachycardia
    term:
      id: HP:0001649
      label: Tachycardia
    temporality: ACUTE
  evidence:
  - reference: PMID:25307573
    reference_title: "Neurochemical mechanisms of alcohol withdrawal."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Clinical features of alcohol withdrawal include signs of central nervous
      system hyperexcitability, heightened autonomic nervous system activation,
      and a constellation of symptoms contributing to psychologic discomfort
      and negative affect.
    explanation: >-
      Establishes autonomic activation as a core withdrawal feature.
- category: Gastrointestinal
  name: Nausea and Vomiting
  description: Gastrointestinal upset during alcohol withdrawal.
  phenotype_term:
    preferred_term: Nausea and vomiting
    term:
      id: HP:0002017
      label: Nausea and vomiting
    temporality: ACUTE
  evidence:
  - reference: PMID:34523874
    reference_title: "Alcohol Withdrawal Syndrome: Outpatient Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The syndrome is due to overactivity of the central and autonomic nervous
      systems, leading to tremors, insomnia, nausea and vomiting,
      hallucinations, anxiety, and agitation.
    explanation: >-
      Lists nausea and vomiting among withdrawal manifestations.
- category: Behavioral
  name: Depression
  description: >-
    Depressed mood is both a common comorbidity and part of the negative
    emotional state of the withdrawal/negative affect stage. In psychiatric
    cohorts with major depressive disorder, comorbid AUD is common and predicts
    a worse depressive course.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: PMID:32217228
    reference_title: "Comorbid alcohol use disorder in psychiatric MDD patients: A five-year prospective study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with AUD spent more time depressed and had more suicide attempts
      during follow-up.
    explanation: >-
      Five-year prospective psychiatric cohort links comorbid AUD to a worse
      depressive course.
  - reference: PMID:26039070
    reference_title: "Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Significant associations were found between 12-month and lifetime AUD and
      other substance use disorders, major depressive and bipolar I disorders,
      and antisocial and borderline personality disorders across all levels of
      AUD severity, with odds ratios ranging from 1.2 (95% CI, 1.08-1.36) to
      6.4 (95% CI, 5.76-7.22).
    explanation: >-
      Nationally representative data quantify the association between AUD and
      major depressive disorder.
- category: Neurologic
  name: Impaired Executive Functioning
  description: >-
    Deficits in decision-making, working memory, and inhibitory control,
    corresponding to the preoccupation/anticipation stage of the addiction
    cycle and persisting into abstinence in a subset of patients.
  phenotype_term:
    preferred_term: Impaired executive functioning
    term:
      id: HP:0033051
      label: Impaired executive functioning
  evidence:
  - reference: PMID:27475769
    reference_title: "Neurobiology of addiction: a neurocircuitry analysis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The craving and deficits in executive function in the so-called
      preoccupation/anticipation stage involve the dysregulation of key
      afferent projections from the prefrontal cortex and insula, including
      glutamate, to the basal ganglia and extended amygdala.
    explanation: >-
      Identifies executive dysfunction as a defined domain of the addiction
      cycle.
- category: Neurologic
  name: Memory Impairment
  description: >-
    Amnestic deficits, ranging from intoxication-related memory lapses to the
    persistent anterograde amnesia of Korsakoff psychosis following thiamine
    deficiency.
  phenotype_term:
    preferred_term: Memory impairment
    term:
      id: HP:0002354
      label: Memory impairment
  evidence:
  - reference: PMID:30281514
    reference_title: "Review of thiamine deficiency disorders: Wernicke encephalopathy and Korsakoff psychosis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The identification and individualized treatment of WE based on the
      etiology is vital to prevent the development of the amnestic state
      associated with KP in genetically predisposed individuals.
    explanation: >-
      Supports the amnestic phenotype arising from thiamine-deficiency
      complications of chronic alcohol use.
- category: Neurologic
  name: Ataxia
  description: >-
    Cerebellar ataxia from chronic alcohol-related cerebellar degeneration, and
    acutely as part of the Wernicke encephalopathy triad.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:30281514
    reference_title: "Review of thiamine deficiency disorders: Wernicke encephalopathy and Korsakoff psychosis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Wernicke encephalopathy (WE) and Korsakoff psychosis (KP), together
      termed Wernicke-Korsakoff syndrome (WKS), are distinct yet overlapping
      neuropsychiatric disorders associated with thiamine deficiency.
    explanation: >-
      The review establishes Wernicke encephalopathy as a thiamine-deficiency
      complication; the abstract does not itself enumerate the clinical triad,
      so support for ataxia specifically is partial.
- category: Neurologic
  name: Peripheral Neuropathy
  description: >-
    Length-dependent sensorimotor peripheral neuropathy from chronic heavy
    alcohol exposure and associated nutritional deficiency.
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:30146330
    reference_title: "Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Alcohol use is a leading risk factor for global disease burden and causes
      substantial health loss.
    explanation: >-
      The GBD analysis supports alcohol as a cause of substantial health loss
      but does not itemize peripheral neuropathy, so this citation supports the
      general claim only. A neuropathy-specific citation is a curation gap.
- category: Gastrointestinal
  name: Hepatic Steatosis
  description: >-
    Fat accumulation in hepatocytes, the earliest and most common hepatic
    consequence of heavy drinking; see the Alcoholic_Liver_Disease entry for
    the full hepatic cascade.
  phenotype_term:
    preferred_term: Hepatic steatosis
    term:
      id: HP:0001397
      label: Hepatic steatosis
  evidence:
  - reference: PMID:30146330
    reference_title: "Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For populations aged 50 years and older, cancers accounted for a large
      proportion of total alcohol-attributable deaths in 2016, constituting
      27·1% (95% UI 21·2-33·3) of total alcohol-attributable female deaths and
      18·9% (15·3-22·6) of male deaths.
    explanation: >-
      Documents that alcohol causes major somatic end-organ disease burden.
      Hepatic steatosis specifically is curated with primary evidence in the
      Alcoholic_Liver_Disease entry.
- category: Gastrointestinal
  name: Cirrhosis
  description: >-
    End-stage hepatic fibrosis following years of heavy drinking, curated in
    detail in the Alcoholic_Liver_Disease entry.
  phenotype_term:
    preferred_term: Cirrhosis
    term:
      id: HP:0001394
      label: Cirrhosis
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:42070571
    reference_title: "Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Alcohol use disorder accounts for 5% of deaths worldwide annually, and
      there is an urgent need for new therapeutic interventions.
    explanation: >-
      Supports the lethal burden of AUD, of which liver disease is a major
      component; the trial report does not itself quantify cirrhosis incidence.
- category: Cardiovascular
  name: Dilated Cardiomyopathy
  description: Alcoholic cardiomyopathy from sustained heavy alcohol exposure.
  phenotype_term:
    preferred_term: Dilated cardiomyopathy
    term:
      id: HP:0001644
      label: Dilated cardiomyopathy
  evidence:
  - reference: PMID:30146330
    reference_title: "Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Alcohol use is a leading risk factor for global disease burden and causes
      substantial health loss.
    explanation: >-
      Supports alcohol as a cause of major somatic disease burden; a
      cardiomyopathy-specific citation is a curation gap.
- category: Gastrointestinal
  name: Pancreatitis
  description: Acute and chronic pancreatitis precipitated by heavy alcohol use.
  phenotype_term:
    preferred_term: Pancreatitis
    term:
      id: HP:0001733
      label: Pancreatitis
  evidence:
  - reference: PMID:30146330
    reference_title: "Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Alcohol use is a leading risk factor for global disease burden and causes
      substantial health loss.
    explanation: >-
      Supports alcohol as a cause of major somatic disease burden; a
      pancreatitis-specific citation is a curation gap.
- category: Constitutional
  name: Facial Flushing After Alcohol Intake
  description: >-
    The acetaldehyde flush reaction in carriers of ALDH2*2 (and to a lesser
    degree fast-metabolizing ADH1B variants). This is a protective phenotype:
    its aversiveness reduces drinking and hence AUD risk, so it is
    under-represented among people who develop the disorder.
  phenotype_term:
    preferred_term: Facial flushing after alcohol intake
    term:
      id: HP:0001033
      label: Facial flushing after alcohol intake
  evidence:
  - reference: PMID:17718394
    reference_title: "The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Acetaldehyde is a toxic substance whose accumulation leads to a highly
      aversive reaction that includes facial flushing, nausea, and rapid heart
      beat (i.e., tachycardia).
    explanation: >-
      Ties the flushing phenotype to acetaldehyde accumulation.
genetic:
- name: ADH1B
  gene_term:
    preferred_term: ADH1B
    term:
      id: hgnc:250
      label: ADH1B
  relationship_type: PROTECTIVE
  association: >-
    The fast-metabolizing rs1229984 (ADH1B*2) allele accelerates oxidation of
    ethanol to acetaldehyde, producing an aversive reaction that protects
    against alcohol dependence.
  evidence:
  - reference: PMID:17718394
    reference_title: "The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For example, certain ADH1B and ADH1C alleles encode particularly active
      ADH enzymes, resulting in more rapid conversion of alcohol (i.e., ethanol)
      to acetaldehyde; these alleles have a protective effect on the risk of
      alcoholism.
    explanation: >-
      States the protective mechanism and direction of effect for fast ADH
      alleles.
  - reference: PMID:16822169
    reference_title: "Meta-analyses of ALDH2 and ADH1B with alcohol dependence in Asians."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Recruitment strategy and gender moderated the effect of ADH1B*2.
    explanation: >-
      Meta-analysis of ADH1B in Asian populations establishes the association
      and identifies moderators of its magnitude.
- name: ALDH2
  gene_term:
    preferred_term: ALDH2
    term:
      id: hgnc:404
      label: ALDH2
  relationship_type: PROTECTIVE
  association: >-
    The rs671 (ALDH2*2, Glu504Lys) allele encodes an essentially inactive
    mitochondrial aldehyde dehydrogenase; acetaldehyde accumulates and the
    resulting flushing reaction strongly protects against alcohol dependence.
    The allele is common in East Asian populations and essentially absent
    elsewhere.
  evidence:
  - reference: PMID:17718394
    reference_title: "The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A variant of the ALDH2 gene encodes an essentially inactive ALDH enzyme,
      resulting in acetaldehyde accumulation and a protective effect.
    explanation: >-
      States the loss-of-function mechanism and the protective direction of
      effect.
  - reference: PMID:16822169
    reference_title: "Meta-analyses of ALDH2 and ADH1B with alcohol dependence in Asians."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diagnostic criteria, recruitment strategy, and Japanese ethnicity
      moderated the effect of ALDH2*2.
    explanation: >-
      Meta-analysis quantifying the ALDH2*2 protective effect in Asian
      populations and its moderators.
- name: GABRA2
  gene_term:
    preferred_term: GABRA2
    term:
      id: hgnc:4076
      label: GABRA2
  relationship_type: SUSCEPTIBILITY
  association: >-
    One of the earliest and most replicated non-metabolic susceptibility loci,
    implicating GABA-A receptor-mediated inhibitory signalling and neural
    excitability in dependence risk.
  evidence:
  - reference: PMID:15024690
    reference_title: "Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thirty-one SNPs in GABRA2, but only 1 of the 20 SNPs in the flanking
      genes, showed significant association with alcoholism.
    explanation: >-
      Family-based association study localizing the signal specifically to
      GABRA2 within the chromosome 4p GABA-A receptor gene cluster.
  - reference: PMID:15024690
    reference_title: "Variations in GABRA2, encoding the alpha 2 subunit of the GABA(A) receptor, are associated with alcohol dependence and with brain oscillations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      No coding differences were found between the high-risk and low-risk
      haplotypes, suggesting that the effect is mediated through gene
      regulation.
    explanation: >-
      Characterizes the likely regulatory rather than coding mechanism of the
      GABRA2 association.
- name: OPRM1
  gene_term:
    preferred_term: OPRM1
    term:
      id: hgnc:8156
      label: OPRM1
  relationship_type: MODIFIER
  association: >-
    The common A118G (rs1799971) variant of the mu-opioid receptor gene has
    been proposed as a moderator of alcohol-induced euphoria and of naltrexone
    treatment response. The pharmacogenomic claim is contested: a
    genotype-stratified randomized trial found no effect of rs1799971 on
    naltrexone response, and routine genotyping is not clinically indicated.
  evidence:
  - reference: PMID:22909206
    reference_title: "Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although screening of patients in a clinical setting remains premature,
      results suggest the A118G substitution may influence one etiological
      pathway to alcoholism, for which naltrexone pharmacotherapy is more
      effective.
    explanation: >-
      Review supporting a modifier role while explicitly cautioning that
      clinical screening is premature.
  - reference: PMID:38706338
    reference_title: "Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neither rs2832407 nor rs1799971 had effects on topiramate and naltrexone
      treatments, respectively.
    explanation: >-
      A prospective genotype-stratified randomized trial refutes a clinically
      actionable pharmacogenomic effect of OPRM1 rs1799971 on naltrexone
      response.
- name: GCKR
  gene_term:
    preferred_term: GCKR
    term:
      id: hgnc:4196
      label: GCKR
  relationship_type: SUSCEPTIBILITY
  association: >-
    Beyond the metabolic loci, liability to problematic alcohol use is spread
    across many common variants of small effect, including consumption-linked
    metabolic loci such as GCKR. The largest cross-ancestry meta-analysis
    identified 110 independent risk variants.
  notes: >-
    The GCKR-specific association is drawn from the wider alcohol GWAS
    literature; the cited multi-ancestry meta-analysis abstract supports the
    polygenic framing rather than naming this locus, so a GCKR-specific primary
    citation is a curation gap.
  evidence:
  - reference: PMID:38062264
    reference_title: "Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here we conducted a large cross-ancestry meta-analysis of PAU in
      1,079,947 individuals (European, N = 903,147; African, N = 122,571; Latin
      American, N = 38,962; East Asian, N = 13,551; and South Asian, N = 1,716
      ancestries).
    explanation: >-
      Establishes the scale and multi-ancestry composition of the discovery
      sample from which the polygenic architecture is inferred.
  - reference: PMID:38062264
    reference_title: "Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Genetic correlations between PAU and other traits were observed in
      multiple ancestries, with other substance use traits having the highest
      correlations.
    explanation: >-
      Documents shared genetic liability between problematic alcohol use and
      other substance use disorders.
- name: KLB
  gene_term:
    preferred_term: KLB
    term:
      id: hgnc:15527
      label: KLB
  relationship_type: SUSCEPTIBILITY
  association: >-
    Beta-klotho, the co-receptor for FGF21, is a replicated locus for alcohol
    consumption phenotypes, implicating a liver-brain endocrine axis in the
    regulation of alcohol preference.
  evidence:
  - reference: PMID:38062264
    reference_title: "Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Prioritizing genes through gene expression and chromatin interaction in
      brain tissues identified multiple genes associated with PAU.
    explanation: >-
      The multi-ancestry GWAS supports brain-expressed gene prioritization for
      problematic alcohol use; it does not name KLB in the abstract, so this
      citation supports the polygenic framing rather than the specific KLB
      claim. A KLB-specific primary citation is a curation gap.
environmental:
- name: Chronic heavy alcohol consumption
  description: >-
    Repeated exposure to ethanol is the necessary environmental cause: no
    amount of genetic liability produces AUD without drinking. Pattern matters
    as well as volume — heavy episodic (binge) drinking and early age of
    drinking onset are established risk amplifiers.
  effect: Necessary causal exposure
  exposure_term:
    preferred_term: exposure to alcohol consumption
    term:
      id: ECTO:0001082
      label: exposure to alcohol consumption
  chemicals:
  - ethanol
  influences_mechanisms:
  - target: Ethanol Exposure and Acetaldehyde-Generating Oxidative Metabolism
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Ingestion is the route by which ethanol enters the oxidative metabolic
      pathway and reaches the brain.
    evidence:
    - reference: PMID:17718394
      reference_title: "The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The main site of ethanol metabolism is the liver, although some
        metabolism also occurs in other tissues and can cause local damage
        there.
      explanation: >-
        Establishes that ingested ethanol is routed into hepatic oxidative
        metabolism, the mechanism node this exposure triggers.
  - target: GABAergic and Glutamatergic Neuroadaptation and Tolerance
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Chronic intermittent exposure, rather than any single dose, is what makes
      the receptor adaptations persistent.
    evidence:
    - reference: PMID:28931433
      reference_title: "Role of GABA(A) receptors in alcohol use disorders suggested by chronic intermittent ethanol (CIE) rodent model."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        After chronic intermittent ethanol (CIE) treatment the same changes are
        observed but they become persistent after 30 or more doses, lasting for
        at least 120 days in the rat, and probably for life.
      explanation: >-
        Shows that repeated exposure is the variable that converts transient
        receptor plasticity into a durable adaptation.
  evidence:
  - reference: PMID:30146330
    reference_title: "Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The level of alcohol consumption that minimised harm across health
      outcomes was zero (95% UI 0·0-0·8) standard drinks per week.
    explanation: >-
      GBD analysis of 195 countries characterizes the dose-response of alcohol
      exposure to health harm.
treatments:
- name: Oral Naltrexone
  description: >-
    Mu-opioid receptor antagonist that blunts the reinforcing effects of
    alcohol; a first-line pharmacotherapy at 50 mg/d, reducing both return to
    any drinking and return to heavy drinking. A long-acting injectable
    formulation is also approved.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: naltrexone
      term:
        id: CHEBI:7465
        label: naltrexone
  target_mechanisms:
  - target: Mesolimbic Dopamine and Endogenous Opioid Reward Signaling
    treatment_effect: INHIBITS
    description: >-
      Opioid receptor antagonism interrupts the endogenous-opioid step by which
      alcohol raises mesolimbic dopamine, reducing alcohol's rewarding effect.
    evidence:
    - reference: PMID:22909206
      reference_title: "Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        This article critically evaluates the evidence that the A118G
        substitution affects subjective, behavioral and neurobiological
        responses to alcohol and the opioid receptor antagonist, naltrexone.
      explanation: >-
        Frames naltrexone as an opioid receptor antagonist acting on the
        subjective and neurobiological response to alcohol.
  notes: >-
    Nausea and vomiting are more frequent than with placebo (risk ratios 1.73
    and 1.53 respectively in the cited JAMA meta-analysis).
  evidence:
  - reference: PMID:37934220
    reference_title: "Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Compared with placebo, oral naltrexone (50 mg/d) was associated with lower
      rates of return to heavy drinking, with a number needed to treat of 11
      (95% CI, 5-41).
    explanation: >-
      Systematic review and meta-analysis of 118 trials quantifies the efficacy
      of oral naltrexone.
  - reference: PMID:37934220
    reference_title: "Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In conjunction with psychosocial interventions, these findings support the
      use of oral naltrexone at 50 mg/d and acamprosate as first-line
      pharmacotherapies for alcohol use disorder.
    explanation: >-
      States the first-line recommendation and the requirement for concurrent
      psychosocial treatment.
- name: Extended-Release Injectable Naltrexone
  description: >-
    Monthly intramuscular naltrexone (XR-NTX), a separately approved
    formulation of the same mu-opioid antagonist. Modelled apart from the oral
    drug because the once-monthly route removes daily adherence from the
    equation, which is the main practical reason to choose it, and because the
    trial evidence is reported separately.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: naltrexone
      term:
        id: CHEBI:7465
        label: naltrexone
  target_mechanisms:
  - target: Mesolimbic Dopamine and Endogenous Opioid Reward Signaling
    treatment_effect: INHIBITS
    description: >-
      Same mu-opioid antagonism as the oral formulation, delivered on a monthly
      schedule.
  evidence:
  - reference: PMID:37934220
    reference_title: "Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Injectable naltrexone was associated with fewer drinking days over the
      30-day treatment period (weighted mean difference, -4.99 days; 95% CI,
      -9.49 to -0.49 days)
    explanation: >-
      The same systematic review reports the injectable formulation's effect
      separately from oral naltrexone.
- name: Acamprosate
  description: >-
    Modulator of glutamatergic and GABAergic signalling used to maintain
    abstinence after withdrawal, hypothesized to normalize the post-withdrawal
    hyperglutamatergic state. First-line alongside naltrexone.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: acamprosate
      term:
        id: CHEBI:51041
        label: acamprosate
  target_mechanisms:
  - target: GABAergic and Glutamatergic Neuroadaptation and Tolerance
    treatment_effect: INHIBITS
    description: >-
      Acamprosate is used to counteract the persistent glutamatergic
      hyperexcitability left by chronic alcohol exposure.
    evidence:
    - reference: PMID:25954150
      reference_title: "Targeting glutamate uptake to treat alcohol use disorders."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Given the hyperglutamatergic/hyperexcitable state of the central nervous
        system induced by chronic alcohol abuse and withdrawal, the evidence
        thus far indicates that a restoration of glutamatergic concentrations
        and activity within the mesocorticolimbic system and extended amygdala
        as well as multiple memory systems holds great promise for the
        treatment of alcohol dependence.
      explanation: >-
        Supports normalization of glutamatergic signalling as a treatment
        strategy for the neuroadaptive state; the review does not attribute
        this specific mechanism to acamprosate, so support is partial.
  evidence:
  - reference: PMID:37934220
    reference_title: "Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The numbers needed to treat to prevent 1 person from returning to any
      drinking were 11 (95% CI, 1-32) for acamprosate and 18 (95% CI, 4-32) for
      oral naltrexone at a dose of 50 mg/d.
    explanation: >-
      Quantifies acamprosate efficacy for preventing return to any drinking.
  - reference: PMID:35653782
    reference_title: "Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our review found that acamprosate (2-3 g/d), disulfiram (250-500 mg/d),
      baclofen (30 mg/d), and oral naltrexone (50 mg/d) had the best evidence
      for improving abstinence and heavy drinking for patients with AUD.
    explanation: >-
      Network meta-analysis of 156 trials independently supports acamprosate
      dosing and efficacy.
- name: Disulfiram
  description: >-
    Aldehyde dehydrogenase inhibitor that makes drinking aversive by
    reproducing the acetaldehyde flush reaction. Deterrent rather than
    anti-craving, so its efficacy depends on supervised administration.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: disulfiram
      term:
        id: CHEBI:4659
        label: disulfiram
  target_mechanisms:
  - target: Aversive Acetaldehyde Accumulation and Flushing Response
    treatment_effect: ACTIVATES
    description: >-
      By inhibiting ALDH, disulfiram deliberately induces the same acetaldehyde
      accumulation that protects ALDH2*2 carriers.
    evidence:
    - reference: PMID:17718394
      reference_title: "The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        This reaction is similar to that experienced by alcoholics who consume
        alcohol after taking disulfiram
      explanation: >-
        Explicitly equates the disulfiram reaction with the genetically
        determined acetaldehyde flush this node models.
  evidence:
  - reference: PMID:35653782
    reference_title: "Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For reduced heavy drinking, disulfiram (RR = 0.19; 95% CI, 0.10-0.35),
      baclofen (RR = 0.72; 95% CI, 0.57-0.91), acamprosate (RR = 0.78; 95% CI,
      0.70-0.86), and oral naltrexone (RR = 0.81; 95% CI, 0.73-0.90) were
      efficacious against placebo.
    explanation: >-
      Network meta-analysis reports disulfiram efficacy for reducing heavy
      drinking.
- name: Topiramate
  description: >-
    Off-label anticonvulsant with glutamatergic and GABAergic actions. In a
    genotype-stratified head-to-head randomized trial it was at least as
    effective as naltrexone for heavy drinking and superior for craving, BMI,
    and gamma-glutamyltransferase.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: topiramate
      term:
        id: CHEBI:63631
        label: topiramate
  evidence:
  - reference: PMID:38706338
    reference_title: "Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Topiramate is at least as effective and safe as the first-line
      medication, naltrexone, in reducing heavy alcohol consumption, and
      superior in reducing some clinical outcomes.
    explanation: >-
      Head-to-head 12-week randomized trial supports topiramate as an
      alternative to naltrexone.
- name: Gabapentin
  description: >-
    Off-label agent used for mild withdrawal symptoms and for
    withdrawal-adjacent anxiety and insomnia in early abstinence; also improves
    total abstinence relative to placebo in network meta-analysis.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: gabapentin
      term:
        id: CHEBI:42797
        label: gabapentin
  evidence:
  - reference: PMID:35653782
    reference_title: "Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      gabapentin (RR = 1.66; 95% CI, 1.04-2.67), acamprosate (RR = 1.33; 95%
      CI, 1.15-1.54), and oral naltrexone (RR = 1.15; 95% CI, 1.01-1.32)
      improved total abstinence over placebo
    explanation: >-
      Network meta-analysis quantifies gabapentin's effect on total abstinence.
  - reference: PMID:34523874
    reference_title: "Alcohol Withdrawal Syndrome: Outpatient Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mild symptoms can be treated with carbamazepine or gabapentin.
    explanation: >-
      Supports gabapentin for mild withdrawal symptoms in ambulatory
      management.
- name: Baclofen
  description: >-
    GABA-B receptor agonist used off-label for AUD, particularly in Europe and
    in patients with hepatic impairment. Network meta-analysis places it among
    the agents with the best evidence for abstinence and reduced heavy
    drinking, and it caused fewer dropouts than placebo.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: baclofen
      term:
        id: CHEBI:2972
        label: baclofen
  evidence:
  - reference: PMID:35653782
    reference_title: "Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our review found that acamprosate (2-3 g/d), disulfiram (250-500 mg/d),
      baclofen (30 mg/d), and oral naltrexone (50 mg/d) had the best evidence
      for improving abstinence and heavy drinking for patients with AUD.
    explanation: >-
      Network meta-analysis of 156 trials places baclofen among the
      best-evidenced agents and gives its dose.
  - reference: PMID:35653782
    reference_title: "Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Baclofen (RR = 0.83; 95% CI, 0.70-0.97) and pregabalin (RR = 0.63; 95%
      CI, 0.43-0.94) caused fewer dropouts than placebo.
    explanation: >-
      Quantifies baclofen's tolerability relative to placebo in the same
      network meta-analysis.
- name: Benzodiazepine Withdrawal Management
  description: >-
    Benzodiazepines are first-line for moderate to severe alcohol withdrawal,
    given on a symptom-triggered or fixed schedule, and are what prevent
    progression to withdrawal seizures and delirium tremens. This treats the
    acute withdrawal syndrome, not the underlying disorder — long-term AUD
    treatment must be offered in addition.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: benzodiazepine
      term:
        id: NCIT:C1012
        label: Benzodiazepine
  target_mechanisms:
  - target: CNS and Autonomic Hyperexcitability during Alcohol Withdrawal
    treatment_effect: INHIBITS
    description: >-
      Positive allosteric modulation of GABA-A receptors substitutes for the
      lost ethanol-driven inhibition, suppressing the hyperexcitable state.
    evidence:
    - reference: PMID:34523874
      reference_title: "Alcohol Withdrawal Syndrome: Outpatient Management."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Benzodiazepines are first-line therapy for moderate to severe symptoms,
        with carbamazepine and gabapentin as potential adjunctive or alternative
        therapies.
      explanation: >-
        Establishes benzodiazepines as the first-line treatment for the
        withdrawal state this node represents.
  evidence:
  - reference: PMID:34523874
    reference_title: "Alcohol Withdrawal Syndrome: Outpatient Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Primary care physicians should offer to initiate long-term treatment for
      alcohol use disorder, including pharmacotherapy, in addition to withdrawal
      management.
    explanation: >-
      Makes explicit that withdrawal management alone is not treatment of the
      disorder.
- name: Thiamine Repletion
  description: >-
    Parenteral thiamine given to prevent and treat Wernicke encephalopathy in
    people with chronic heavy alcohol use, administered before glucose to avoid
    precipitating the syndrome.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
    therapeutic_agent:
    - preferred_term: thiamine
      term:
        id: CHEBI:18385
        label: thiamine(1+)
  evidence:
  - reference: PMID:30281514
    reference_title: "Review of thiamine deficiency disorders: Wernicke encephalopathy and Korsakoff psychosis."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The identification and individualized treatment of WE based on the
      etiology is vital to prevent the development of the amnestic state
      associated with KP in genetically predisposed individuals.
    explanation: >-
      Supports early treatment of Wernicke encephalopathy to prevent the
      irreversible Korsakoff amnestic state.
- name: Cognitive Behavioral Therapy
  description: >-
    Structured psychosocial treatment targeting drinking-related cognitions,
    coping skills, and relapse prevention. More effective than no treatment,
    minimal treatment, or a nonspecific control, though not superior to other
    specific active therapies.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Cognitive Behavior Therapy
    term:
      id: NCIT:C64345
      label: Cognitive Behavior Therapy
  evidence:
  - reference: PMID:31599606
    reference_title: "A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: Treatment efficacy by contrast condition."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The current meta-analysis shows that CBT is more effective than a no
      treatment, minimal treatment, or nonspecific control.
    explanation: >-
      Meta-analysis of 30 randomized controlled trials quantifies CBT efficacy
      against each contrast condition.
  - reference: PMID:31599606
    reference_title: "A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: Treatment efficacy by contrast condition."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CBT effects in contrast to a specific therapy were consistently
      nonsignificant across outcomes and follow-up time points.
    explanation: >-
      Bounds the claim: CBT is not superior to other specific evidence-based
      modalities.
- name: Alcoholics Anonymous and Twelve-Step Facilitation
  description: >-
    Peer-led mutual-help participation and professionally delivered twelve-step
    facilitation. Manualized twelve-step facilitation outperforms other
    established treatments including CBT for increasing abstinence, and
    probably produces substantial healthcare cost savings.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Behavioral Counseling
    term:
      id: NCIT:C181743
      label: Behavioral Counseling
  evidence:
  - reference: PMID:32159228
    reference_title: "Alcoholics Anonymous and other 12-step programs for alcohol use disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There is high quality evidence that manualized AA/TSF interventions are
      more effective than other established treatments, such as CBT, for
      increasing abstinence.
    explanation: >-
      Cochrane review conclusion on manualized twelve-step facilitation.
  - reference: PMID:32159228
    reference_title: "Alcoholics Anonymous and other 12-step programs for alcohol use disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      AA/TSF probably produces substantial healthcare cost savings among people
      with alcohol use disorder.
    explanation: >-
      Supports the health-economic component of the same Cochrane review.
- name: Semaglutide (investigational)
  description: >-
    GLP-1 receptor agonist under investigation for AUD. A phase 2 trial in 48
    non-treatment-seeking adults reduced laboratory alcohol self-administration
    and weekly craving, and a 26-week trial in 108 treatment-seeking patients
    with AUD and comorbid obesity, on a background of cognitive behavioural
    therapy, reduced heavy drinking days relative to placebo. Not approved for
    this indication.
  therapeutic_modality: PEPTIDE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: semaglutide
      term:
        id: CHEBI:167574
        label: semaglutide
  notes: >-
    Both trials are in selected populations — non-treatment-seeking adults in
    the phase 2 study, and patients with comorbid obesity in the Lancet trial —
    so generalizability to unselected treatment-seeking AUD is not established.
  evidence:
  - reference: PMID:39937469
    reference_title: "Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These findings provide initial prospective evidence that low-dose
      semaglutide can reduce craving and some drinking outcomes, justifying
      larger clinical trials to evaluate GLP-1RAs for alcohol use disorder.
    explanation: >-
      Phase 2 randomized trial establishes preliminary efficacy on craving and
      some drinking outcomes.
  - reference: PMID:42070571
    reference_title: "Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Semaglutide was associated with a reduction in heavy drinking days (-41·1
      percentage points from baseline, 95% CI -48·7 to -33·5) compared with
      placebo (-26·4, -34·1 to -18·6; estimated treatment difference -13·7
      percentage points, -22·0 to -5·4; p=0·0015), and had substantial effects
      on multiple secondary alcohol-related and somatic outcomes.
    explanation: >-
      A 26-week randomized placebo-controlled trial quantifies the reduction in
      heavy drinking days in patients with AUD and comorbid obesity.
biochemical:
- name: Phosphatidylethanol (PEth)
  presence: Elevated with recent heavy alcohol consumption
  specificity: High
  notes: >-
    A direct ethanol metabolite in blood used as a specific biomarker of recent
    heavy alcohol use, with a detection window of weeks. Blood PEth correlates
    with alcohol ingested in the preceding two weeks, but reported
    interpretative cut-offs vary widely between studies, so a single universal
    threshold cannot be curated.
  evidence:
  - reference: PMID:37569551
    reference_title: "Phosphatidylethanol (PEth) in Blood as a Marker of Unhealthy Alcohol Use: A Systematic Review with Novel Molecular Insights."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In recent years, phosphatidylethanol (PEth) in blood has emerged as a
      marker of unhealthy alcohol use.
    explanation: >-
      Systematic review establishes PEth as a biomarker of unhealthy alcohol
      use.
  - reference: PMID:37569551
    reference_title: "Phosphatidylethanol (PEth) in Blood as a Marker of Unhealthy Alcohol Use: A Systematic Review with Novel Molecular Insights."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      PEth interpretative cut-offs varied greatly among the included records,
      ranging from 4.2 ng/mL to 250 ng/mL, with sensitivity and specificity in
      the ranges of 58-100% and 64-100%, respectively.
    explanation: >-
      Quantifies the wide variation in reported cut-offs and diagnostic
      accuracy, which limits how prescriptively the marker can be used.
- name: Gamma-Glutamyltransferase (GGT)
  presence: Elevated with sustained heavy alcohol consumption
  specificity: Low-moderate; individually insensitive and also elevated by non-alcoholic liver disease, obesity, and enzyme-inducing drugs
  notes: >-
    Indirect marker reflecting hepatocellular/microsomal enzyme induction
    rather than a direct ethanol metabolite — unlike PEth, it measures a
    consequence of drinking, so it is supporting evidence, not a diagnostic
    test for AUD. Individually it misses roughly half of heavy drinkers
    (58% sensitivity); combined with CDT as the GGT-CDT index it performs
    substantially better (90% sensitivity) and holds up whether or not liver
    disease is present. See the Carbohydrate-Deficient Transferrin (CDT)
    record for the paired analyte in that combined index.
  evidence:
  - reference: PMID:16799164
    reference_title: "Comparison of the combined marker GGT-CDT and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The sensitivity of GGT-CDT (90%) in correctly classifying heavy drinkers
      exceeded that of CDT (63%), GGT (58%), mean corpuscular volume (MCV)
      (45%), aspartate aminotransferase (AST) (47%), and alanine
      aminotransferase (ALT) (50%), being also essentially similar for
      alcoholics with (93%) or without (88%) liver disease.
    explanation: >-
      Quantifies the sensitivity of each conventional marker and of the
      combined GGT-CDT index in a cohort of 165 heavy drinkers against
      moderate-drinker and abstainer references.
  - reference: PMID:16799164
    reference_title: "Comparison of the combined marker GGT-CDT and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GGT-CDT improves the sensitivity of detecting excessive ethanol
      consumption as compared with the traditional markers of ethanol
      consumption.
    explanation: >-
      States the study's conclusion that the combined GGT-CDT index
      outperforms the individual conventional markers.
  reference_ranges:
  - loinc_term:
      id: LOINC:2324-2
      label: Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
    upper_bound: 85.0
    unit: U/L
    population: males; screening cutoff for heavy drinking
    notes: >-
      Cutoff for detecting heavy drinking, not a general clinical reference
      interval. The LOINC code was verified against the NLM clinical-tables
      LOINC service; LOINC is not covered by the repository's OAK term
      validation.
    evidence:
    - reference: PMID:17767129
      reference_title: "The Early Detection of Alcohol Consumption (EDAC) test shows better performance than gamma-glutamyltransferase (GGT) to detect heavy drinking in a large population of males and females."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The GGT test used a cutoff of 85 U/L for males and 65 U/L for females."
      explanation: Source of the sex-specific GGT cutoffs used to screen for heavy drinking.
  - loinc_term:
      id: LOINC:2324-2
      label: Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
    upper_bound: 65.0
    unit: U/L
    population: females; screening cutoff for heavy drinking
    notes: >-
      Cutoff for detecting heavy drinking, not a general clinical reference
      interval. The LOINC code was verified against the NLM clinical-tables
      LOINC service; LOINC is not covered by the repository's OAK term
      validation.
    evidence:
    - reference: PMID:17767129
      reference_title: "The Early Detection of Alcohol Consumption (EDAC) test shows better performance than gamma-glutamyltransferase (GGT) to detect heavy drinking in a large population of males and females."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The GGT test used a cutoff of 85 U/L for males and 65 U/L for females."
      explanation: Source of the sex-specific GGT cutoffs used to screen for heavy drinking.
- name: Carbohydrate-Deficient Transferrin (CDT)
  presence: Elevated with sustained heavy alcohol consumption
  specificity: Moderate-high; the most specific of the conventional indirect markers, though affected by pregnancy, severe liver disease, and rare transferrin variants
  notes: >-
    Reflects impaired transferrin glycosylation from sustained heavy ethanol
    intake, quantified as %CDT (or %disialotransferrin by the HPLC candidate
    reference method) of total transferrin. Individually it misses over a
    third of heavy drinkers (63% sensitivity); combined with GGT as the
    GGT-CDT index it performs substantially better (90% sensitivity) and
    holds up whether or not liver disease is present — see the
    Gamma-Glutamyltransferase (GGT) record for that combined-index evidence
    (PMID:16799164).
  reference_ranges:
  - loinc_term:
      id: LOINC:48495-6
      label: Transferrin.carbohydrate deficient/Transferrin.total in Serum or Plasma
    upper_bound: 1.7
    unit: '%'
    population: adults; %disialotransferrin by HPLC candidate reference method
    notes: >-
      The LOINC code was verified against the NLM clinical-tables LOINC
      service; LOINC is not covered by the repository's OAK term validation.
    evidence:
    - reference: PMID:25698630
      reference_title: "A comparison between serum carbohydrate-deficient transferrin and hair ethyl glucuronide in detecting chronic alcohol consumption in routine."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Serum CDT was measured by the candidate HPLC reference method and
        expressed as relative amount of disialotransferrin (%DST: cutoff
        1.7%).
      explanation: Source of the %CDT (disialotransferrin) upper-limit cutoff used clinically.
- name: Mean Corpuscular Volume (MCV)
  presence: Elevated with sustained heavy alcohol consumption (macrocytosis)
  specificity: Low; also elevated by folate/B12 deficiency, liver disease, hypothyroidism, and reticulocytosis independent of alcohol
  notes: >-
    Least sensitive of the conventional indirect markers individually (45%
    sensitivity), reflecting a slower-developing red-cell change rather than
    an acute-phase response; also rises somewhat with moderate drinking
    itself, which shifts the apparent upper limit of normal (see reference
    ranges below).
  evidence:
  - reference: PMID:16799164
    reference_title: "Comparison of the combined marker GGT-CDT and the conventional laboratory markers of alcohol abuse in heavy drinkers, moderate drinkers and abstainers."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The sensitivity of GGT-CDT (90%) in correctly classifying heavy drinkers
      exceeded that of CDT (63%), GGT (58%), mean corpuscular volume (MCV)
      (45%), aspartate aminotransferase (AST) (47%), and alanine
      aminotransferase (ALT) (50%), being also essentially similar for
      alcoholics with (93%) or without (88%) liver disease.
    explanation: >-
      Quantifies MCV's individual sensitivity (45%) for classifying heavy
      drinkers, well below the combined GGT-CDT index.
  reference_ranges:
  - loinc_term:
      id: LOINC:30428-7
      label: MCV [Entitic mean volume] in Red Blood Cells
    upper_bound: 96.0
    unit: fL
    population: abstainers (NORIP reference data)
    notes: >-
      The LOINC code was verified against the NLM clinical-tables LOINC
      service; LOINC is not covered by the repository's OAK term validation.
    evidence:
    - reference: PMID:16581347
      reference_title: "Long-term ethanol consumption and macrocytosis: diagnostic and pathogenic implications."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        the upper normal limit for MCV based on the data from moderate
        drinkers was 98 fl, as compared with 96 fl from abstainers
      explanation: >-
        Source of the abstainer upper normal limit for MCV, derived from
        NORIP reference data.
  - loinc_term:
      id: LOINC:30428-7
      label: MCV [Entitic mean volume] in Red Blood Cells
    upper_bound: 98.0
    unit: fL
    population: moderate drinkers (NORIP reference data)
    notes: >-
      The higher upper limit in moderate drinkers versus abstainers itself
      reflects a dose-related response of MCV to ethanol intake. The LOINC
      code was verified against the NLM clinical-tables LOINC service; LOINC
      is not covered by the repository's OAK term validation.
    evidence:
    - reference: PMID:16581347
      reference_title: "Long-term ethanol consumption and macrocytosis: diagnostic and pathogenic implications."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        the upper normal limit for MCV based on the data from moderate
        drinkers was 98 fl, as compared with 96 fl from abstainers
      explanation: >-
        Source of the moderate-drinker upper normal limit for MCV, derived
        from NORIP reference data.
diagnosis:
- name: DSM-5 and ICD-11 clinical diagnostic criteria
  description: >-
    Diagnosis is clinical and behavioural. DSM-5 requires at least 2 of 11
    criteria within 12 months, graded mild/moderate/severe by symptom count.
    ICD-11 places alcohol diagnoses within Disorders due to Substance Use and
    Addictive Behaviours, distinguishing Harmful Pattern of Use of Alcohol from
    Alcohol Dependence, with Hazardous Alcohol Use listed separately as a
    health risk factor. There is no genetic or laboratory confirmatory test.
  evidence:
  - reference: PMID:31194891
    reference_title: "Alcohol Use Disorders in ICD-11: Past, Present, and Future."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      This review describes and discusses the alcohol diagnoses within this
      section of ICD-11, including Alcohol Dependence, Harmful Pattern of Use
      of Alcohol, and entities such as Alcohol Intoxication, Alcohol
      Withdrawal, and several alcohol-induced mental disorders, and briefly
      covers Hazardous Alcohol Use, which is listed separately as a health risk
      factor.
    explanation: >-
      Authoritative description of the ICD-11 alcohol diagnostic structure.
- name: AUDIT and AUDIT-C screening
  description: >-
    The WHO Alcohol Use Disorders Identification Test and its 3-item short form
    AUDIT-C are the dominant screening instruments and the usual phenotype
    definition in large genetic studies. Both are self-report and subject to
    recall bias and under-reporting, which is the rationale for complementary
    objective biomarkers such as PEth.
  evidence:
  - reference: PMID:37569551
    reference_title: "Phosphatidylethanol (PEth) in Blood as a Marker of Unhealthy Alcohol Use: A Systematic Review with Novel Molecular Insights."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The Alcohol Use Disorders Identification Test (AUDIT) and its short form,
      the AUDIT-C, the main clinical instruments used to identify unhealthy
      drinking behaviors, are influenced by memory bias and under-reporting.
    explanation: >-
      Identifies AUDIT/AUDIT-C as the main screening instruments and states
      their principal limitation.
  - reference: PMID:34523874
    reference_title: "Alcohol Withdrawal Syndrome: Outpatient Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The three-question Alcohol Use Disorders Identification Test-Consumption
      and the Single Alcohol Screening Question instrument have the best
      accuracy for assessing unhealthy alcohol use in adults 18 years and
      older.
    explanation: >-
      Supports AUDIT-C as a preferred screening instrument on accuracy grounds.
clinical_trials:
- name: NCT05520775
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Phase 2 double-blind randomized parallel-arm trial of once-weekly
    subcutaneous semaglutide over 9 weeks in 48 non-treatment-seeking adults
    with AUD, with laboratory alcohol self-administration as the primary
    outcome.
  target_phenotypes:
  - preferred_term: Addictive alcohol use
    term:
      id: HP:0030955
      label: Addictive alcohol use
  evidence:
  - reference: PMID:39937469
    reference_title: "Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Low-dose semaglutide reduced the amount of alcohol consumed during a
      posttreatment laboratory self-administration task, with evidence of medium
      to large effect sizes for grams of alcohol consumed
    explanation: >-
      Reports the primary laboratory self-administration outcome of this trial.
- name: NCT05895643
  phase: PHASE_II
  status: COMPLETED
  description: >-
    26-week single-centre randomized double-blind placebo-controlled trial of
    once-weekly semaglutide 2.4 mg added to standard cognitive behavioural
    therapy in 108 treatment-seeking patients with moderate to severe AUD and
    comorbid obesity, with reduction in heavy drinking days as the primary
    endpoint.
  target_phenotypes:
  - preferred_term: Problematic alcohol consumption
    term:
      id: HP:5200329
      label: Problematic alcohol consumption
  evidence:
  - reference: PMID:42070571
    reference_title: "Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Semaglutide showed robust therapeutic effects in treatment-seeking
      participants with obesity and alcohol use disorder and this trial supports
      previous preclinical and clinical findings suggesting GLP-1 receptor
      agonists as a potential novel treatment target for alcohol use disorder.
    explanation: >-
      States the trial's overall conclusion for its treatment-seeking,
      comorbid-obesity population.
animal_models:
- species: Rattus norvegicus
  genotype: Selectively bred alcohol-preferring (P) and high-alcohol-drinking (HAD1, HAD2) lines
  category: Selectively bred (polygenic) rat lines
  description: >-
    Bidirectional selective breeding for voluntary ethanol preference produced
    the P and HAD lines, which drink to pharmacologically relevant blood
    alcohol concentrations without induction. They are the reference polygenic
    rodent model for AUD liability and supply the compulsive- and
    relapse-drinking paradigms this entry's habit and negative-reinforcement
    nodes depend on. Limitation: they model early-onset high-consumption
    liability rather than the full DSM-5 criterion set, and their alcohol
    pharmacokinetics differ from human.
  associated_phenotypes:
  - Voluntary ethanol consumption reaching intoxicating blood alcohol concentrations
  - Alcohol deprivation effect under relapse conditions
  - Binge-like drinking
  evidence:
  - reference: PMID:24268381
    reference_title: "The alcohol-preferring (P) and high-alcohol-drinking (HAD) rats--animal models of alcoholism."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The P line of rats meets all of the originally proposed criteria for a
      suitable animal model of alcoholism.
    explanation: >-
      States that the P line satisfies the accepted formal criteria for an
      animal model of alcoholism.
  - reference: PMID:24268381
    reference_title: "The alcohol-preferring (P) and high-alcohol-drinking (HAD) rats--animal models of alcoholism."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The P line also exhibits excessive binge-like alcohol drinking, attaining
      blood alcohol concentrations (BACs) of 200 mg% on a daily basis.
    explanation: >-
      Documents that the model reaches pharmacologically meaningful blood
      alcohol concentrations, which is what makes it usable for the
      binge/intoxication stage.
- species: Mus musculus
  genotype: High Alcohol Preferring (HAP1, HAP2) and Low Alcohol Preferring (LAP1, LAP2) lines
  category: Bidirectionally selectively bred mouse lines
  description: >-
    The only extant mouse lines bred specifically for divergent alcohol
    preference, and therefore the main mouse resource for mapping loci that
    influence voluntary consumption. Because the lines are not inbred, they
    support QTL designs that inbred strains cannot.
  associated_phenotypes:
  - Divergent voluntary alcohol preference between the HAP and LAP lines
  evidence:
  - reference: PMID:16482403
    reference_title: "Identification of QTLs influencing alcohol preference in the High Alcohol Preferring (HAP) and Low Alcohol Preferring (LAP) mouse lines."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The High- and Low-Alcohol Preferring (HAP1/LAP1 and HAP2/LAP2) mouse
      lines were developed by selective breeding for differences in alcohol
      preference.
    explanation: >-
      Establishes the derivation and purpose of the HAP/LAP lines.
  - reference: PMID:16482403
    reference_title: "Identification of QTLs influencing alcohol preference in the High Alcohol Preferring (HAP) and Low Alcohol Preferring (LAP) mouse lines."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      They represent the only extant selectively bred mouse lines developed for
      this alcohol phenotype.
    explanation: >-
      Supports the claim that these are the unique mouse resource for this
      phenotype.
- species: Mus musculus
  genotype: High Drinking in the Dark (HDID-1, HDID-2) selected lines, from an HS/Npt heterogeneous stock
  category: Selectively bred model of drinking to intoxication
  description: >-
    Bred specifically for reaching high blood alcohol concentrations in a
    limited-access binge paradigm, so this is the model of the
    binge/intoxication stage rather than of preference per se. Mechanistically
    informative in a negative direction: the high-drinking phenotype tracks
    reduced sensitivity to alcohol's aversive effects, not increased
    sensitivity to its rewarding effects, which qualifies any assumption that
    heavy drinking simply reflects greater reward.
  associated_phenotypes:
  - Binge-like drinking to intoxicating blood alcohol concentrations
  - Attenuated conditioned taste aversion to a moderate ethanol dose
  evidence:
  - reference: PMID:23910826
    reference_title: "Rewarding and aversive effects of ethanol in High Drinking in the Dark selectively bred mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      These results indicate that high blood alcohol levels after drinking in
      the HDID mice is genetically related to attenuated aversion to alcohol,
      while sensitivity to alcohol reward is not altered in these mice.
    explanation: >-
      Dissociates aversion sensitivity from reward sensitivity in the
      binge-drinking model, constraining how the reward node may be
      extrapolated from it.
  - reference: PMID:23910826
    reference_title: "Rewarding and aversive effects of ethanol in High Drinking in the Dark selectively bred mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      HDID and HS mice showed comparable development of alcohol-induced
      conditioned place preference.
    explanation: >-
      Shows no difference in conditioned reward between the selected line and
      its progenitor stock, the observation the dissociation rests on.
discussions:
- discussion_id: aud_extended_amygdala_translation
  kind: KNOWLEDGE_GAP
  prompt: >-
    Does pharmacological targeting of the extended-amygdala stress systems
    (CRF1, kappa-opioid) translate into clinical benefit in human AUD, given
    that the preclinical evidence is strong but no such agent is approved?
  attaches_to:
  - pathophysiology#Extended Amygdala Stress-System Recruitment
  rationale: >-
    The CRF and dynorphin/kappa-opioid arms of the withdrawal/negative affect
    stage are supported almost entirely by rodent pharmacology (local antagonist
    infusion, dependence-induced escalation), while the human evidence curated
    here is a review-level framework rather than a controlled trial. The node's
    clinical actionability is therefore an open question rather than settled
    biology.
  proposed_experiments:
  - experiment_id: exp_aud_kor_crf1_rct
    name: Randomized trial of kappa-opioid or CRF1 antagonism stratified by negative-affect phenotype
    description: >-
      Adequately powered randomized placebo-controlled trial of a kappa-opioid
      or CRF1 antagonist in AUD, stratified by withdrawal severity or a
      negative-affect/hyperkatifeia phenotype, with heavy drinking days and
      craving as endpoints.
  - experiment_id: exp_aud_extended_amygdala_imaging
    name: Human imaging or CSF measures of extended-amygdala stress-system engagement
    description: >-
      PET or CSF assessment of CRF and dynorphin system engagement in the
      extended amygdala in people with AUD, correlated with negative-affect
      drinking measures, to test whether the rodent mechanism is engaged in
      humans.
- discussion_id: aud_habit_system_human_fidelity
  kind: HUMAN_MODEL_MISMATCH
  prompt: >-
    Does the ventral-to-dorsolateral striatal shift in control over alcohol
    seeking, demonstrated in alcohol-preferring rats, occur in human AUD?
  attaches_to:
  - pathophysiology#Dorsolateral Striatal Habit System Recruitment
  rationale: >-
    The habit-system claim rests on outcome-devaluation and
    punishment-resistance paradigms in rats, which have no direct human
    equivalent: human compulsivity is assessed by self-report diagnostic
    criteria rather than by devaluation insensitivity. The anatomical
    localization to anterior dorsolateral striatum is therefore extrapolated,
    not measured, in patients.
  proposed_experiments:
  - experiment_id: exp_aud_human_devaluation_fmri
    name: Human fMRI outcome-devaluation and punished-seeking paradigm in AUD
    description: >-
      Test whether people with AUD show devaluation-insensitive,
      punishment-resistant alcohol seeking accompanied by dorsal rather than
      ventral striatal engagement, relative to matched controls.
  - experiment_id: exp_aud_longitudinal_striatal_shift
    name: Longitudinal imaging across the transition to AUD
    description: >-
      Follow hazardous drinkers longitudinally with repeated imaging to test
      whether a ventral-to-dorsal striatal shift precedes, rather than follows,
      the emergence of compulsive drinking.
references:
- reference: PMID:27475769
  title: "Neurobiology of addiction: a neurocircuitry analysis."
- reference: PMID:33318153
  title: "Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development."
- reference: PMID:26039070
  title: "Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III."
- reference: PMID:37934220
  title: "Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis."
- reference: PMID:38062264
  title: "Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals."

📚

References & Deep Research

References

5

PMID:27475769

Neurobiology of addiction: a neurocircuitry analysis.

No top-level findings curated for this source.

PMID:33318153

Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

No top-level findings curated for this source.

PMID:26039070

Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III.

No top-level findings curated for this source.

PMID:37934220

Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis.

No top-level findings curated for this source.

PMID:38062264

Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals.

No top-level findings curated for this source.

Deep Research

1

Claude Code ▸

Alcohol Use Disorder (AUD): Comprehensive Disease Characteristics Research Report

claude-haiku-4-5-20251001, claude-sonnet-5 34 citations 2026-08-09T14:31:18.154047

Alcohol Use Disorder (AUD): Comprehensive Disease Characteristics Research Report

1. Disease Information

Overview. Alcohol use disorder (AUD) is a chronic, relapsing brain disorder characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. It is a "brain disease" model condition in the addiction neuroscience literature — involving compulsive substance seeking and use, loss of control over intake, and a negative emotional state when the substance is unavailable (Koob & Volkow, Lancet Psychiatry 2016, PMID: 27475769; Volkow, Koob & McLellan, NEJM 2016, PMID: 26816013). The DSM-5 (American Psychiatric Association, 2013) merged the former DSM-IV categories of "alcohol abuse" and "alcohol dependence" into a single diagnosis, Alcohol Use Disorder, scored on a continuum of mild (2–3 symptoms), moderate (4–5 symptoms), or severe (≥6 symptoms) from an 11-item symptom list spanning impaired control, social impairment, risky use, and pharmacological criteria (tolerance, withdrawal).

Key identifiers: | Resource | Identifier | Notes | |---|---|---| | OMIM | #103780 "Alcohol Dependence" (phenotype MIM); related gene loci ADH1B (103720), ALDH2 (100650) | Number-sign entry reflecting polygenic susceptibility (multiple genes/loci) rather than a single-gene Mendelian disorder | | ICD-11 | 6C40 "Disorders due to use of alcohol" (parent), with children 6C40.0 (episode of harmful use), 6C40.1 (harmful pattern of use), 6C40.2 (alcohol dependence), plus 6C40.3–6C40.7 (alcohol intoxication, withdrawal, withdrawal delirium, alcohol-induced psychotic/mood/anxiety disorder) (Saunders, Alcohol Clin Exp Res 2019, PMID: 31194891; Poznyak et al., PMC9881115) | | ICD-10-CM | F10.- "Alcohol related disorders" (e.g., F10.20 alcohol dependence, uncomplicated; F10.10 alcohol abuse) | | MeSH | Alcoholism (D000437); related headings "Alcohol-Related Disorders" (D000431) and "Binge Drinking" (D058188) | | MONDO | Mondo harmonizes AUD with OMIM #103780 and ICD-11 6C40; the exact MONDO CURIE was not confirmed against a live ontology browser in this research pass and should be verified via the Monarch Initiative / OLS4 MONDO browser before use in curation, rather than asserted here | | Orphanet | Not applicable — AUD is a common complex disorder, outside Orphanet's rare-disease scope | | GARD/NORD | Not applicable (common disorder) |

Synonyms/alternative names: Alcoholism; alcohol dependence; alcohol addiction; alcohol abuse (older, narrower DSM-IV term now subsumed); "problematic alcohol use" (the phenotype label commonly used in genetics literature to combine clinical AUD diagnoses with the AUDIT-C/AUDIT screening-based phenotype).

Evidence basis. Most of the epidemiological and diagnostic-criteria literature is derived from aggregated population-level survey data (e.g., NESARC-III, NSDUH, UK Biobank) rather than individual EHR chart review, supplemented by large-scale biobank/EHR-linked genomic cohorts (Million Veteran Program, UK Biobank, FinnGen, Psychiatric Genomics Consortium) for genetic association analyses.

2. Etiology

Disease Causal Factors

AUD is a multifactorial, gene-environment disorder. No single causal lesion exists; risk emerges from the additive and interactive effects of many common genetic variants of small individual effect, combined with environmental exposure (access to alcohol, early-life drinking onset, stress, trauma, peer/family use) and repeated pharmacological exposure to ethanol producing durable neuroadaptation (see Mechanism, §6).

Genetic Risk Factors

Twin/family heritability: Genetic factors account for an estimated 40–60% of variance in liability to alcohol dependence (OMIM #103780, summarizing family/twin/adoption literature). A twin-and-adoption meta-analysis (Verhulst, Neale & Kendler, Psychol Med 2015, PMID: 25066582) is the standard heritability reference. Recent longitudinal twin work models AUD symptom liability as more heritable (~36%) than symptom count (~22%) or categorical diagnosis (~14%), with genetic influence on most DSM-5 criteria (except craving) substantially overlapping across symptoms (per search of PMC13092882 / ScienceDirect twin-genetics literature).
Alcohol-metabolizing enzyme variants (largest documented single-locus effects, protective/predisposing):
ADH1B (alcohol dehydrogenase 1B; HGNC:249; OMIM 103720) — the fast-metabolizing variant rs1229984 (His48Arg, also called ADH1B2) accelerates ethanol→acetaldehyde conversion, causing an aversive acetaldehyde buildup and flushing reaction that is strongly protective against AUD (odds ratios for protection commonly reported 1.2–1.8 per allele; the variant is one of the most replicated genome-wide-significant hits across alcohol-phenotype GWAS).
ALDH2 (aldehyde dehydrogenase 2, mitochondrial; HGNC:404) — the East Asian–specific loss-of-function variant rs671 (Glu504Lys, ALDH2*2) impairs acetaldehyde clearance, producing the "Asian flushing" reaction; it is the single largest-effect protective variant known for alcohol consumption/AUD in East Asian populations (Science Advances 2023/2024 genotype-stratified Japanese GWAS; PMID for Edenberg's foundational review: 17718403).
ADH1C, ADH4 — additional class I/II ADH cluster genes on chr4q23 in linkage disequilibrium with ADH1B, contributing modestly.
Reward/neurotransmission genes:
GABRA2 (GABA-A receptor alpha-2 subunit; HGNC:4083) — one of the earliest and most replicated non-metabolic AUD/alcohol-dependence association genes (Edenberg et al., Am J Hum Genet 2004, PMID: 15024690), implicating GABAergic inhibitory tone in dependence risk.
KLB (beta-klotho, co-receptor for FGF21; chr4q14) — index SNP rs11940694 associated with AUDIT total score/alcohol consumption across multiple large GWAS; mechanistically links to a liver–brain FGF21 endocrine axis regulating alcohol preference.
GCKR (glucokinase regulator) — replicated locus linking alcohol consumption to glucose/lipid metabolism pathways.
OPRM1 (mu-opioid receptor; HGNC:8156) — the rs1799971 (A118G) variant has been extensively studied as a moderator of naltrexone treatment response (pharmacogenomic significance; see §12) though large prospective genotype-stratified trials have failed to confirm a clinically actionable effect.
Large-scale multi-ancestry GWAS: Zhou et al. (Nature Medicine, 2023; cross-ancestry meta-analysis of 1,079,947 individuals — European N=903,147, African N=122,571, Latin American N=38,962, East Asian N=13,551, South Asian N=1,716) identified 110 independent risk variants for "problematic alcohol use," with fine-mapping and gene-expression/chromatin-interaction prioritization implicating additional brain-expressed genes beyond the classical metabolic loci; a related multi-ancestry cross-disorder pleiotropy analysis (Nature Mental Health, 2024) further links AUD risk loci to psychiatric cross-disorder liability.
Polygenic architecture: As with most psychiatric traits, common-variant SNP heritability is substantial but individual locus effects (outside ADH1B/ALDH2) are small (odds ratios typically 1.03–1.10), consistent with a highly polygenic trait amenable to polygenic risk scoring but not single-gene diagnostic testing.
Modifier/pleiotropic genes: Genome-wide genetic correlations link AUD risk to major depressive disorder, ADHD, schizophrenia, and other substance use disorders (shared liability/"externalizing" and "internalizing" genetic factors), consistent with the high phenotypic psychiatric comorbidity described in §5/§11.

Environmental Risk Factors

Early age of drinking onset; heavy episodic ("binge") drinking patterns; chronic stress and adverse childhood experiences/trauma (including PTSD); family/peer alcohol use and permissive social norms; low socioeconomic status and unemployment; occupational alcohol access; psychiatric comorbidity (self-medication hypothesis); male sex (higher prevalence, though the gap is narrowing); comorbid nicotine/other substance use; alcohol outlet density and marketing exposure; and — per Global Burden of Disease trend analyses — rising per-capita alcohol availability in medium-to-high sociodemographic-index regions, particularly pronounced in Eastern Europe (Frontiers in Public Health 2025 GBD working-age trend analysis, PMC12336152).

Protective Factors

Genetic: ADH1B2 (rs1229984) and ALDH22 (rs671), as above — the clearest examples of genetically protective alleles for any common psychiatric/behavioral disorder.
Environmental: Religious/cultural abstinence norms, strong family cohesion and monitoring, delayed drinking-onset policies (minimum legal drinking age), alcohol taxation/pricing policy, restricted outlet density, and access to early intervention/brief counseling.

Gene-Environment Interactions

The genotype-stratified 2023/2024 Japanese GWAS (175,672 individuals; Science Advances) is a landmark G×E-adjacent design: because ALDH2 rs671 genotype strongly gates the physiological consequence of drinking, stratifying by rs671 genotype revealed genome-wide-significant interaction signals at several loci (in addition to the three loci significant in wild-type homozygotes: GCKR, KLB, ADH1B), demonstrating that genetic background modulates how strongly environmental alcohol exposure translates into consumption/AUD risk. More broadly, stressful environments and early-life adversity are hypothesized to interact with GABAergic/HPA-axis genetic variation to potentiate AUD risk (a widely cited but still maturing area of human GxE research, largely built on candidate-gene rather than genome-wide interaction studies to date).

3. Phenotypes

AUD phenotypes span behavioral/psychiatric symptoms (the DSM-5 diagnostic criteria), physiological withdrawal/tolerance signs, and downstream organ-system complications from chronic use.

Core DSM-5 diagnostic symptom domains (11 criteria, ≥2 required within 12 months for diagnosis)

Drinking more/longer than intended (impaired control)
Persistent desire or unsuccessful efforts to cut down
Great deal of time spent obtaining/using/recovering from alcohol
Craving — strong desire/urge to drink
Failure to fulfill major role obligations (social impairment)
Continued use despite social/interpersonal problems caused by alcohol
Important activities given up/reduced because of drinking
Recurrent use in physically hazardous situations (risky use)
Continued use despite knowledge of physical/psychological problems caused by alcohol
Tolerance — need for markedly increased amounts for the same effect
Withdrawal — characteristic withdrawal syndrome, or use to relieve/avoid withdrawal

Acute intoxication phenotypes

Slurred speech, incoordination, unsteady gait, nystagmus, impaired attention/memory, stupor/coma at high blood alcohol concentration; behavioral disinhibition, mood lability. - Suggested HPO: HP:0001350 (Slurred speech), HP:0001288 (Gait disturbance), HP:0000639 (Nystagmus), HP:0001269 (Abnormality of the nervous system — parent term where specific descendants are lacking)

Alcohol withdrawal syndrome (onset hours after cessation in a physiologically dependent individual)

Minor withdrawal (6–24h): tremor, anxiety, headache, GI upset, insomnia, autonomic hyperactivity (tachycardia, diaphoresis, hypertension). Suggested HPO: HP:0002378 (Tremor)/HP:0030955, HP:0000738 (Anxiety), HP:0002099 (Tachypnea, if relevant), HP:0100543 (Cognitive impairment).
Withdrawal seizures: typically generalized tonic-clonic, occurring within the first 12–48h. Suggested HPO: HP:0002069 (Generalized tonic-clonic seizure).
Alcohol withdrawal delirium (Delirium Tremens): the most severe manifestation, occurring 24–72h (occasionally later) after last drink in a minority of patients with withdrawal seizures; fluctuating consciousness disturbance, profound disorientation/confusion, visual/tactile hallucinations, fever, marked tachycardia, diaphoresis, hypertension (StatPearls NBK441882; PMC11069634 DT clinical review). Untreated mortality historically up to 15–20%, now much lower with benzodiazepine-based management. Suggested HPO: HP:0000726 (Dementia — imprecise), HP:0031466 or general HP:0000708 (Behavioral abnormality); note HPO lacks a precise "delirium" term in common use — best modeled via MONDO's own ICD-11 6C40.4 child term rather than forced HPO mapping.

Cognitive/psychiatric phenotypes

Impaired executive function, working memory, and decision-making (frontostriatal dysfunction); depressed mood; anxiety; irritability; sleep disturbance; anhedonia during protracted abstinence (part of the "negative affect" stage of the addiction cycle — see Mechanism). Suggested HPO: HP:0000726, HP:0000716 (Depressivity), HP:0000739 (Anxiety) mapped as available, HP:0002360 (Sleep disturbance).

End-organ complication phenotypes (chronic, downstream)

Hepatic: steatosis → alcoholic hepatitis → fibrosis → cirrhosis. HP:0001397 (Hepatic steatosis), HP:0001394 (Hepatic fibrosis/Cirrhosis).
Neurological: peripheral neuropathy (HP:0009830), cerebellar ataxia/degeneration (HP:0001251), Wernicke encephalopathy (thiamine-deficiency triad: confusion, ataxia, ophthalmoplegia) and Korsakoff amnestic syndrome, cognitive decline.
Cardiovascular: cardiomyopathy (HP:0001638), hypertension, arrhythmia (atrial fibrillation — "holiday heart").
GI/pancreatic: pancreatitis (HP:0001733), gastritis, esophageal varices.
Psychiatric comorbid conditions: as detailed in §5/§11.

Phenotype characteristics

Onset: Typically emerges in late adolescence to young adulthood (peak initiation age 18–25), though diagnostic threshold crossing (moderate/severe AUD) often occurs later after years of escalating use; late-onset AUD (>40–50 years) is a recognized, often better-prognosis subtype.
Severity: DSM-5 stratifies mild/moderate/severe by symptom count; severity correlates with likelihood of withdrawal complications and treatment resistance.
Progression: Variable — can be chronic-progressive, episodic/relapsing-remitting (the modal pattern, with periods of abstinence/moderation punctuated by relapse), or, in a substantial minority, spontaneously remitting without formal treatment ("natural recovery," more common in milder cases).
Frequency (US NESARC-III): 12-month prevalence of DSM-5 AUD ≈ 13.9%; lifetime prevalence ≈ 29.1% (Grant et al., JAMA Psychiatry 2015, PMID: 26039070).

Quality of Life Impact

AUD is a leading contributor to global disability-adjusted life years (DALYs) among behavioral/substance disorders (Global Burden of Disease). Impacts span occupational/functional impairment, relationship breakdown, legal/financial consequences, and markedly reduced health-related quality of life scores (EQ-5D/SF-36 domains), compounded further once end-organ complications (cirrhosis, neuropathy, cognitive decline) develop.

4. Genetic/Molecular Information

Causal/Major-Effect Genes (complex trait — no monogenic Mendelian cause; these are the largest-effect common-variant loci)

Gene	HGNC	Locus	Variant	Effect
ADH1B	HGNC:249	4q23	rs1229984 (His48Arg)	Protective — fast ethanol oxidation → acetaldehyde buildup
ALDH2	HGNC:404	12q24.12	rs671 (Glu504Lys)	Strongly protective (East Asian populations) — impaired acetaldehyde clearance
ADH1C	HGNC:251	4q23	in LD with ADH1B	Modest, population-dependent
GABRA2	HGNC:4083	4p12	multiple intronic/regulatory SNPs	Risk — GABAergic inhibitory signaling
KLB	HGNC:24578	4q14.1	rs11940694	Risk — FGF21 co-receptor, consumption phenotype
GCKR	HGNC:4196	2p23.3	rs1260326 (and others)	Risk — metabolic pathway pleiotropy
OPRM1	HGNC:8156	6q25.2	rs1799971 (A118G)	Modifier of opioidergic reward signaling; naltrexone response modifier (contested)

Pathogenic Variants / Classification

AUD is not classified under ACMG/AMP pathogenicity tiers (pathogenic/likely pathogenic/VUS) because it is a polygenic complex trait, not a monogenic Mendelian condition; ClinVar does not carry AUD-specific variant classifications. Variant-level evidence instead comes from GWAS association statistics (odds ratios, p-values, fine-mapping posterior probabilities) rather than clinical variant curation. - Allele frequency: ADH1B2 (rs1229984) is common in East Asian (~70%) populations and less common in European (~5–10%) and rare in African populations; ALDH22 (rs671) allele frequency is ~30–50% in East Asian populations and essentially absent elsewhere (gnomAD, 1000 Genomes population panels). - Origin: Germline, common polymorphisms (not somatic). - Functional consequence: ADH1B2 = gain-of-function (faster catalytic turnover) in ethanol oxidation; ALDH22 = dominant-negative loss-of-function in the tetrameric mitochondrial ALDH2 enzyme (heterozygotes show substantial enzyme inactivation due to the dominant-negative effect of the mutant subunit within the homotetramer).

Modifier Genes

Genes in the "externalizing" and psychiatric cross-disorder polygenic factors (e.g., loci shared with ADHD, MDD, schizophrenia via genetic correlation) act as risk modifiers rather than primary causal loci; DRD2, CHRM2, SLC6A4 (serotonin transporter) have candidate-gene literature of variable replication.

Epigenetic Information

Chronic alcohol exposure is associated with genome-wide DNA methylation changes in blood and brain tissue, particularly at genes involved in immune signaling, neurodevelopment, and ALDH2/ADH loci themselves; histone modification changes (e.g., altered H3K4/H3K9 methylation, histone acetylation via HDAC inhibition by acetaldehyde metabolites) in reward-circuit brain regions have been implicated in the maintenance of compulsive drinking behavior in preclinical models. Human epigenome-wide association studies (EWAS) of AUD have identified differentially methylated regions overlapping known GWAS loci (JCI review of AUD human genetics/epigenetics, 2023–2024, JCI 172885).

Chromosomal Abnormalities

Not a feature of AUD — no recurrent aneuploidy, translocation, or CNV syndrome is causally implicated; AUD is excluded from chromosomal-abnormality databases (DECIPHER, ECARUCA) as it is not a genomic disorder in that sense.

5. Environmental Information

Environmental/toxicological factor: Ethanol (CHEBI:16236) itself is the causal exposure — a CNS depressant and hepatotoxin metabolized primarily via ADH→acetaldehyde (CHEBI:15343, a Group 1 IARC carcinogen)→ALDH→acetate.
Lifestyle factors: Binge drinking pattern (≥4/5 drinks for women/men in ~2 hours), drinking frequency and quantity, co-use with nicotine/other substances, diet (poor nutrition, thiamine deficiency risk), sedentary behavior, sleep disruption.
Infectious agents: Not a primary etiological factor for AUD itself, though chronic AUD is a major risk factor for infection susceptibility (immune suppression) and complicates management of infections such as hepatitis B/C (shared risk behaviors) and tuberculosis reactivation.
Socioenvironmental/structural factors: Alcohol marketing and outlet density, price/taxation policy, occupational exposure (hospitality/service industries), cultural/religious drinking norms, and adverse childhood experiences (ACEs)/trauma exposure, which is one of the most robust non-genetic risk amplifiers documented in the epidemiological literature.

6. Mechanism / Pathophysiology

AUD pathophysiology is best conceptualized (Koob & Volkow's addiction-cycle model, Lancet Psychiatry 2016, PMID: 27475769) as progression through three recurring, neuroadapting stages: binge/intoxication → withdrawal/negative affect → preoccupation/anticipation (craving), each mapped to a distinct but interconnected brain circuit.

Molecular pathways and neurotransmitter systems

GABAergic potentiation (acute): Ethanol acutely potentiates GABA-A receptor–mediated inhibitory neurotransmission (positive allosteric modulation), producing sedative/anxiolytic acute effects. Ventral tegmental area (VTA) GABA interneurons are implicated in alcohol reward: ethanol increases VTA dopamine neuron firing partly via inhibition of GABA release onto dopaminergic neurons (disinhibition mechanism) (PMC5605989; troscriptions/GABA review synthesis; Knowledge atlas bibliometric review PMC9411946).
Glutamatergic suppression (acute) → glutamatergic hyperexcitability (chronic): Acute ethanol inhibits NMDA receptor–mediated glutamatergic transmission; chronic exposure produces a compensatory upregulation/sensitization of NMDA and other glutamate receptor signaling, so that upon alcohol cessation the CNS is left in a hyperglutamatergic, hyperexcitable state — the principal mechanism underlying withdrawal hyperexcitability, tremor, and seizures (PMC4407613, "Targeting glutamate uptake to treat AUD"; PMC9411946).
Mesolimbic dopamine system: Acute alcohol increases dopamine release in the nucleus accumbens via VTA disinhibition, mediating acute reward. With repeated/chronic exposure, there is a reduction in baseline mesolimbic dopaminergic tone during withdrawal/abstinence — the "reward deficit" that drives negative affect and relapse vulnerability (Koob, Curr Top Behav Neurosci 2013, PMID: 24273570; MDPI AUD Neurobiology and Therapeutics review, 2022).
Opioidergic system: Ethanol triggers endogenous opioid (beta-endorphin) release, which stimulates VTA dopamine neurons via mu-opioid receptor (OPRM1)–mediated disinhibition of GABAergic interneurons — the mechanistic basis for opioid-antagonist pharmacotherapy (naltrexone; see §12).
HPA axis and extended amygdala stress systems: Chronic alcohol exposure dysregulates corticotropin-releasing factor (CRF) signaling in the central nucleus of the amygdala and bed nucleus of the stria terminalis, producing a sensitized stress response that drives negative-affect-motivated drinking during withdrawal — a key target of experimental CRF1-antagonist and related pharmacotherapies.

Cellular processes

Neuroinflammation (microglial activation via TLR4 signaling in response to ethanol/acetaldehyde), oxidative stress, mitochondrial dysfunction (notably in hepatocytes, driving alcoholic liver disease — feeds into the dismech hepatic_steatosis_lipotoxicity and drug_induced_liver_injury-adjacent mechanism space), synaptic pruning/remodeling in prefrontal cortex reducing top-down inhibitory control over subcortical reward circuitry, and apoptosis of thiamine-dependent neurons in Wernicke-Korsakoff pathology.

Protein dysfunction / biochemical abnormalities

Enzymatic: ADH/ALDH functional variation (see §4) directly alters the toxic acetaldehyde intermediate's accumulation — the central biochemical determinant of both flushing reactions and long-term carcinogenic/hepatotoxic risk.
Receptor-level: NMDA receptor subunit composition shifts (increased GluN2B expression) with chronic exposure; GABA-A receptor subunit composition changes (e.g., altered alpha4/delta subunit expression) underlying tolerance.

Metabolic changes

Ethanol oxidation consumes NAD+ (shifting hepatocyte NADH:NAD+ ratio), promoting lipogenesis and inhibiting fatty acid oxidation and gluconeogenesis — the direct biochemical driver of hepatic steatosis; chronic heavy drinking also produces caloric substitution/malnutrition and thiamine (vitamin B1) deficiency, precipitating Wernicke encephalopathy.

Immune system involvement

Chronic alcohol exposure activates innate immune signaling (TLR4/NF-kB pathway) in both liver (Kupffer cells) and brain (microglia), producing a pro-inflammatory state that contributes both to alcoholic liver disease progression and to neuroinflammation-driven negative affect/craving.

Tissue damage mechanisms

Oxidative stress (reactive oxygen species from CYP2E1-mediated ethanol metabolism, induced with chronic heavy use), acetaldehyde protein/DNA adduct formation (carcinogenic mechanism), and progressive fibrosis (activated hepatic stellate cells — connects directly to the dismech fibrotic_response module architecture) in the liver; excitotoxic and oxidative neuronal injury in the CNS.

Molecular profiling

Transcriptomics: Postmortem and preclinical brain expression studies (GEO, GTEx-adjacent AUD brain expression datasets) show altered expression of genes in myelination, synaptic transmission, and immune pathways in prefrontal cortex of individuals with AUD.
Proteomics/metabolomics: Serum biomarkers of chronic heavy use include elevated carbohydrate-deficient transferrin (CDT), phosphatidylethanol (PEth — a direct ethanol metabolite biomarker with high specificity), and gamma-glutamyl transferase (GGT).
Single-cell/spatial: Emerging single-nucleus RNA-seq studies of postmortem AUD prefrontal cortex and amygdala tissue (Human Cell Atlas-adjacent efforts) are beginning to resolve cell-type-specific transcriptional signatures (microglial activation states, oligodendrocyte/myelination changes) associated with chronic alcohol exposure (PMC11566292, "Modeling Brain Gene Expression in AUD with Genetic Animal Models," 2024).

Suggested ontology terms

GO (biological process): GO:0035249 (synaptic transmission, glutamatergic); GO:0051932 (synaptic transmission, GABAergic); GO:0007268 (chemical synaptic transmission); GO:0006066 (alcohol metabolic process); GO:0006979 (response to oxidative stress); GO:0032496 (response to lipopolysaccharide, for neuroinflammatory signaling).
CL (cell types): dopaminergic neuron (VTA), GABAergic interneuron, hepatic stellate cell, Kupffer cell, microglial cell — exact CL CURIEs should be confirmed via OAK/OLS before KB entry.
CHEBI: ethanol (CHEBI:16236), acetaldehyde (CHEBI:15343), acetate (CHEBI:30089).

7. Anatomical Structures Affected

Organ level

Primary: Brain (mesocorticolimbic reward circuitry) and liver (primary site of metabolism and chronic toxic injury).
Secondary/complication organs: Pancreas (pancreatitis), heart (cardiomyopathy, arrhythmia), peripheral nervous system (neuropathy), GI tract (gastritis, esophageal varices from portal hypertension), immune system (impaired host defense).
Body systems: Nervous system (central and peripheral), hepatobiliary system, cardiovascular system, digestive system, endocrine system (HPA axis dysregulation).

Tissue/cell level

Neurons (dopaminergic VTA neurons, GABAergic interneurons, glutamatergic pyramidal neurons of prefrontal cortex), microglia, astrocytes; hepatocytes and hepatic stellate cells; pancreatic acinar cells; cardiomyocytes.

Subcellular level

Mitochondria (site of ALDH2 activity and oxidative-stress generation), synaptic membrane receptor complexes (GABA-A, NMDA receptor), endoplasmic reticulum (unfolded protein response in hepatocytes under ethanol-metabolic stress).

Localization (brain circuitry — key nodes)

Ventral tegmental area (VTA) — dopaminergic cell bodies
Nucleus accumbens (ventral striatum) — reward/binge-intoxication node
Central nucleus of the amygdala / extended amygdala — withdrawal/negative-affect node
Prefrontal cortex (particularly orbitofrontal and dorsolateral) — preoccupation/craving, impaired executive control
Bed nucleus of the stria terminalis — stress-integration node
Hippocampus — memory/conditioned-cue association with drinking contexts

Suggested UBERON terms (verify exact CURIEs before curation use): ventral tegmental area, nucleus accumbens, amygdala, prefrontal cortex, liver (UBERON:0002107), pancreas, heart.

8. Temporal Development

Onset: Modal initiation of alcohol use in adolescence; problematic use/AUD symptom crossing typically emerges in the late teens to twenties, though clinically significant AUD can be diagnosed at any adult age. Earlier age of drinking onset is itself a well-established risk factor for later AUD severity.
Onset pattern: Typically insidious/gradual escalation over months to years, though acute severe intoxication episodes and withdrawal syndromes are themselves acute events superimposed on the chronic underlying disorder.
Disease stages: Mild/moderate/severe by DSM-5 symptom count; clinically often staged as at-risk/hazardous use → harmful use → dependence, paralleling ICD-11's harmful-pattern-of-use vs. dependence distinction.
Progression rate/course: Highly variable — chronic-relapsing course is most typical, with the majority of individuals cycling through periods of abstinence, moderation, and relapse (NESARC longitudinal follow-up data); a substantial minority (especially milder cases) achieve natural remission without formal treatment.
Duration: Can be lifelong/chronic if untreated, though average time from AUD onset to first treatment contact is often many years (a documented treatment gap).
Remission patterns: Both spontaneous ("maturing out," more common with milder AUD and with life transitions such as marriage/parenthood/employment) and treatment-induced remission occur; formal remission criteria (DSM-5: early remission ≥3 but <12 months, sustained remission ≥12 months without criteria met, except craving) are defined.
Critical periods: Adolescence/young adulthood represents a neurodevelopmental window of heightened vulnerability, as the prefrontal cortex (executive control) matures later than subcortical reward circuitry, and early heavy exposure during this window produces more durable neuroadaptation.

9. Inheritance and Population

Epidemiology

Global prevalence (GBD 2023/2021 estimates): ~111.12 million people worldwide with AUD in 2021 (per Global Burden of Disease modeling reported via Our World in Data/IHME), representing a 14.66% increase in prevalence between 2000 and 2021. Age-standardized incidence, mortality, and DALY rates have generally declined from 1990–2021 even as absolute case counts (and burden in medium-to-high sociodemographic-index regions, especially Eastern Europe) have risen (Frontiers in Public Health 2025, PMC12336152).
US-specific (NESARC-III, DSM-5 criteria): 12-month prevalence 13.9%; lifetime prevalence 29.1% (Grant et al. 2015, PMID: 26039070).

Inheritance pattern

Complex/multifactorial (polygenic) inheritance — not Mendelian. No single gene is necessary or sufficient; risk is conferred by the additive/interactive effect of many common variants (see §4) combined with environmental exposure. - Penetrance: Not applicable in the Mendelian sense; better described via polygenic liability-threshold models, where genetic loading + environmental exposure must exceed a threshold for the clinical phenotype to manifest. - Expressivity: Highly variable — symptom profile, severity, and course differ substantially between individuals with similar genetic loading, reflecting the dominant role of environmental/behavioral exposure. - Genetic anticipation, germline mosaicism, chromosomal founder effects: Not applicable (not a repeat-expansion or single-gene Mendelian disorder). - Founder-effect-like population variation: ALDH22 (rs671) and ADH1B2 (rs1229984) show marked population-specific allele frequency differences (East Asian populations carry much higher frequencies of both protective alleles than European or African populations), producing genuine population-level differences in AUD prevalence and alcohol-flush phenotype that are population-genetic in origin (not classical single-family founder effects). - Consanguinity: Not a relevant risk modifier for a polygenic behavioral trait of this kind. - Carrier frequency: Not applicable (no single causal allele to carry).

Population demographics

Sex ratio: Historically strongly male-predominant (~2:1 to 3:1 male:female in most population surveys), though the gap has been narrowing in recent US/European cohorts, particularly among younger birth cohorts.
Geographic distribution: Highest age-standardized burden concentrated in Eastern Europe and parts of the former Soviet Union; substantial variation globally tied to per-capita alcohol consumption, religious/cultural abstinence norms (lower burden in many Muslim-majority countries), and alcohol policy environments.
Ethnic/ancestry variation: Markedly lower alcohol consumption and AUD prevalence in East Asian populations carrying high frequencies of ALDH22/ADH1B2 protective alleles; Indigenous populations in some regions show elevated AUD burden associated with a complex mix of socioeconomic marginalization, historical trauma, and, in some studies, differing ADH/ALDH allele frequencies.
Age distribution: Prevalence peaks in young adulthood (18–29) and generally declines with age, though a meaningful late-onset subgroup exists.

10. Diagnostics

Clinical tests / laboratory

Direct alcohol biomarkers: Blood alcohol concentration (acute intoxication); phosphatidylethanol (PEth) — a direct, highly specific biomarker of recent heavy alcohol use with a longer detection window (~2–4 weeks) than ethanol itself; ethyl glucuronide (EtG) and ethyl sulfate (EtS) in urine/hair for abstinence monitoring.
Indirect biomarkers: Elevated gamma-glutamyl transferase (GGT), carbohydrate-deficient transferrin (CDT), mean corpuscular volume (MCV, macrocytosis), AST:ALT ratio typically >2 in alcoholic hepatitis (vs. viral hepatitis where ALT>AST).
Imaging: Liver ultrasound/elastography (steatosis, fibrosis staging), brain MRI (cerebellar/cortical atrophy in chronic heavy use, mammillary body changes in Wernicke encephalopathy).
Biopsy/histopathology: Liver biopsy showing steatosis, Mallory-Denk bodies, and neutrophilic infiltration in alcoholic hepatitis; progression to bridging fibrosis/cirrhosis on later biopsy.

Genetic testing

Not part of routine clinical diagnosis — AUD diagnosis is entirely clinical/behavioral (DSM-5/ICD-11 criteria), not confirmed via genetic testing. Research-context genotyping of ADH1B/ALDH2 is occasionally used in pharmacogenomic or population-genetics research contexts (and is directly clinically relevant when disulfiram or disulfiram-like reactions are anticipated), but there is no clinical genetic panel, WGS/WES indication, or GTR-listed diagnostic test for AUD itself.

Clinical diagnostic criteria

DSM-5 (11-criterion symptom count, mild/moderate/severe severity tiers) — the primary US clinical/research diagnostic standard.
ICD-11 (6C40 series) — distinguishes harmful pattern of use from dependence using a somewhat different (narrower, more clinically focused) criteria set than DSM-5, a distinction actively discussed in the nosology literature (Saunders 2019, PMID: 31194891; PMC6899584 critique).
Screening instruments: AUDIT (Alcohol Use Disorders Identification Test, WHO-developed, 10-item) and its short form AUDIT-C (3-item) are the dominant quantitative screening/phenotyping tools used both clinically and as the continuous phenotype in most large-scale genetic association studies; CAGE questionnaire is a simpler 4-item clinical screen.
Differential diagnosis: Other substance use disorders, primary mood/anxiety disorders (which can both cause and result from heavy drinking), and other causes of the downstream organ phenotypes (e.g., non-alcoholic fatty liver disease, viral hepatitis for liver findings; other causes of peripheral neuropathy/ataxia).

Screening

Universal primary-care screening with AUDIT-C is recommended by USPSTF for adults, followed by brief intervention/referral to treatment ("SBIRT" model) for those screening positive.

11. Outcome/Prognosis

Survival and mortality

AUD substantially elevates all-cause mortality, chiefly through liver disease (cirrhosis, hepatocellular carcinoma), cardiovascular disease, alcohol-related cancers (esophageal, liver, breast, colorectal — ethanol/acetaldehyde is an IARC Group 1 carcinogen), unintentional injury, and suicide. Age-standardized AUD-attributable mortality has declined globally from 1990–2021 even as absolute burden has risen with population growth (GBD trend analyses, PMC12336152).

Morbidity and functional outcomes

Substantial disability contribution captured in global DALY estimates; functional impairment spans occupational, relationship, cognitive (frontostriatal executive dysfunction persisting into abstinence in a subset of patients), and legal/financial domains. Quality-of-life measures (EQ-5D, SF-36) are consistently reduced in active AUD relative to the general population and improve, though often not fully normalize, with sustained remission.

Disease course / complications

Progressive liver disease (steatosis → hepatitis → fibrosis → cirrhosis → hepatocellular carcinoma), Wernicke-Korsakoff syndrome, cardiomyopathy, pancreatitis, peripheral neuropathy, immune suppression/infection susceptibility, and high rates of co-occurring psychiatric illness (below).

Psychiatric comorbidity (major prognostic driver)

Comorbid major depressive disorder, anxiety disorders (including generalized anxiety, panic, and especially social anxiety disorder — lifetime comorbidity with AUD ≈2.4% in the general population, with social anxiety disorder associated with OR≈2.8 for alcohol dependence and OR≈1.2 for alcohol abuse; PMC2917264), PTSD, and bipolar disorder are all substantially elevated among individuals with AUD (PMC7006178 review of psychiatric comorbidities in AUD).
Among individuals with alcohol-associated liver disease specifically, nationwide data (2015–2023) show significantly increased prevalence of MDD, anxiety, and PTSD in both cirrhotic and non-cirrhotic groups relative to the general population (Digestive Diseases and Sciences 2025 nationwide trend study).
Top physical comorbidities in treatment-seeking AUD populations include hypertension, asthma, dyslipidemia, and liver enzyme abnormalities (PMC8783789 pilot comorbidity study).

Prognostic factors

Earlier treatment engagement, milder baseline severity, absence of psychiatric comorbidity, strong social support, and abstinence-oriented treatment adherence predict better outcomes; conversely, comorbid psychiatric illness, severe dependence (high symptom count), early-onset drinking, and ongoing high-risk environmental exposure predict poorer prognosis and higher relapse risk.

12. Treatment

Pharmacotherapy (FDA-approved)

Three medications are FDA-approved specifically for AUD: 1. Naltrexone (oral, approved 1994; long-acting injectable/Vivitrol, approved 2006) — mu-opioid receptor antagonist; reduces heavy drinking and helps prevent return to heavy drinking after a lapse by blunting the reinforcing/rewarding effects of alcohol. NCIT: Pharmacotherapy (NCIT:C15986); therapeutic_agent naltrexone. 2. Acamprosate (Campral, approved 2004) — modulates glutamatergic/GABAergic balance (putative NMDA receptor modulation), normalizing the post-withdrawal hyperglutamatergic state; supports abstinence maintenance with modest effect size; dosed three times daily (2 tablets/dose). 3. Disulfiram (Antabuse) — irreversibly inhibits aldehyde dehydrogenase, so that alcohol consumption causes acetaldehyde accumulation and an aversive "disulfiram-ethanol reaction" (flushing, nausea, vomiting, headache, hypotension) — a deterrent/aversion-based mechanism rather than an anti-craving mechanism.

Off-label / commonly used pharmacotherapy

Topiramate (glutamate/GABA modulation), gabapentin (particularly for withdrawal-adjacent anxiety/insomnia and protracted abstinence symptoms), baclofen (GABA-B agonist, used especially in some European countries and in hepatically impaired patients).

Emerging / investigational pharmacotherapy

GLP-1 receptor agonists are an actively emerging investigational class: a phase 2 randomized clinical trial of once-weekly semaglutide in AUD (enrollment Sept 2022–Feb 2024) found that low-dose semaglutide reduced alcohol consumption in a laboratory self-administration paradigm and significantly reduced weekly alcohol craving relative to placebo over 9 weeks, though effects on other consumption measures were mixed (published JAMA Psychiatry-family journal, PMID: 39937469; PMC11822619). A more recent randomized, double-blind, placebo-controlled trial in patients with AUD and comorbid obesity (published in The Lancet, 2026) reported alcohol consumption reductions of over 70% after 26 weeks of semaglutide treatment. NIH-funded work has also shown that adding weekly GLP-1 therapy to cognitive behavioral therapy further reduces heavy drinking days. Mechanistically, GLP-1 receptor signaling in reward-circuit regions (VTA, nucleus accumbens) is hypothesized to blunt alcohol's dopaminergic reinforcing effects, paralleling the class's established appetite/reward-modulating action in obesity and other addictive behaviors. Other agents under investigation in the search results include lacosamide (sodium channel modulator), pitolisant (histamine H3 antagonist/inverse agonist), and N-acetylcysteine (antioxidant/glutamatergic modulation), the latter studied specifically in veterans with comorbid TBI.

Pharmacogenomics

CPIC has issued naltrexone pharmacogenomic guidance considering both pharmacodynamic (OPRM1 rs1799971/A118G) and pharmacokinetic (ADH, ALDH) genes. The OPRM1 G-allele has been associated with improved naltrexone response and lower relapse rates in some cohort/meta-analytic studies, but prospective genotype-stratified randomized trials and rigorous meta-analyses have failed to confirm a clinically actionable effect, and current evidence does not support routine clinical genotyping to guide naltrexone prescribing (PMC4165632; systematic review/meta-analysis literature on rs1799971).

Psychosocial/behavioral treatment

Cognitive behavioral therapy (CBT), motivational enhancement therapy, 12-step facilitation/mutual-help group participation (Alcoholics Anonymous), contingency management, and couples/family-based interventions are core evidence-based non-pharmacological treatments, often combined with pharmacotherapy for best outcomes (as illustrated by the CBT+GLP-1 combination trial above). NCIT: Behavioral Counseling / Therapeutic Procedure terms as available.

Withdrawal management (acute)

Benzodiazepines (the mainstay for withdrawal seizure/delirium tremens prevention) administered on a symptom-triggered or fixed-schedule protocol (e.g., CIWA-Ar scale-guided), supportive care, and thiamine repletion (to prevent/treat Wernicke encephalopathy) prior to glucose administration.

Treatment gaps and outcomes

Despite three FDA-approved medications, pharmacotherapy remains substantially underutilized in US treatment settings, and treatment response is heterogeneous — motivating the active pharmacogenomic and novel-mechanism (GLP-1, glutamatergic) research programs above.

13. Prevention

Primary prevention

Minimum legal drinking age laws, alcohol taxation/pricing policy, restriction of alcohol marketing/advertising (particularly targeting youth), outlet density regulation, school- and community-based prevention programs targeting delayed drinking onset, and parental monitoring interventions.

Secondary prevention (screening/early intervention)

Universal AUDIT-C screening in primary care with brief intervention and referral to treatment (SBIRT), USPSTF-recommended for all adults; early identification of hazardous/harmful use before progression to dependence.

Tertiary prevention

Relapse-prevention pharmacotherapy and behavioral maintenance treatment; management of comorbid psychiatric illness to reduce self-medication-driven relapse; thiamine supplementation in at-risk chronic drinkers to prevent Wernicke-Korsakoff progression; vaccination and infection-prevention counseling given AUD-associated immune suppression.

Genetic/risk counseling

While not a Mendelian disorder amenable to individual genetic counseling in the classical sense, family history discussion (given the well-established ~40–60% heritability) is a recognized part of risk communication in primary care and psychiatric practice, and population-level ALDH2/ADH1B genotype distribution informs public-health messaging in East Asian populations regarding flush-reaction and elevated esophageal cancer risk with continued heavy drinking despite the aversive reaction.

Public health

Policy-level interventions (minimum unit pricing, taxation, marketing restriction, drunk-driving law enforcement) have the strongest population-level evidence base among all prevention strategies for reducing AUD-attributable morbidity/mortality (WHO Global Status Report on Alcohol and Health framework).

14. Other Species / Natural Disease

AUD as clinically defined is a human diagnostic construct; however, alcohol-preference and alcohol-dependence-like phenotypes are extensively modeled and, to a lesser degree, observed naturalistically across species: - NCBI Taxon:9606 (Homo sapiens) — the disease itself. - No well-characterized naturally occurring veterinary/companion-animal AUD analog exists in the way that, e.g., diabetes or cancer have veterinary natural-disease counterparts (OMIA does not carry an AUD entry); alcohol-related pathology in other species is essentially always experimentally induced rather than naturally occurring. - Orthologous genes: ADH1B and ALDH2 orthologs are present and functionally conserved across mammals (mouse Adh1, Aldh2), underpinning the validity of rodent metabolic/behavioral models. - Comparative biology: The core mesocorticolimbic dopamine reward circuitry and its ethanol-responsive GABA/glutamate physiology are highly evolutionarily conserved from rodents to primates to humans, which is the biological basis for the strong translational utility of animal models (§15) despite AUD itself being a uniquely human diagnostic/behavioral construct. - Zoonotic potential: Not applicable.

15. Model Organisms

A broad and mechanistically informative set of model systems is used to dissect AUD biology (Cservenka & Ray review and others; PMC6683838 "Animal Models for the Genetic Study of Human Alcohol Phenotypes"; PMC11566292, 2024 review of genetic animal models for brain gene expression in AUD; translational review PMC/Nature Translational Psychiatry 2021):

Mammalian genetic/selectively-bred models

Selectively bred rat/mouse lines: High Alcohol Preference (HAP) and Low Alcohol Preference (LAP) mouse lines (bred from HS/Ibg founders; cHAP = crossed HAP replicate lines) and the classic alcohol-preferring (P) vs. non-preferring (NP) rat lines model genetic variation in voluntary alcohol consumption.
High Drinking in the Dark (HDID)-1 and HDID-2 mice: selectively bred over 20+ generations for reaching high blood alcohol concentrations in a binge-like "drinking in the dark" assay — models the binge-drinking phenotype specifically.
Knockout/transgenic/conditional models: Gene-targeted mice (e.g., Gabra2, Oprm1, Aldh2 knockouts/humanized alleles) used to causally test candidate genes identified in human GWAS; IMPC/KOMP/MGI-cataloged alcohol-related phenotyping data available for many such lines.
Non-human primates: Used for studies requiring closer translational fidelity to human social drinking patterns, voluntary chronic self-administration, and neuroimaging-comparable circuit studies.

Non-mammalian models

Zebrafish (Danio rerio): Increasingly used given transparent embryos enabling live anatomical/circuit characterization and high-throughput genetic screening of alcohol-response behavior.
Drosophila melanogaster: Shows conditioned place-preference-like responses to ethanol-paired cues and robust ethanol-induced behavioral sensitization/tolerance paradigms, exploiting powerful Drosophila genetic tools.
C. elegans: A genetically fully tractable invertebrate model with conserved ethanol-response pathways, used both for mechanistic dissection and for small-molecule/therapeutic screening (PMC/ScienceDirect C. elegans AUD therapeutics screening literature).

Model characteristics — phenotype recapitulation and limitations

Rodent models robustly recapitulate voluntary consumption, escape/withdrawal-associated hyperexcitability (tremor, seizure susceptibility), and core neurocircuit adaptations (mesolimbic dopamine blunting, glutamatergic sensitization) seen in human AUD. Limitations include the difficulty of modeling the complex, criterion-based DSM-5 psychiatric diagnosis (craving, social/role impairment) in non-verbal organisms, and cross-species differences in alcohol pharmacokinetics/metabolism rate that require careful dose calibration for translational validity — an important human-model-fidelity caveat analogous to the dismech schema's HUMAN_MODEL_MISMATCH discussion category, particularly relevant for translating rodent withdrawal-severity or craving-proxy behavioral assays to the human clinical phenotype.

Applications

These models collectively support dissection of genetic risk-locus function (knockout/humanized-allele validation of GWAS hits), neurocircuit-level mechanism (optogenetic/chemogenetic manipulation of VTA-NAc-amygdala-PFC circuitry), withdrawal pharmacology (benzodiazepine/anticonvulsant testing), and preclinical efficacy screening for novel pharmacotherapies (e.g., the preclinical GLP-1RA evidence base that motivated the semaglutide human trials in §12).

Resources

MGI, IMPC/KOMP (mouse gene-targeted lines and phenotyping), RGD (rat genomic resources for P/NP lines), ZFIN (zebrafish), FlyBase (Drosophila), WormBase (C. elegans), IMSR (strain repository).

Summary Table: Suggested Ontology Term Anchors for KB Curation

Domain	Suggested term (verify CURIE via OAK/OLS before committing)
Disease	OMIM:103780; ICD-11 6C40 series; MONDO CURIE — unconfirmed, verify live
Causal/risk genes	HGNC:249 (ADH1B), HGNC:404 (ALDH2), HGNC:4083 (GABRA2), HGNC:24578 (KLB), HGNC:4196 (GCKR), HGNC:8156 (OPRM1)
Chemicals	CHEBI:16236 (ethanol), CHEBI:15343 (acetaldehyde)
Biological processes	GO:0006066 (alcohol metabolic process), GO:0035249 (glutamatergic synaptic transmission), GO:0051932 (GABAergic synaptic transmission)
Anatomy	UBERON terms for ventral tegmental area, nucleus accumbens, amygdala, prefrontal cortex, liver — verify exact CURIEs
Phenotypes	HP:0002378/HP:0030955 (tremor), HP:0002069 (generalized tonic-clonic seizure), HP:0001394 (cirrhosis), HP:0009830 (peripheral neuropathy), HP:0001397 (hepatic steatosis)
Treatment	NCIT:C15986 (Pharmacotherapy) + therapeutic_agent naltrexone/acamprosate/disulfiram/semaglutide; NCIT term for Behavioral Counseling

Key Gaps / Items Needing Further Verification Before KB Entry

Exact MONDO CURIE for alcohol use disorder/alcohol dependence — not confirmed via live ontology lookup in this pass; must be resolved via OLS/Monarch before curation to avoid a mismatched identifier.
Exact PMIDs for the Zhou et al. 2023 Nature Medicine multi-ancestry GWAS and the 2024 Nature Mental Health cross-disorder pleiotropy paper were not independently confirmed to the numeric PMID in this pass — the papers and journals are correctly identified, but curators should run just fetch-reference against the specific PMID before citing.
HPO coverage of AUD-specific behavioral/psychiatric criteria (craving, impaired control, social impairment) is sparse — HPO is built for somatic/syndromic phenotypes, so most DSM-5 AUD criteria will need to be captured as free-text/description content rather than forced HP term bindings; only the physiological/withdrawal and end-organ-complication phenotypes map cleanly to existing HP terms.
CL and UBERON exact CURIEs for brain reward-circuit cell types and regions listed above are given at the recall/best-estimate level and should be independently verified with runoak before use in a schema-bound annotation.

Ask OpenScientist

OpenScientist Report

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Environmental Factors

Biochemical Markers

Diagnosis

Prevalence

Clinical Burden

Clinical Trials

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Alcohol Use Disorder (AUD): Comprehensive Disease Characteristics Research Report

1. Disease Information

2. Etiology

Disease Causal Factors

Genetic Risk Factors

Environmental Risk Factors

Protective Factors

Gene-Environment Interactions

3. Phenotypes

Core DSM-5 diagnostic symptom domains (11 criteria, ≥2 required within 12 months for diagnosis)

Acute intoxication phenotypes

Alcohol withdrawal syndrome (onset hours after cessation in a physiologically dependent individual)

Cognitive/psychiatric phenotypes

End-organ complication phenotypes (chronic, downstream)

Phenotype characteristics

Quality of Life Impact

4. Genetic/Molecular Information

Causal/Major-Effect Genes (complex trait — no monogenic Mendelian cause; these are the largest-effect common-variant loci)

Pathogenic Variants / Classification

Modifier Genes

Epigenetic Information

Chromosomal Abnormalities

5. Environmental Information

6. Mechanism / Pathophysiology

Molecular pathways and neurotransmitter systems

Cellular processes

Protein dysfunction / biochemical abnormalities

Metabolic changes

Immune system involvement

Tissue damage mechanisms

Molecular profiling

Suggested ontology terms

7. Anatomical Structures Affected

Organ level

Tissue/cell level

Subcellular level

Localization (brain circuitry — key nodes)

8. Temporal Development

9. Inheritance and Population

Epidemiology

Inheritance pattern

Population demographics

10. Diagnostics

Clinical tests / laboratory

Genetic testing

Clinical diagnostic criteria

Screening

11. Outcome/Prognosis

Survival and mortality

Morbidity and functional outcomes

Disease course / complications

Psychiatric comorbidity (major prognostic driver)

Prognostic factors

12. Treatment

Pharmacotherapy (FDA-approved)

Off-label / commonly used pharmacotherapy

Emerging / investigational pharmacotherapy

Pharmacogenomics

Psychosocial/behavioral treatment

Withdrawal management (acute)